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ABSTRACT 
 
Polyfunctional pyrroles  are interesting heterocyclic intermediates as they have a 
range of reactive centres and the chemoselectivity of their reactions under a range 
of conditions, is therefore, of much interest. Polyfunctionalised heterocycles are 
relatively difficult to prepare, but the reactions of these substituted pyrroles allow 
access  to  a  wide  variety  of  new  substituted  heterocyclic  compounds  via  these 
intermediates.  
The  aim  of  this  project  was  to  synthesise  polyfunctional  pyrroles  in  order  to 
investigate  their  use  in  the  preparation  of  libraries  and  compounds  with  known 
biological activity. The synthesis and initial investigation of the regioselectivity of 
polyfunctional pyrroles, such as 3,5-dichloro-1H-pyrrole-2,4-dicarboxaldehyde, has 
previously been described; this work investigated only nucleophilic substitutions. 
We have investigated the chemoselectivity of the reaction of these pyrroles with a 
range of reagents and a number of pyrrole derivatives were synthesised via selective 
functional group transformations. All new compounds were fully characterised by 
spectroscopic and elemental analysis. 
Another  aim  of  this  project  was  to  discover  novel  agents  that  inhibit  VEGF 
receptors using structure based drug design. We have identified hit compounds and 
synthesised them using regioselective reactions of functional groups present on the 
pyrrole ring. The compounds were tested for anti-proliferative activity against the 
HaCaT, human keratinocyte cell line, and also against HT29 and CaCo-2, human 
colon cell lines using the MTT assay.  
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1. INTRODUCTION 
1.1 Background 
 
About half of all known compounds contain a heterocyclic ring, and many of these 
contain an aromatic heterocyclic ring. Heterocyclic rings can be found in many of the 
products of both primary and secondary metabolism, as well as in many synthetic 
compounds  of  commercial  interest,  such  as  drugs,  pest  control  agents,  colouring 
agents and flavourings.
1  
In the last few decades, the chemistry of pyrrole and its derivatives has received 
growing  interest.  Pyrroles  are  widely  used  intermediates  in  pharmaceuticals,
2 
agrochemicals
2  and  dyes
2  and  are  also  highly  flexible  building  blocks  for  a  wide 
variety of other compounds, including natural products.
3 For example, the pyrrole 
ring is the main component of naturally occurring tetrapyrroles such as haeme and 
chlorophyll,  while  the  pentasubstituted  pyrroles,  Atorvastatin  (Lipitor
R)
4  1  and 
Fluvastatin  (Lescol
R)
4  2  are  the  most  common  prescription  drugs  for  lowering 
cholesterol levels, Figure 1.  
N
H3C
H3C
O
N
H
F
N
H3C CH3
O
OH
F
OH OH
2
HO
O
OH
OH
1  
Figure 1. Structures of the clinically used pyrroles Atorvastatin 1 and Fluvastatin 2  Introduction                                                                                            Chapter One 
 
3 
Pyrrole
5  3  is  an  electron  rich,  five-membered  aromatic  heterocycle  which  was 
discovered in 1834 by Runge,
3b who identified it in coal tar, and was first isolated in 
1857 by Anderson through the dry distillation of bone material. In the 1870s, after the 
description of their structure, chemists became increasingly interested in pyrroles and 
their aromatic properties.
6  
 
N
H
1 2
3 4
5 

3  
 
In the 19
th Century, Paal and Knorr published highly effective synthetic routes to 
pyrrole  and  its  derivatives,
7,8  using  efficient  cyclisation  reactions  for  the  direct 
synthesis of pyrroles from easily accessible starting materials such as acetoacetates, 
ketones and amines.  
During the 20
th Century extensive studies continued on the synthesis and chemical 
behaviour  of  pyrroles  and  particular  effort  was  directed  towards  the  study  of  the 
reactions of such systems with electrophiles.
9 
Today,  although  different  synthetic  approaches  to  substituted  pyrroles  exist,  the 
synthesis of highly functionalised pyrroles and the study of modified pyrroles remains 
challenging.
10 
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1.2 Importance of pyrroles  
 
Pyrrole and its derivatives are important heterocyclic compounds, not only because of 
their interesting chemical reactions, but they are also essential building blocks for 
several natural products such as haemoglobin, chlorophyll, bile pigments or vitamin 
B12.
11 Pyrroles are widely used as intermediates in the synthesis of pharmaceuticals, 
medicines, agrochemicals, perfumes, compounds in many foods and also exhibit a 
wide variety of optical and electronic properties.
12 Pyrroles are also used as catalysts 
for polymerisation processes and as corrosion inhibitors.
13  
Polypyrroles (PPy) 4 are among the most extensively studied conducting polymers, 
since  monomeric  pyrrole  is  easily  oxidised,  water-soluble  and  commercially 
available.  They  exhibit  special  interest  because  of  their  high  conductivity  and 
stability, easy preparation and good mechanical properties and they are suitable for 
use in batteries, electronic devices or sensors.
14  
 
N
H
H
N
N
H
H
N
n
4  
Polypyrrole 
 
One  of  the  most  studied applications  of  PPy  is  in  the  manufacture  of  capacitor 
devices.  For  example,  a  PPy-aluminum  solid  electrolytic  capacitor  shows  good 
frequency and temperature features, as well as good thermal and moisture stabilities. 
This capacitor can function continuously for more than 3600 h at 150 °C without Introduction                                                                                            Chapter One 
 
5 
deterioration.
15 Porphyrins
16 are an extremely important group of organic compounds 
and their basic structure contains four pyrrole molecules joined together by methene 
bridges,  forming  the  tetrapyrrole  structure.  The  parent  compound  of  this  class  is 
porphine 5, Figure 2. Each of the nitrogen atoms can form a bond with small metal 
cations such as Mg
2+, Fe
2+, Zn
2+, and Co
2+.   
Haeme 6 is a porphyrin derivative in which the ferrous ion is held in the centre of the 
macrocycle,  Figure  2.  When  haeme  combines  with  the  protein  globin  it  forms 
haemoglobin (contained in red blood cells), which is responsible for oxygen transport 
from the lung to the tissues through the blood and also plays an important role in the 
transport of carbon dioxide from the tissues back to the lung.   
 
N
N
N
N Fe
HOOC
HOOC
NH
N
N
HN
5 6  
 
Figure 2. The structure of Porphin 5 and Haeme 6 where the four pyrrole rings are 
highlighted in blue, the side groups which were added to the porphine in 
purple and the central atom in red 
 
Another important porphyrin, called chlorophyll, a green pigment, occurs in most 
plants and algae and is responsible for the absorption of energy from sunlight – it Introduction                                                                                            Chapter One 
 
6 
absorbs  the  red  and  blue  /  violet  parts  of  the  spectrum  but  reflects  the  green. 
Chlorophyll has a similar structure to haeme, with a magnesium ion at the centre of 
the complex. Vitamin B12 or cobalamin is also a porphyrin derivative and plays an 
important role in the nervous system and in blood.
17  
 
1.2.1  Importance  of  halogenated  pyrroles  in  agrochemistry  and        
pharmaceuticals 
 
It is well known that halogenated pyrroles, isolated from Nature, are lead compounds 
in agrochemistry and pharmaceuticals.  
 
1.2.1.1 Agrochemistry 
 
Fenpiclonil  7a  and  Fludioxonil  7b  are  phenylpyrrole  fungicides  derived  from  the 
natural antibiotic pyrrolnitrin 7c which was isolated from the bacterium Pseudomonas 
pyrociniae.
18  Phenylpyrroles  are  used  to  control  a  variety  of  important  plant-
pathogenic  fungi
19  and,  together  with  anilinopyrimidines  and  dicarboximides,  the 
phenylpyrroles belong to the most powerful botryticides. Chlorofenapyr 8 was the 
first  commercialised  pyrrole  insecticide  for  the  control  of  agricultural  pests  and 
termites. In addition, substituted analogues with cyano- or carboxylic acid moieties at 
the ʱ-position are important intermediates in porphyrin syntheses,
20 Figure 3.  
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N
H
R1
R2
R3
N
NC Br
OEt
CF3
Cl
8 Chlorofenapyr
7a Fenpiclonil, BeretR (R1 = CN, R2, R3 = Cl)
7b Fludioxonil, CelesteR (R1 = CN, R2 = R3 = OCF2O )
7c Pyrrolnitrin (R1 = R3 = Cl, R2 = NO2)  
 
Figure 3. Pyrrolnitrin and its derivatives 
 
Pyoluteorin
21 9 is an antibiotic substance, produced naturally by certain strains of 
Pseudomonas species, which led to the discovery of synthetic analogues 10 and 11 
with herbicidal activity, Figure 4. 
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Figure 4. Pyoluteorin and its derivatives 
 
The 2-aryl-3-cyanopyrrole derivatives 12, 13 and 14 exhibit mollusicidal, insecticidal, 
fungicidal and herbicidal activity, Figure 5.
21-22  
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Figure  5.  Halopyrroles  with  mollusicidal,  insecticidal,  fungicidal  and  herbicidal 
activity 
 
1.2.1.2 Pharmaceuticals 
 
Pyrrole containing compounds are a promising starting point in drug research in view 
of their various pharmacological activities.  
Zomepirac 15 and Tolmetin 16 are non-steroidal anti-inflammatory drugs (NSAID) 
and they exhibit anti-inflammatory, analgesic and antipyretic properties,
23 Figure 6.
  
 
N
CH3
H3C
COOH
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CH3
COOH
O
H3C
15 16  
Figure 6. The anti-inflammatory agents, Zomepirac and Tolmetin 
 
Atorvastatin (Lipitor
R) 1 is one of the most prescribed drugs in the US and Europe for 
the lowering of cholesterol levels and it has been shown that Atorvastatin, like other 
statin drugs, has potential in the treatment of Alzheimer’s disease.
24  
In the last few decades, fungal infections have increased significantly in number, 
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from cancer, AIDS or tuberculosis. A small number of agents are currently available 
to  treat  fungal  infections.  Antifungal  azole  agents  such  as  fluconazole  and 
voriconazole
25 17
 have some drawbacks, such as poor central nervous system (CNS) 
penetration or high cost. Onnis et al. reported on the synthesis and antifungal activity 
of new potential pyrrole derivatives 18 and 19 which also have a wide spectrum of 
activity against breast, lung and CNS cancer, Figure 7.
26  
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Figure 7. Voriconazole and new potential antifungal activity pyrrole derivatives 
 
3-Halopyrroles,  isolated  from  micro-organisms,  have  special  importance  in  both 
pharmaceuticals and agrochemistry, although their synthesis is difficult because of 
problems  with  overhalogenation.  3-Chloropyrrole  20  is  a  fibrosis  inhibitor,  while 
roseophilin 21, isolated from Streptomyces griseoviridis in 1992 by Seto et al., has 
antileukemic and antibiotic properties, Figure 8.
27  
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Figure 8. Halopyrroles  
 
Pentabromopseudilin 22 was first isolated from the marine bacterium Alteromonas 
luteoviolaceus  and  exhibits  antitumour  and  antibacterial  activities,  Figure  9.  This 
polybrominated  pyrrole  also  inhibits  a  number  of  different  enzyme  systems  and 
cholesterol  biosynthesis.
28  Tetrapyrrolic  compounds  are  commonly  used  as 
therapeutic agents in photodynamic therapy (PDT) for the treatment of cancer.
29  
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Figure 9. Pentabromopseudilin 
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1.2.2 Importance of pyrroles in dyes 
 
Several pyrrole derivatives have been found to be useful as both laser and textile 
dyes. For example, the boron pyrromethene-BF2 complex 23 are well-known as laser 
dyes (broadband laser activity in the region 530-580 nm under flash lamp excitation) 
and  fluorescent  labels  in  biology.
30  The  alkaloid  ageladine  A  24  is  a  pyrrole-
pyridoimidazole and shows fluorescence in the blue–green region during excitation 
with UV light at 370 nm, Figure 10.
31  
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Figure 10. Laser dyes 
 
Raposo et al. reported the first synthesis of a series of thienylpyrrole azo dyes 25, 
Figure  11.
32  Azo  dyes  with  heterocyclic  diazo  components  have  been  widely 
investigated for the creation of bright and strong colour shades, ranging from red to 
greenish blue, on synthetic fabrics.
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25
 
Figure 11. Thienylpyrrole azo dyes 
 
 
1.2.3 Importance of pyrroles in food chemistry 
 
Acetylpyrrole is found in many foods as a component of baked, fried and roasted 
flavourings.
33  Siegmund  et  al.  reported  on  the  importance  of  2-acetylpyrrole  26, 
which is responsible for the roasted flavour of the pumpkin oil, while N-methyl-2-
acetylpyrrole 27 is responsible for some of the sweet aromas in coffee, Figure 12. In 
addition, pyrroles are important components of cosmetics and alcoholic perfumery.
34  
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Figure 12. Acetylpyrroles in food chemistry 
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1.3 Pyrrole-containing natural products 
 
Natural products are an important source of new therapeutic agents and an increasing 
number are being discovered from sources ranging from insects, sponges and plants 
to bacteria.
 Pyrrole alkaloids represent one of the most important groups of natural 
products  –  they  exhibit  various  biological  properties  and  are  important  as  lead 
compounds for drug development.
35,36  Several monopyrroles have been isolated from 
birds and frogs. An interesting example is batrachotoxin 28, which was first isolated 
from the skin of poison arrow frogs from Columbian rainforests and is one of the 
most toxic substances known, Figure 13.
36 
One of the growing classes of pyrrole alkaloids are the bromopyrroles, derived from 
marine  sponges,  and  several  members  of  this  group  have  interesting  biological 
properties.
37  For  example,  hymenialdisine  29  and  its  debrominated  analogue  30, 
collected from tropical regions, have anti-inflammatory properties and several other 
bromopyrroles show antibacterial properties, Figure 13.
37 
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Figure 13. Bromopyrrole alkaloids 
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A  number  of  compounds  containing  the  indole-2-one  structure  show  important 
biological properties. For example, indole-2-one
38 31 has antitumour activity while 
indole-2-ones  32  and  33  have  phosphodiesterase
39  and  tyrosine  kinase  inhibitory 
activity, Figure 14.
40  
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Figure 14. Indole-2-one containing natural products 
 
Pyrrole derivatives with two aryl groups are especially important  classes of natural 
products  and  some  of  them  exhibit  remarkable  biological  and  pharmacological 
properties. For example, lamellarin natural products are specially interesting due to 
their high biological activities and a great deal of attention has thus been focused on 
the synthesis of lamellarins and related 3,4-diarylpyrrole derivatives. Lamellarins O 
34, P 35, Q 36 and R 37 are 2-carboxylic acid esters and they belong to a large group 
of  DOPA-derived  pyrrole  alkaloids.
41  Most  of  the  lamellarins  show  cytotoxic 
properties against a large range of cancer cell lines and the most effective of these 
compounds are lamellarins D 38, M 39, and K 40 (GI50 38-110 μM), Figure 15.
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34 R = 4-(MeO)C6H4COCH2
35 R = (2-OH, 4-MeO)C6H3COCH2
36 R = H
37 R = 4-(OH)C6H4
38 R1 = X = H; R2 = R3 = Me
39 R1 = R2 = R3 = Me; X = OH
R1 = R2 = H;  R3 = Me  
Figure 15. Pyrrole derivatives with aryl groups 
 
1.4 Chemical reactions and synthesis of pyrroles  
 
1.4.1 Protonation of pyrroles 
 
Chiang et al. investigated the pKa values of a huge range of pyrroles.
43 Pyrrole itself 
is a very weak base (pKa -3.8) compared to amines or pyridine, in which the ring 
nitrogen is not bonded to a hydrogen atom. In pyrrole the lone pair of the nitrogen is 
part of the 6π aromatic ring and protonation destroys the aromaticity. In very acidic 
solutions, protonation takes place most readily on the carbon atoms of the ring and 
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Scheme 1. Protonation of the pyrrole ring 
 
Basicity can be increased markedly with the introduction of alkyl substituents on the 
ring  as  these  have  a  stabilising  effect  on  cations;  for  example,  2,3,4,5-
tetramethylpyrrole has a pKa of +3.7. 
 
 
1.4.2 Substitution of pyrroles 
 
 
Pyrrole  is  an  electron-rich  heteroaromatic  compound  and  so  its  major  chemical 
reactivity is through attack by electrophiles and subsequent substitution reactions.
11b 
There are three possible positions for substitution in pyrrole 3, Figure 16 to give the 
N-, ʱ- and β-substituted products. The difference in these positions is their distance 
from the nitrogen heteroatom, which represents the polar centre of the ring, and the 
possibilities for resonance. All three of these products can be obtained, depending 
upon  the  reaction  conditions  used
5a  and  the  regioselectivity  can  be  controlled  by 
varying the reaction conditions or the use of protecting groups.
44 
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Figure 16. Different positions for substitution of pyrrole 3 
 
1.4.2.1 Substitution on nitrogen 
 
The lone pair on the nitrogen in pyrrole is involved in the aromatic π-system and is 
thus, not easily available for reaction with electrophiles. N-Substitution of pyrroles 
can,  however,  be  readily  achieved  after  deprotonation,  to  give  the  corresponding 
anion, followed by reaction with an electrophile.
44,45 
Pyrrole  is  much  more  acidic  (pKa  17.7)  than  comparable  saturated  amines;  for 
example,  the  pKa  of  pyrrolidine  is  ~  35,  while  the  pKa  of  anilines  is  30.  The 
unsubstituted pyrrole 3 can be deprotonated easily with a strong base, such as NaH or 
butyllithium, to form the corresponding anion, Scheme 2.
45 
 
N
H
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Scheme 2. Pyrrole anion 
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For  example,  the  pyrrole  anion  of  41  can  be  N-alkylated  to  give  42,  43  or  N-
acetylated to give 44 in excellent yield; the N-alkyl analogues of pyrroles can be 
readily prepared using alkyl iodides as the electrophiles and sodium hydride in DMF 
as the base, Scheme 3.
46 
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N
H
CHO
Cl OHC
Cl N
R
CHO
Cl OHC
Cl
(a), (b) or (c)
42 R = Me 41
43 R = Et
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89-97%
 
 
Scheme 3. Examples of the N-alkylation and acylation of pyrrole 41. Reagents and 
conditions; a) NaH, DMF, MeI, r.t., 89%; b) NaH, DMF, EtBr, r.t., 97%; 
c) KH, THF, AcCl, r.t., 90%  
 
1.4.2.2 Electrophilic substitution at the C-2 and C-3 positions 
 
Good yields in the N-substitution of pyrroles depend upon the selective deprotonation 
of  the  nitrogen.  Without  previous  deprotonation  pyrrole  normally  reacts  with 
electrophiles (E
+) at the kinetically preferred C-2 (ʱ) position in preference to the 
thermodynamically more stable C-3 (β). The explanation of the ʱ-selectivity of the 
substitution  reactions  is  clear  from  the  mechanism  outlined  in  Scheme  4.  The 
intermediate  formed  by  electrophilic  attack  at  C-2  is  stabilised  by  charge 
delocalisation to a greater degree than the intermediate from C-3 attack. From the 
Hammond postulate, the activation energy for substitution at the former position is Introduction                                                                                            Chapter One 
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less  than  the  latter  substitution.  Attack  at  nitrogen  is  inhibited  because  no 
delocalisation of charge is possible in the resulting intermediate.
47 
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Scheme 4. Electrophilic substitution at C-2 and C-3 position of pyrroles 
 
 
 
Electrophilic substitution at the C-3 position is possible but the β-isomer is usually 
formed only in minor quantities; for example, β-acetylpyrrole 45 is a by-product of 
the ʱ-acetylation of pyrrole 26,
 Scheme 5.
48 
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Scheme 5. Example of electrophilic substitution at the β-position 
 
The position of substitution can be controlled by the protection of the pyrrole nitrogen 
with sterically bulky groups, such as the tert-butyl or triisopropylsilyl groups, which 
block substitution at the C-2 position.
44a,45a For example, the triisopropylsilyl (TIPS) Introduction                                                                                            Chapter One 
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protecting group was found to be useful for the preparation of 3-formylpyrrole 49. 
The first step in this synthesis is to protect the pyrrole 3 with TIPS, followed by the 
bromination  at  the  C-3  position  with  N-bromosuccinimide  (NBS)  to  result  in  the 
brominated  product  47.  Halogen-metal  exchange  then  allows  selective 
functionalisation  at  the  C-3  position.  Reaction  of  the  carbanion  with  N,N-
dimethylformamide provided β-formyl derivative 48, the desilylation of which was 
performed  using  tetrabutylammonium  fluoride  (TBAF)  in  THF  to  afford  3-
formylpyrrole 49 in good overall yield from 3, Scheme 6.
49 
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THF, -80oC
93%
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95%
BuLi, THF
-78oC, DMF
82%
86% TBAF, 
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
N
TIPS
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N
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N
H
N
H
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3 46 47 48
49  
Scheme 6. Synthesis of β-formylpyrrole 49 
 
Gaunt  et  al.  investigated  the  regioselective  alkenylation  of  pyrroles  under  mild, 
aerobic, palladium catalysed conditions. Electron withdrawing N-protecting groups 
(N-Ac,  N-Ts,  N-Boc)  decrease  the  reactivity  of  pyrroles  and  result  only  in  C-2 
substituted product e.g. 50, in contrast with the reaction with N-TIPS pyrrole which 
afforded the C-3 product 51, Scheme 7.
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Scheme 7. Regioselective C-H alkenylation of pyrrole 
 
1.4.3 Interconversion of substituents  
 
Interconversion  of  functional  groups  is  another  feasible  method  if  the  direct 
introduction of the corresponding substituent is not possible because of instability 
under the reaction conditions or unfavourable regiochemistry. 
 
1.4.3.1 Transformation of the formyl group 
 
The formyl group is the most reactive centre in 5-formyl-1H-pyrrole-2-carboxylic 
acid  methyl  ester  52  and  this  can  undergo  functional  group  interconversion  in  a 
number of ways. Oxidation with potassium permanganate results in the corresponding 
carboxylic acid 53 in 75% yield,
51 while selective reduction with sodium borohydride 
provides the alcohol  54 in  good  yield,  without  affecting the  ester  group, Scheme 
8.
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Scheme 8. Selective oxidation and reduction of aldehyde 
 
1.4.3.2 Halogenation via radical reactions 
 
The ʱ-methyl group of pyrrole 55 can be chlorinated selectively through a radical 
substitution reaction using sulphuryl chloride as the halogenating agent, to result in ʱ-
chloromethylpyrrole  56,  despite  the  other  alkyl  groups  in  the  molecule.  The 
alcoholysis of 56, in ethanol, results 57, while condensation in acidic ethanol with 
another  pyrrole  results  in  the  formation  of  the  dipyrrole  58,  which  is  a  key 
intermediate in chlorophyll synthesis, Scheme 9.
54  
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Scheme 9. Chlorination of ʱ-methylpyrrole 55. Reagents and conditions; a) SO2Cl2, 
AcOH, 55 
oC, 1h; b) EtOH, Δ; c) 3-ethoxycarbonyl-4-methylpyrrole, HCl, 
EtOH, reflux, 1h 
 
Radical β-halogenation can also be achieved if the substituent on the ʱ-position is 
unreactive toward radical reactions and there is no free hydrogen on the ring. For 
example, both methyl groups of pyrrole 59 can be brominated selectively using NBS 
to afford the dibromide 60, Scheme 10.
55 The dibromopyrrole 60 can then be used in 
further  reactions  as  an  electrophile.  For  example,  the  reaction  with  n-hexanol 
produces compound 61, and cyclization of 60, with 1,2,4,5-tetrahydroxybenzene as 
nucleophile, can be achieved to provide the pentacycle 62.
47,55 
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Scheme 10. Halogenation of the β-alkyl group of pyrroles. Reagent and conditions; a) 
NBS, AIBN, CCl4, reflux, 2.5 h; b) n-hexane-1-ol, toluene, Et3N, reflux, 
20 h; c) DMSO, Cs2CO3, r.t., 3 h 
 
1.4.4 Synthesis of substituted pyrroles via cyclisation reactions 
 
Considering the importance of this class of heterocycle, it is not a great surprise that a 
huge number of procedures have been developed for the synthesis of pyrroles.
2c, 5a, 56 
Most  chemical  research  in  this  area  involves  substituted  pyrroles  rather  than  the 
parent  compound  itself.  Different  synthetic  routes  to  these  substituted  derivatives 
exist and they can be readily obtained by substitution reactions of simple pyrroles, 
while alternative routes utilise suitable starting materials for direct cyclisation into 
substituted  pyrroles,  the  functionalisation  of  already  substituted  pyrroles,  or  the 
interconversion of substituent groups.
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Several different methods exist for the construction of a pyrrole ring using classical 
condensation  reactions,  the most common  disconnections  for  which are shown in 
Figure 17.  
N
H
N
H
N
H
N
H
Type 1 Type 2 Type 3 Type 4  
 
Figure 17. Different methods for the retrosynthetic cleavage of pyrroles 
 
For each cyclisation method, a huge number of modifications have been developed in 
addition to the classical examples, so it is often difficult to predict which synthetic 
approach will be the most suited for the preparation of any specific pyrrole. 
 
1.4.4.1 Knorr pyrrole synthesis 
 
One  of  the  most  common  syntheses  of  pyrroles  is  the  classical  Knorr  reaction
7 
(retrosynthetic cleavage of type 1), which for e.g. results in the formation of pyrrole 
66 after condensation of a ketone 64 with an ʱ-aminoketone 65, Scheme 11. The ʱ-
aminoketones must be prepared in situ, by the reduction of an oxime 63 (using zinc 
and acetic acid or sodium dithionite), because they self condense very readily (to 
form  the  corresponding  pyrazines).  The  reaction  proceeds  rapidly  at  room 
temperature in ethanol, and provides the pyrrole 66 in high yield.
57 N-Substituted 
pyrroles can be prepared using secondary amines, which again have to be synthesised 
prior to the Knorr reaction.
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Scheme 11. The Knorr pyrrole synthesis 
 
1.4.4.2 Hantzsch pyrrole synthesis 
 
Another widely used reaction is the Hantzsch pyrrole synthesis (same retrosynthetic 
cleavage  as  the  Knorr  reaction,  Type  1).  Substituted  2-alkylpyrrole-3-carboxylic 
esters  are  easily  prepared  from  the  reaction  of  a  dicarbonyl  compound  67  with 
ammonia to give for e.g. the corresponding enamine 68, followed by condensation 
with chloroacetone 69 to provide the pyrrole 70, Scheme 12. This is an interesting 
alternative  route  to  the  Knorr  reaction  as  the  use  of  primary  amines  instead  of 
ammonia gives N-substituted pyrroles.
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Scheme 12. The Hantzsch pyrrole synthesis 
 
1.4.4.3 Paal-Knorr pyrrole synthesis 
 
N-Substituted pyrroles can also be prepared by the Paal-Knorr synthesis, in which 
1,4-dicarbonyl  compounds  react  with  ammonia  or  primary  amines  to  give  3,4-
disubstituted  or  1,3,4-trisubstituted  pyrroles.  As  an  example  of  this  method,  1,4-
diketone 71 was reacted with methylamine at room temperature to provide pyrrole 72 
in high yield, Scheme 13.
59  
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Scheme 13. Example of the Paal-Knorr synthesis of pyrroles 
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Banik and co-workers have reported a simple method for the synthesis of substituted 
pyrroles using iodine or montmorillonite KSF clay as the catalyst. The reaction was 
carried out at room temperature by mixing the catalyst with different amines 73 and 
substituted diketones 74 in the appropriate solvent, and then the solution was kept at 
room  temperature  for  a  specified  time  and  resulted  in  pyrroles  75  in  good  yield, 
Scheme 14.
60  
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Scheme 14. Synthesis of substituted pyrroles  
 
Several  synthetic  methods  have  been  described  for  the  synthesis  of  pyrrole 
derivatives with two aryl groups on adjacent positions.
61 3,4-Diarylpyrroles are the 
building  blocks  for  the  naturally  occurring  lamellarins
61e  or  ningalins.
61f  The  3,4-
diarylpyrroles  79  were  prepared  from  dimethyl  N-acetyliminodiacetate  77  and 
diketone  76  in  the  presence  of  sodium  methoxide,  followed  by  hydrolysis  and 
decarboxylation, Scheme 15.
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Scheme 15. Synthesis of 3,4-diarylpyrroles 
.  
1-(4-Fluorophenyl)-2-aryl-1H-pyrrole  derivatives  82  were  synthesized  by  Khanna 
and co-workers by the reaction of a 1,4-ketoacetal 80 and anilines 81, in toluene in 
the presence of p-toluenesulfonic acid, Scheme 16.
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Scheme 16. Synthesis of 1,2-diaryl-1H-pyrroles 
 
Rao et al. investigated the simple one-pot synthesis of 2,5-di- and 1,2,5-trisubstituted 
pyrrole derivatives 85 from (E)-1,4-diaryl-2-butene-1,4-diones 83 using ammonium Introduction                                                                                            Chapter One 
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formates  84  in  the  presence  of  Pd/C  in  different  solvents,  under  microwave 
irradiation, Scheme 17.
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Scheme 17. Reaction of (E)-1,4-diaryl-2-butene-1,4-diones with ammonium formates 
 
Su  et  al.  have  reported  a  new  catalytic  procedure  for  the  synthesis  of  1,2,5-
trisubstituted  pyrrole  derivatives  86.  Most  of  the  existing  methods  suffer  from 
disadvantages such as long reaction times, harmful organic solvents or the use of an 
excess  of  acid.  These  workers  reported  an  environmental  friendly  synthesis  of 
pyrroles using metal triflates which are inexpensive, have low toxicity, high stability 
and can be easily recovered from water, Scheme 18.
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Scheme 18.   Sc(OTf)3 catalysed synthesis of trisubstituted pyrroles under solvent-
free conditions 
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1.4.4.4 Modified Knorr syntheses 
 
An interesting example of the Type 3 cyclisation method (Figure 17) is the modified 
Knorr  synthesis,  in  which  the  β-diketone  87  reacts  with  an  ʱ-amino  carbonyl 
compound 88.
64 In the classical Knorr reaction, both reactants contribute two carbon 
atoms to the heterocyclic ring, while using the modified Knorr reaction three carbon 
atoms  are  derived  from  the  1,3-dicarbonyl  compound  and  the  amino  compound 
donates one, in addition to the nitrogen, Scheme 19.
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Scheme  19.  Modified  Knorr  pyrrole  synthesis  of  compound 89.  Reagents  and 
conditions; AcOH, H2O, reflux, 89% 
 
Appropriately  substituted  1,3-dicarbonyl  compounds  are  required  as  the  starting 
materials  for  the  preparation  of  unsymmetrical  β-substituted  compounds  because 
differentiation in the β-positions is not possible. The amino derivative was prepared 
in situ by the reduction of oxime 91 then reaction with one of the ketone functions of 
90, and a final cyclisation resulted in pyrrole 92 in good yield, Scheme 20.
65  
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Scheme 20. The modified Knorr reaction of the diester compound 92. Reagents and 
conditions; Zn, AcOH, NaOAc, reflux, 2 h, 75% 
 
Using suitable starting materials, pyrroles can be prepared with two different ester 
groups. The reaction of acetoacetate 94 with sodium nitrite results in a β-diketo-ʱ-
oxime, then an in situ reduction with zinc results in an amine which undergoes the 
modified Knorr reaction with diketone 93 to result in pyrrole 95, Scheme 21.
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Scheme 21. Modified Knorr synthesis for the preparation of 95. Reagents and 
conditions; a) NaNO2, AcOH, H2O, 0 
oC, 12h, b) Zn, 65 
oC, 12 h 
 
Another  interesting  process  is  the  synthesis  of  different  3,4-disubstituted  pyrroles 
(according to the type 4 retrosynthetic cleavage). The reaction of an  ʱ-dicarbonyl Introduction                                                                                            Chapter One 
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compound 96 with a secondary amine 97 under basic conditions results in pyrrole 98 
in good yield, Scheme 22.
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Scheme  22.  Synthesis  of  3,4 -disubstituted  pyrroles.  Reagents  and  conditions; 
NaOMe, MeOH, reflux, 5 h, 61% 
 
1.4.4.5 Unconventional pyrrole syntheses 
 
The  synthesis  of  polysubstituted  pyrrole  rings  is  usually  based  on  the  classical 
condensation  methods,  as  stated  above,  although  these  approaches  suffer  from  a 
limitation  in  the  substituents  which  can  be  introduced.  Recently,  several  novel 
syntheses  have  been  described;
61  however,  efficient  multi-component  coupling 
reactions, with methods involving fewer steps or regioselective approaches are still an 
extremely attractive area in the synthesis of multi-substituted pyrroles. 
Buchwald  and  co-workers  described  a  convenient  and  selective  Piloty-Robinson 
synthesis of highly substituted pyrroles.
68 The reaction involves two sequential Cu-
catalysed  couplings of the corresponding vinyl  iodides  99  and 102 with bis-Boc-
hydrazine 100, then a cyclisation to produce the substituted pyrrole 103, Scheme 23. 
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Scheme 23. Synthesis of pyrroles through cupper-catalysed vinylation of hydrazides. 
Reagents  and  conditions;  a)  CuI  (5  mol%),  1,10-phenanthroline  (10 
mol%), Cs2CO3 (1.2 equiv), DMF, 80 
oC, 12-13h; b) CuI (10 mol%), 
1,10-phenanthroline (20 mol%), Cs2CO3 (1.2 equiv), DMF, 80 
oC, 22-
36h; c) xylene, 140 
oC, 24-48 h; d) p-TsOH (2 equiv), r.t., 1-6 h 
 
Scheidt et al. have recently devised a new and efficient method for the synthesis of N-
acyl-3,4-disubstituted pyrroles which, compared to the previously reported method,
69 
avoids high temperatures and long reaction times and produces high yields.
70 The 
process requires only two purification steps, uses inexpensive starting materials, and 
involves  the  reaction  of  a  symmetric  azine  105  from  hydrazine  and  a  saturated 
aldehyde 104. Benzoyl chloride is then used, under microwave irradiation, for the 
cyclisation to afford the disubstituted N-acylpyrrole 106 in good yield, Scheme 24.
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Scheme 24. Synthesis of 3,4-disubstituted pyrroles 
 
In  recent  years  symmetric  3,4-disubstituted  pyrroles  have  received  special  interest 
since they are the basic building blocks for highly substituted porphyrins. For e.g. the 
product  106  could  be  converted  to  the  free  N-H  pyrrole  107  by  simple  basic 
hydrolysis and then used directly in the synthesis of porphyrins 108 and 109, Scheme 
25.
71 
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Scheme 25. Synthesis of porphyrin derivatives 108 and 109 from 3,4-disubstituted 
pyrrole 107 
 
Yavari and co-workers recently reported on a novel synthesis of functionalised 2,5-
dihydro-1H-pyrroles  113,  based  on  the  reaction  of  benzoyl  chloride  and  dialkyl 
acetylenedicarboxylates 111 in the presence of isocyanides 110. From the reaction 
with  benzoyl  chlorides  112,  which  had  electron-withdrawing  groups  at  the  para 
position,  tetrasubstituted  furans  114  were  obtained,  but  the  presence  of  electron 
donating Me or OMe groups afforded complex reaction mixtures, Scheme 26.
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Scheme 26. Synthesis of functionalised pyrrole and furan derivatives 
 
Narasaka  et  al.  described  new  synthetic  routes  for  the  preparation  of  tetra-  and 
trisubstituted pyrroles from vinyl azides and 1,3-dicarbonyl compounds. The reaction 
of the corresponding vinyl azide 115 with acetylacetone 116, in toluene at 100
oC, 
afforded several pyrrole derivatives 117. To improve the yield these workers decided 
to use different additives, such as acids or bases, but the results did not show any 
significant improvement, although the reaction in the presence of a catalytic amount 
of Cu(OTf)2, in CH3CN gave the unexpected formation of pyrrole 118, Scheme 27.
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Scheme 27. Reaction of vinyl azides with acetylacetone 
 
Shindo  and  co-workers  reported  an  efficient  one  pot  synthesis  of  pyrroles  using 
ynolates 119 and ʱ-acylaminoketones 120 which was carried out at -20
oC over 2-3h. 
The  reaction  with  aromatic,  aliphatic  and  cyclic  ketones  resulted  in  penta-  and 
tetrasubstituted  pyrroles  and  sterically  hindered,  electron-withdrawing  and 
functionalised acyl groups afforded the expected pyrroles 121, Scheme 28.
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Scheme 28. One-pot synthesis of pyrroles 
 
An interesting multi-component reaction has been reported by Scheidt et al. The one 
pot  reaction  of  acylsilane  122,  as  an  acyl  anion  precursor,  unsaturated  carbonyl 
compound  123  and  amine  125,  catalysed  by  a  thiazolium  salt  124,  gave  highly 
substituted pyrroles 126 in over 80% yield, Scheme 29.
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Scheme 29. Multi-component pyrrole synthesis 
 
Arndsten and co-workers described a palladium-catalysed multi-component coupling 
of imines 127, acid chlorides 128 and alkynes 129 to generate a number of substituted 
pyrroles 131.
76 These workers found some limitations in using this approach, such as 
the slow rate of catalysis or using alkyl-substituted imines or acid chlorides which 
underwent  rapid  decomposition.  Recently,  these  workers  have  developed  an 
alternative route involving isocyanides 130 instead of the palladium-catalyst, and this 
allowed the use of a wide range of imines of aromatic and heteroaromatic aldehydes 
and a number of acid chlorides, Scheme 30.
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Scheme 30. Direct pyrrole synthesis 
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Kim  et  al.  synthesised  several  polysubstituted  pyrroles  135  from  Baylis-Hillman 
adduct 132, which was N-alkylated with phenacyl bromide 133, in DMF and in the 
presence of K2CO3, to result in a mixture of diastereoisomeric tetrahydropyrroles 134. 
The elimination of p-toluenesulfinic acid was carried out with DBU in CH3CN to 
give the pyrroles 135, Scheme 31.
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Scheme 31. Synthesis of polyfunctionalised pyrroles 
 
Yamamoto  et  al.  have  developed  a  new  regioselective  synthesis  of  substituted 
pyrroles  via  [3+2]  cycloadditions  between  isocyanides  138  and  electron  deficient 
alkynes 137. The reaction in the presence of Cu2O afforded 2,4-disubstituted pyrroles 
136,  while  the  phosphine-catalysed  reaction  gave  2,3-disubstituted  pyrroles  139 
regioselectively, Scheme 32.
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Scheme 32. Regioselective pyrrole synthesis 
 
These workers applied the phosphine-catalysed condensation to the synthesis of the 
trail pheromone 147 of a leaf-cutting ant. This synthesis starts with the condensation 
of 2-butynoic acid 140 and 2-(trimethylsilyl)ethanol 141, followed by the phosphine-
catalysed reaction of ester 142 and methyl isocyanoacetate 143 to result in pyrrole 
144. The Boc-protected pyrrole  145 was  then treated with  TBAF to  result in the 
carboxylic acid 146, which was decarboxylated by Cu(OAc)2 in 
iPr2NEt / anisole, 
Scheme 33.
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Scheme 33.  Ant  trail  pheromone  synthesis. Reagents  and  conditions;  a)  DCC, 
pyridine, DCM, 0 
oC, 1h; b) dppp, 1,4-dioxane, 100
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2. Results and Discussion 
 
2.1 Aims 
 
The initial aims of this research project were the synthesis of polyfunctional pyrroles 
and the further investigation of the chemoselectivity of the reactions of these pyrroles 
with a range of reagents in order to determine the regioselectivity of the reactions of 
these  heterocyclic  building  blocks  and  to  investigate  the  use  of  these  substituted 
pyrroles in libraries. The first investigations of the chemoselectivity of the reactions 
of multifunctional pyrroles with a range of nucleophiles were previously undertaken 
in  this  Department,  and  our  aim  was  to  continue  this  work.  These  pyrroles  are 
interesting heterocyclic intermediates as they have a range of reactive centres, and the 
chemoselectivity of their reactions under a range of conditions is, therefore, of much 
interest. Polyfunctional pyrroles are relatively difficult to prepare, but the reactions of 
these substituted pyrroles allows the preparation of a wide variety of new substituted 
heterocyclic compounds via these intermediates. 
 
2.2 Synthesis of 3,5-dichloro-1H-pyrrole-2,4-dicarboxaldehyde 
 
3,5-Dichloro-1H-pyrrole-2,4-dicarboxaldehyde  41  was  first  synthesised  by 
Balasundaram  and  co-workers  in  1993  using  the  Vilsmeier  reaction  of  N-
acetylglycine  148,  Scheme  34.
1  and  it  was  also  successfully  synthesized  in  this 
Department, in 44% yield.
2 We initially attempted to improve the yield of the pyrrole 
from the Vilsmeier reaction of N-acetylglycine 148 and a chlorinating agent. In the 
original method, DMF, N-acetylglycine and POCl3 were added together at 0 
oC but  
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we prepared the Vilsmeier reagent first, from DMF and POCl3 at 0 
oC, and then 
stirred for half an hour at ambient temperature. N-Acetylglycine was added to the 
reaction at room temperature and, after stirring for 1 hour, the mixture was refluxed, 
Scheme 34. This small variation led to an increase in the yield (56% instead of 44%). 
Replacement of the chlorinating agent used initially, POCl3, by oxalyl chloride (thus 
allowing  isolation  of  a  crystalline  Vilsmeier  reagent  before  the  reaction  with  N-
acetylglycine) did not lead to an improvement in the yield. 
We  then  found  another  method  to  increase  the  yield,  based  on  the  continuous 
extraction of the product from the aqueous phase into the organic layer, and this 
variation gave the desired pyrrole in 70% yield. 
3,5-Dichloro-1H-pyrrole-2,4-dicarboxaldehyde 41 is polyfunctional, with 5 reactive 
centres  (2 aldehyde  groups,  2 electrophilic carbons  of the pyrrole ring  bonded to 
chlorine atoms, and an NH) and there are, therefore, a range of potential reactions of 
this pyrrole with nucleophiles. 
Substituted analogues (42, 43, 149 and 150) were readily prepared by alkylation of 
the pyrrole anion, Scheme 34.
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Scheme 34 
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2.2.1 Nucleophilic substitution of 3,5-dichloro-1H-pyrrole-2,4-dicarboxaldehyde 
 
The  reaction  of  polyfunctional  pyrroles  with  nucleophiles  has  already  been 
investigated
2  and  the  initial  results  indicate  that  these  pyrroles  undergo 
chemoselective reactions with nucleophiles. The reaction of the parent  pyrrole  41 
with morpholine or piperidine gives the 5-methylenepyrroles 151 via nucleophilic 
attack on the 2-formyl group, and the reaction with dibenzylamine resulted in the 
novel  compound  151a  which  is  more  stable  than  the  piperidine  and  morpholine 
analogues, Scheme 35. 
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Scheme 35 
 
In order to facilitate nucleophilic substitution of the chloro-substituents, the labile NH 
proton was replaced by an alkyl  group. For the substituted pyrrole  43,  attack  by 
sulphur or amino nucleophiles takes place at C-5, presumably due to the reduced  
54 
electrophilic  nature  of  the  C-3  `enamine-like´  position,  to  give  the  pyrroles  152. 
Substitution  of  both  chloro  groups,  to  give  pyrrole  153,  requires  more  forcing 
conditions, Scheme 36.
2  
 
N
Cl CHO
Cl
Et
OHC
43
N
Cl CHO
N
Et
OHC
O
N
N CHO
N
Et
OHC
O
O
152
153
a
b
 
 
Scheme 36.
2 Reagents and conditions; (a) 2.5 equiv. morpholine, DMSO, r.t., 3 days,   
45%; (b) 5 equiv. morpholine, EtOH, Δ, 70 h, 21%
 
 
2.3 Reaction of the aldehyde groups 
 
Carbonyl  groups  in  indoles  maintain  their  characteristic  properties  due  to  the 
inductive effect of the nitrogen and the aldehyde group in the ʱ-position increases the 
electrophilicity of the aldehyde carbon, Figure 18. 
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Figure 18 
 
2.3.1 Conversion of aldehydes into nitriles 
 
The transformation of an aldehyde into a nitrile is an important process in organic 
chemistry,
3 and nitriles are especially useful starting materials for the synthesis of 
various  bioactive  molecules.
4  Several  procedures  are  available  for  the  one-step 
conversion of aldehydes into nitriles using different chemical reagents,
5 but most of 
these methods suffer from serious drawbacks which include the use of hazardous /  
expensive / commercially non-available reagents, long reaction times and low yields. 
A  useful  procedure  for  the  direct  conversion  of  aromatic  aldehydes  into  the 
corresponding  nitriles  involves  refluxing  a  solution  of  the  aldehyde  and 
hydroxylamine hydrochloride in 95-98% formic acid and this has been reported to 
result in the nitrile in 1 hour, in excellent yield, Scheme 37.
6  
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Scheme 37  
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It was hoped that the reaction of 1 equivalent of the unsubstituted pyrrole 41 with 1.2 
equivalents of hydroxylamine hydrochloride in 95-98% formic acid would give the 2-
carbonitrile,  however,  the  reaction  afforded  a  mixture  of  the  2-  155  and  4- 
carbonitriles  154,  Scheme  38.  The  main  product  was  the  2-carbonitrile  155, 
presumably because the carbon of the aldehyde group in the 2-position of the pyrrole 
possesses  a  greater  positive  charge  (is  more  electrophilic)  than  the  carbon  of  the 
aldehyde group in 4-position. 
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Scheme 38 
 
The  separation  of  these  products  proved  to  be  difficult  so  we  decided  to  use the 
hydroxylamine hydrochloride in excess (2.4 equivalents). The unsubstituted pyrrole 
was heated at 85
oC in the presence of NH2OH.HCl and formic acid for 1 hour. Work 
up gave the crude oxime 156 via reaction at both aldehyde groups. Further reaction 
with formic acid afforded the mononitrile compound 157 in 44% yield, Scheme 39, 
Method A. 
An  alternative  method  was  proposed  in  order  to  improve  the  yield,  using 
hydroxylamine hydrochloride and ethanol in the presence of pyridine, and after 2 
hours at reflux the crude oxime 156 was obtained. This oxime was dehydrated in  
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refluxing  acetic  anhydride  (Ac2O)  to  give  3,5-dichloro-4-cyano-1H-pyrrole-2-
carboxaldehyde oxime 157 in 72% yield, Scheme 39, Method B. 
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Scheme 39. Reagent and conditions; Method A: 1) NH2OH.HCl, HCOOH, 40 min, ∆; 
2) HCOOH, 1 h, ∆, 44%; Method B: 1) NH2OH.HCl, EtOH, pyridine, 2 
h, ∆; 2) Ac2O, 1,5 h, ∆, 72% 
 
The structure of the 3,5-dichloro-4-cyano-1H-pyrrole-2-carboxaldehyde oxime 157 
was confirmed by its infra-red spectrum, with a broad NH and OH stretch at 3170 cm
-
1  and  a  CN  stretch  at  2234  cm
-1,  whilst  the 
1H  NMR  spectrum  showed  the 
disappearance of the protons of the aldehyde groups, and  the appearance of a new 
CH proton at  ʴ7.89 and a carbon signal at ʴ139.2. After the reaction with formic acid 
it is not obvious which oxime has been transformed to the nitrile group to give the 
mononitrile but this was determined using the HMBC spectrum, in which two carbon 
atoms (C-2 and C-3) and the NH gave cross peak signals to the hydrogen of the 
oxime in 157, Figure 19. 
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Figure 19. HMBC spectrum of 3,5-dichloro-4-cyano-1H-pyrrole-2-carboxaldehyde 
oxime 157 (300 Hz, d6-DMSO) 
 
 
Reddy et al. reported a simple one-pot synthesis of benzopyrone derivatives from 2-
hydroxyacetophenones under mild conditions, in which 3-cyano-4-benzopyrones 161 
are generally prepared in 3 steps, starting from 2-hydroxyacetophenone 158.
7 The 
Vilsmeier-Haack  reaction of the  starting material results  in  3-formylbenzopyrones 
159,  which  then  react  with  hydroxylamine-hydrochloride  in  ethanol  to  give  the 
corresponding oximes 160. Finally, the dehydration of the oximes results in 3-cyano-
4-benzopyrones 161, using different dehydrating agents, such as hydrochloric acid, 
acetic  anhydride  or  sodium  formate  in  formic  acid.  These  methods  have  some 
drawbacks, such as the isolation of the intermediate 3-formylbenzopyrones 159 and 
oximes 160, the use of strongly acidic conditions, long reaction times, and in some 
cases, low yields in the last dehydration step. In view of these difficulties, Reddy and  
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co-workers developed an efficient procedure for the synthesis of cyanobenzopyrones 
and  their  method  has  great  potential  in  the  preparation  of  a  number  of  cyano-
derivatives under mild conditions, Scheme 40.
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Scheme  40.
8  Reagents  and  conditions;  (a)  DMF/POCl3,  Δ,  4  h,  40-70%;  (b) 
NH2OR´.HCl / EtOH, Δ; (c) EtOH/HCl or acetic anhydride, 50-70%; (d) 
DMF / POCl3 / DCM / NH2OH.HCl, 51-72% 
 
Following  the  method  of  Reddy,  we  attempted  to  synthesise  a  3,5-dichloro-1H-
pyrrole-2,4-dicarbonitrile 162. N-Acetylglycine 148 was subjected to the Vilsmeier 
reaction, with DMF and POCl3, and the reaction mixture was subsequently treated in 
situ with hydroxylamine hydrochloride at room temperature. Analysis of the product 
indicated  that  instead  of  the  expected  dicarbonitrile  162,  only  3,5-dichloro-4-
(hydroxyiminomethyl)-1H-pyrrole-2-carbonitrile  157  was  obtained,  in  45%  yield, 
Scheme 41.  
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Scheme 41. Reagent and conditions; a) POCl3, dry DMF, ∆; b) NH2OH, HCl,   
  DCM, 0 
oC, 45% 
 
All  attempts  at  the  preparation  of  dicarbonitrile  162  failed,  even  with  the  alkyl 
substituted pyrroles (methyl, ethyl) and despite varying the reaction conditions. In 
addition, the direct transformation of aldehydes to nitriles with iodine in ammonia / 
water (Fang-method) did not result in any new compounds. 
 
2.3.2 Transformation of aldehydes into amides 
 
An extensive literature search has shown that there are only a few efficient methods 
for  the  transformation  of  aldehydes  into  amides.  Aromatic  aldehydes  can  be 
converted to the corresponding amides in a rapid reaction, in two steps, by reaction 
with a primary or secondary amine in the presence of an equimolar amount of N-
bromosuccinimide (NBS) and AIBN, Scheme 42.
9 The aldehyde 163 and NBS were 
dissolved in CCl4 and heated in the presence of a catalytic amount of AIBN as a  
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radical  initiator.  A  rapid  reaction  resulted  in  the  formation  of  a  precipitate  of 
succinimide and the acid bromide 164, which is thermally and moisture sensitive. It is 
normally easier, therefore, to use the acyl bromides 164 directly to prepare amides 
165 without isolation, Scheme 42. 
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Scheme 42.
9 Preparation of amide from aldehyde
 
 
Following the previous method, methyl substituted pyrrole 42 was dissolved in CCl4 
in the presence of NBS and AIBN and refluxed for 15 minutes, then n-butylamine 
was added dropwise at 0 
oC. After stirring at room temperature for 20 minutes, N-
butyl-3,5-dichloro-4-formyl-1-methyl-1H-pyrrole-2-carboxamide  166  was  obtained, 
Scheme 43. Evidence for the formation of the amide was obtained from both the 
1H 
NMR and 
13C NMR spectra. The aldehyde signal was obvious at ʴ9.66, and a broad 
signal indicated the presence of an NH at ʴ8.21. New CH2 signals appeared at ʴ3.20, 
ʴ1.47 and ʴ1.34, and a CH3 peak at ʴ0.89. The 
13C NMR spectrum showed the new 
carbon signals for the butyl group at ʴ14.1, ʴ19.9, ʴ31.5, and ʴ39.2. We attempted to 
try different  amines,  including allylamine  and  N-methylallylamine  but  the highest 
yield was only 6%, making it clear that an alternative approach to other substituted 
amines was required. 
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Scheme 43 
 
2.3.3 Reduction of the aldehyde groups 
 
Aldehydes can be reduced to primary alcohols by a number of reducing agents
10 and 
the  utility  of  sodium  cyanoborohydride  as  a  selective  reducing  agent  has  been 
reviewed. The reduction under neutral conditions, in water or methanol, is negligible, 
however, at pH 3-4 the rate of reduction is sufficiently rapid.
11 The reduction of 1-
phenyl-2-chloro-3-formylindole  167  with  sodium  borohydride  yields  the 
corresponding alcohol 168, Scheme 44.
12  
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Scheme 44.
12 
 
Beller et al. were interested in the synthesis and further functionalisation of indoles as 
they occur in numerous natural products and are important building blocks for several 
alkaloids.
13  They  reported  a  simple  one-pot  synthesis  of  indole-2,3-dicarboxylates 
from arylhydrazines and acetylene dicarboxylates and, in continuation of this work, 
they  investigated  the  unreported  chemoselective  reduction  of  these  indoles.
14  The  
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reduction of indole-2,3-diester 169 with either NaBH4 or NaCNBH3 did not result in 
the  expected  products,  only  starting  material  was  recovered.  The  reaction  with 
LiAlH4  afforded  a  complex  mixture  of  different  products.  Next,  these  workers 
decided to investigate this reduction in the presence of 2.0 equiv. of DIBAL-H, which 
resulted in the 2-formylindole-3-carboxylate 170 in 90% yield. Using 2.5 equiv. of 
DIBAL-H, however, led to the formation of a major product 171 in 60% yield and the 
aldehyde  170  was  only  obtained  in  minor  quantities.  Reductive  amination  of  2-
formylindole 170 with benzylamine in the presence of NaBH3CN gave the secondary 
amine 172 in 80% yield, Scheme 45. 
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Scheme 45.
14 Reduction of indole derivatives
 
 
We attempted the reduction of the aldehyde groups in the parent pyrrole  41 with 
metal hydrides. Lithium aluminium hydride gave an uncharacterisable product upon 
reaction with either N-methylpyrrole 42 or N-ethylpyrrole 43, while the reduction 
with sodium borohydride in methanol gave the products 173, 174, respectively, from  
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reduction  of  both  aldehyde  groups  (even  when  using  only  0.25  equivalents  of 
NaBH4), Scheme 46.  
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Scheme 46. Reduction of aldehyde groups using NaBH4 
 
The structure of diol 174 was confirmed by its infra-red spectrum, with a broad OH 
stretch at 3338 cm
-1, whilst the 
1H NMR spectrum showed a broad signal for the OH 
groups at ʴ4.71 and ʴ5.13, the expected triplet at ʴ1.25 and quartet at ʴ4.01 (J = 7.2 
Hz) for the ethyl group and two singlets for the CH2 protons at ʴ4.24 and ʴ4.42. The 
spectroscopic data for compound 173 showed similar results but, in this case, high 
resolution mass spectrometry did not confirm the formation of the expected product. 
Selective reduction of the 2-formyl group in the methyl- 42 and ethyl-substituted 
pyrroles 43 was, however, achieved, using sodium cyanoborohydride
15 in methanol 
(pH  3-4),  to  give  the  mono-hydroxymethylpyrrolecarboxaldehydes  176  and  177, 
respectively, Scheme 47. 
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Scheme 47. Selective reduction of aldehyde using NaBH3CN  
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The structure of aldehyde 176 was confirmed by high resolution mass spectrometry 
and 
1H NMR spectroscopy, with singlets at ʴ3.72, ʴ4.54 and ʴ9.84 for the CH3, CH2 
and CHO protons, together with a broad signal at ʴ5.38 for the OH. From the HMBC 
spectrum it was obvious that the 2-formyl group had been reduced to the alcohol, 
since  the  2D  spectrum  showed  that  the  CH2  had  connectivity  to  C-2  and  C-3. 
Compound 177 was identified in a similar manner. 
 
2.3.4 Oxidation of aldehyde groups 
 
Oxidation  of  aldehydes  into  the  corresponding  carboxylic  acids  has  been  an 
extensively studied area, and a variety of methods have been reported using many 
different reagents.
16  
Andreani et al. reported the oxidation of N-benzyl-2-chloroindole-3-carboxaldehydes 
178 to the corresponding carboxylic acids  179 with potassium permanganate in a 
mixture of acetone-water,
17 Scheme 48, whilst Liebscher and Showalter et al. used 
sodium chlorite / H2O2 for the conversion to the 3-carboxylic acid.
18  
 
N Cl
CHO
R
R1
R2
N Cl
COOH
R
R1
R2 KMnO4
R3 R3
178 179 (60-70%)
acetone - H2O
   r.t., 5-16 h
R = H, Cl
R1 = H, OCH3
R2 = H, CH3
R3 = Cl, OCH3, OH, OAc  
Scheme 48.
17 Oxidation of compound 178 to the corresponding carboxylic acid  
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The oxidation of several ʱ-formylpyrroles to pyrrolin-2-ones was carried out by the 
Scott  research  group  using  H2O2  under  mild  conditions.
19  In  2007,  Rhee  et  al. 
investigated the oxidation of various aldehydes under mild and facile conditions using 
a Pd/C catalyst, sodium borohydride and potassium hydroxide in aqueous methanol.
20 
Regioselective oxidation of the pyrrole-2-carboxaldehydes 180 to the corresponding 
3-pyrrolin-2-ones 181 was achieved by Elky et al., utilising hydrogen peroxide and 
sodium  bicarbonate  at  ambient  temperature,  Scheme  49.
21  This  reaction  possibly 
proceeds  via  a  Bayer-Villiger-type  oxidation  of  the  formyl  group,  followed  by 
hydrolysis of the intermediate formate ester. 
 
N
H
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R2 R1
N
H
O
R2 R1
H2O2
Na2CO3
r.t. (3-7 days)
180 181  
Scheme 49.
21 
 
After the successful selective reduction of compound 174, 176, 177 we next turned 
our attention to the investigation of the selective oxidation of the 2-formyl group of 
the unsubstituted pyrrole 41. The reaction with KMnO4 in aqueous acetone did not 
result in the expected product 182, and only starting material was obvious from the 
1H NMR spectrum. Assuming that the reason for this failure was the unprotected 
nitrogen, we decided to solve this problem by introduction of a protecting group. 
After an extensive literature search, the oxidation in the presence of an EWG acyl 
group afforded the expected acid in low yield (3%),
17 so we decided to investigate the 
reaction with the alkyl substituted pyrroles. The initial attempt involved the reaction  
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of pyrrole 42 with KMnO4 in aqueous acetone at room temperature, in the presence of 
crown  ether  but  after  acidic  work  up,  no  product  was  observed.  Subsequent 
experiments  at  reflux  temperature  without  using  the  crown  ether  resulted  in  the 
formation  of  the  desired  monocarboxyl-pyrrolecarboxaldehyde  183.  The  reaction 
with  ethyl  substituted  pyrrole  43  always  gave  a  mixture  of  the  mono-  184a  and 
dicarboxylic acids 184b, Scheme 50. 
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41 R = H
42 R = Me
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
18-crown-6
KMnO4
acetone / H2O
 
 
 
Scheme 50 
 
 
Broad stretches in the IR spectrum at 2588 and 1662
 cm
-1 for the OH and C=O bonds 
respectively, together with a high resolution mass spectrum, confirmed the presence 
of the mono-carboxylic acid. The 
1H NMR spectrum also gave confirmation of the 
structure, with two singlets at ʴ3.87 and ʴ9.72, for the CH3 and CHO, together with a 
broad signal at ʴ13.15 for the OH proton. When the reaction was carried out with four 
equivalents  of  KMnO4,  oxidation  of  both  aldehydes  gave  185,  Scheme  51,  with 
elemental analysis confirming the desired product and the 
1H NMR spectrum also 
showing that the signal from the protons of both aldehyde groups had disappeared. 
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Scheme 51 
 
 
Micheli and co-workers have reported the synthesis and biological properties of 3,5-
dimethylpyrrole-2,4-dicarboxylic  acid-2-propyl  ester
22  and  their  excellent  results 
inspired them to continue their study on this class of pyrroles. They then prepared 
several pyrrole derivatives starting from compound 186, Scheme 52.
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Scheme 52.
23 Reagent and conditions; a) POCl3, DMF, CH2Cl2, from 0
oC to r.t., 50%; 
b) NaBH4, MeOH, 0
oC to r.t., 95%; c) CH3COCl, Py, THF, r.t., 95%; 
d) NaOClO, CH3CN, H2O, r.t., 70%; e) (i) NaCNBH3, R´NH2, THF, 
0
oC, 30%; (ii) H2, Pd/C, 95%; f) R´´´NH2, DCC, THF, r.t., 80%; g) 
(CF3CO)2O, r.t., R´´OH, THF, 80%  
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2.3.4.1 Synthesis of amides from carboxylic acid 
 
Having successfully devised a selective oxidation, we next turned our attention to the 
preparation of a number of pyrrole derivatives, starting from 3,5-dichloro-4-formyl-1-
methyl-1H-pyrrole-2-carboxylic acid. We had already studied the transformation of 
aldehydes into amides in a rapid reaction in the presence of NBS and AIBN in 45% 
yield, so we now aimed to improve the yield of the amide through the conversion of 
the  carboxylic  acid  into  the  corresponding  amide  since  this  is  a  well  established 
functional group transformation in organic chemistry.
24  
The monocarboxyl-pyrrolecarboxaldehyde 183 and SOCl2 were refluxed in toluene 
for 4 hours and this reaction resulted in the formation of the acid chloride. Without 
isolation of the unstable intermediate, the crude mixture was dissolved in DCM then a 
solution of n-butylamine and TEA in DCM was added dropwise at 0 
oC. After stirring 
at room temperature for 2 hours, N-butyl-3,5-dichloro-4-formyl-1-methyl-1H-pyrrole-
2-carboxamide  187e  was  obtained,  but  the  overall  yield  was  only  37%.  We  then 
investigated the reaction of the methyl substituted pyrrole in the presence of different 
amines, giving the corresponding derivatives 187a-d in moderate yields. The results 
are  summarized  in  Table  1.  The  reaction  of  methylallylamine  did  not  give  any 
characterisable product, Scheme 53. 
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187 183
2. TEA, DCM
R-NH2
 
Scheme 53  
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Characterisation  of  the  compounds  was  achieved  by  elemental  analysis  or  high 
resolution mass spectra, and 
1H NMR and 
13C NMR spectroscopy was also used to 
confirm the structures. 
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Entry  Amine  Product  Yield (%)
a,b 
a  PhNH2 
 
 
80 
b  NH[CH(CH3)2]2 
 
 
68 
c  NH2CH2CHCH2 
 
 
54 
d  NH2Bu
 
N
Cl OHC
Cl
CH3
O
NH
Bu
 
 
68 
e  CH3NHCH2CHCH2 
 
 
0 
 
Table 1.  a)  (i)  Reaction  conditions;  pyrrole  183  (1.35  mmol),  SOCl2  (0.49  ml), 
toluene, reflux, 4h; (ii) CH2Cl2, amine (2.01 mmol), TEA (0.19 ml), r.t., 0
oC 
b)  Isolated yield 
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2.3.4.2 Synthesis of esters from carboxylic acids 
 
Effective  esterification  of  carboxylic  acids  with  alcohols  is  one  of  the  most 
fundamental reactions in organic synthesis.
25 
The preparation of the corresponding ester derivatives of acid 183 was achieved using 
SOCl2,  and  dry  MeOH  or  EtOH  to  give  the  expected  compounds  188  and  189 
respectively. Further oxidation of the 4-formyl-2-carboxylic acid methyl ester 188 
resulted in the dicarboxylic acid monoester 190, Scheme 54. The structure of these 
esters was confirmed by spectroscopic methods and elemental analysis. The 
1H NMR 
spectrum of compound 189 showed the presence of the ethyl group, with the expected 
triplet at ʴ1.35 and quartet at ʴ4.35. The signal for the N-CH3 appeared at ʴ3.93 and 
the CHO proton at ʴ9.76.  
The reaction of the carboxylic acid with benzyl alcohol resulted in the benzyl 3,5-
dichloro-4-formyl-1-methyl-1H-pyrrole-2-carboxylate 191 in 38%. Evidence for the 
formation of the product 191 was given by elemental analysis and spectroscopic data. 
The 
1H NMR spectrum gave the conformation of the structure, with the appearance of 
new aromatic protons at ʴ7.41 and a singlet at ʴ5.34 which can be attributed to the 
CH2 protons. The 
13C NMR  also  confirmed the structure of the product with  the 
presence of aromatic carbons at ʴ128.3, ʴ128.5, ʴ128.9 and ʴ136.1 respectively. 
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Scheme 54 
 
2.4 Reactions of two electrophilic centres 
 
There are two functional groups in 3-chloroindole-2-carboxaldehyde 192 which are 
close enough to each other to allow the reaction of both groups simultaneously and 
Yavari and co-workers have observed an interesting reaction between 3-chloroindole-
2-carboxaldehyde 192 and dialkyl acetylenedicarboxylates 193, in the presence of 
triphenylphosphine, which proceeds smoothly, in DCM at ambient temperature, to 
give  dialkyl  9-chloro-3H-pyrrolo[1,2-a]indole-2,3-dicarboxylates  194  in  96-98% 
yields, Scheme 55.
26  
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Scheme 55.
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A one-pot synthesis was subsequently attempted on the parent pyrrole 41 following 
the  Yavari  method.  The  reaction  of  3,5-dichloro-1H-pyrrole-2,4-dicarboxaldehyde 
with  acetylenic  esters  193  a-e,  in  the  presence  of  triphenylphosphine,  proceeded 
smoothly  in  DCM  at  ambient  temperature,  to  produce  5,7-dichloro-6-formyl-3H-
pyrrolizine-2,3-dicarboxylic acid esters 195 a-e, Scheme 56. The reaction with the 
methyl and ethyl esters results in the products 195a and 195b in moderate  yield, 
while using the  t-butyl  ester  gave no  isolated  product,  only starting material was 
recovered. 
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Scheme 56 
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On the basis of the chemistry of trivalent phosphorus nucleophiles, it is reasonable to 
assume that the initial addition of triphenylphosphine to the acetylenic ester, followed 
by protonation of the 1:1 adduct by the NH of pyrrole 41 will result in compound 
195.  The  nitrogen  atom  of  the  conjugate  base  of  the  pyrrole  will  attack  on  the 
positively charged ion to form phosphorane 196, which undergoes an intramolecular 
Wittig reaction to result in the bicyclic pyrrole derivative 195, Scheme 57.  
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Scheme 57 
  
The spectroscopic data confirmed the structure of compound 195a, with the 
1H NMR 
spectrum  exhibiting  a  single  sharp  singlet  for  the  two  methoxy  group  (at  ʴ3.78) 
protons. The two CH groups appear as two doublets, at ʴ6.04 and ʴ7.85, with allylic 
coupling of J = 1.8 Hz. The 
13C NMR spectrum of pyrrolizine 195a includes a signal 
at ʴ65.1 for the N-CH moiety. The 
1H and 
13C NMR spectra of 195b are similar to 
those of the methyl derivative 195a. 
Schulte et al. reported the reaction of 2-chloroindole-3-carboxaldehyde 197 with o-
phenylenediamine  in  MeOH  to  produce  5,6-dihydrobenzo[2,3][1,4]diazepino[5,6-
b]indole 198. Treatment of the same indole with an excess of aniline results in the 
corresponding 2-phenylaminoindole 199, while the reaction with thiourea gives 2-
imino-9H-1,3-thiazino[6,5-b]indole  hydrochloride  200  in  excellent  yield  (97%), 
Scheme 58.
27   
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Scheme 58.
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Suchy  and  his  research  group  decided  to  study  indole  phytoalexins  since  several 
isolated  compounds  of  this  family  have  been  shown  to  have  antifungal  and 
antitumour  activity.
28  These  workers  were  interested  in  the  synthesis  of 
cyclobrassinon  since  its  isolation  from  plants  is  relatively  difficult  and  time 
consuming,  and  a  synthetic  route  to  cyclobrassinon  had  not  previously  been 
described.
29 Further work was focused on a synthesis of cyclobrassinon analogues as 
interesting synthetic targets and on the investigation of their biological properties. 
The  acid  202  was  prepared  by  oxidation  of  2-chloroindole-3-carboxaldehyde  201 
with KMnO4 in aqueous acetone. Heating of this acid with PCl3 in benzene resulted in 
an unstable acid  chloride which, after immediate treatment with  KSCN, gave the 
stable isothiocyanate 203. The reaction of this isothiocyanate with methanol, ethanol 
or 2-propanol  afforded  thiocarbamoyl  compounds  204, which  were  cyclised upon 
treatment with Et3N and afforded 205, Scheme 59.
29  
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Scheme 59.
29 Total synthesis of phytoalexin cyclobrassinon. Reagent and conditions;  
a) KMnO4, acetone/water, r.t.; b) PCl3, benzene, 85-90
oC; c) KSCN, 
acetone, r.t.; d)  MeOH or EtOH or i-PrOH, 60
oC; e) Et3N, r.t., 1-2h
 
 
Following  the  Suchy  method,  we  attempted  to  synthesise  compound  209  since  a 
literature search did not disclose any similar analogues. The synthesis of the expected 
compound  209  was  achieved  by  starting  from  the  monocarboxyl-
pyrrolecarboxaldehyde  183,  which  was  prepared  by  the  oxidation  of  the  methyl 
substituted pyrrole 42  with KMnO4. The acid  chloride 206 was then prepared by 
heating acid 183 with SOCl2 in toluene, and treatment of the acid chloride 206 with 
KSCN  in  acetone  afforded  the  surprisingly  stable  isothiocyanate  207.  The 
conformation of the identity of this product was obtained by the IR spectrum, which 
contained  a  peak  for  the  N=C=S  group  at  1954  cm
-1.  The  next  step  was  the 
nucleophilic addition of the ethanol or methanol to the crude isothiocyanate to give 
the corresponding thiocarbamate 208, Scheme 60. 
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Scheme 60 
 
Characterisation  of  the  3,5-dichloro-4-formyl-1-methyl-1H-pyrrole-2-carbonyl) 
thiocarbamic  acid  O-ethyl  ester  208  was  achieved  by  high  resolution  mass 
spectrometry and spectroscopic data. The 
1H NMR spectrum showed a broad signal 
for the NH group at ʴ9.22, while the 
13C NMR spectrum showed the C=S and C=O 
groups  at  ʴ155.3  and  ʴ177.6,  respectively.  We  hoped  that  the  reaction  of  the 
thiocarbamate 208 with triethylamine would result in the bicycle 209, but the analysis 
of the reaction mixture gave no conclusive evidence for this structure, therefore the 
cyclisation to the bicycle requires further investigation. 
Ivachtchenko et al. were interested in the synthesis of heteroaryl-fused carboxamide 
derivatives  of  3(5)-oxo-1,4-thiazepine  heterocycles
30  since  the  1,4-thiazepine 
fragment is present several natural and synthetic biologically active compounds. They 
initially described two synthetic routes for the preparation of bifunctional reagent 211 
and its use in the modified four component Ugi reaction. According to method A, the 
reaction of chloroindole 201 with methyl mercaptoacetate, in the presence of K2CO3  
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in DMF, gave the intermediate ester 210, which was then hydrolysed to the expected 
aldehyde-substituted  acid  211.  The  relatively  low  overall  yield  of  this  reaction 
inspired them to try an alternative route for the preparation of acid  212 and they 
found  that  the  reaction  of  chloroindole  201  with  disodium  mercaptoacetate  in 
methanol afforded the desired product in better yield and in fewer steps, Scheme 61. 
In a continuation of this study, these workers investigated a synthetic approach to the 
3(5)-oxo-1,4-thiazepine  212  derivatives.  The  reaction  of  acid  211  with  different 
amines and isocyanides in methanol led to the desired product 212. 
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Scheme 61.
30 Synthesis of heteroaryl fused 3(5)-oxo-1,4-thiazepine heterocycles
 
 
We next turned our attention to the investigation of the synthesis of pyrrole fused 
thiazepins  using  the  modified  Ugi  reaction.  Following  the  Ivachtchenko  method, 
formation  of  the  bifunctional  reagents  was  initially  attempted,  using  the  methyl  
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substituted pyrrole 42 and methyl mercaptoacetate, in the presence of K2CO3 in DMF. 
The intermediate ester was then hydrolysed to the expected acid 213, Scheme 62, 
Method A, but analysis of the sample did not show any evidence for the formation of 
the desired product. 
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Scheme 62. Reagent and conditions; Method A: HSCH2CO2CH3, DMF, K2CO3, 35 
oC, 3h then KOH, EtOH, 30 
oC, 1.5h; Method B: NaSCH2CO2Na, dry 
DMF, 4 h, ∆  
 
An  alternative  route  involved  the  reaction  of  substituted  pyrrole  42  with  the 
previously prepared disodium mercaptoacetate in DMF, to afford the 4-chloro-3,5-
diformyl-1-methyl-1H-pyrrole-2-ylsulfanylacetic  acid  213,  Scheme  62,  Method  B, 
but  despite  the 
1H  NMR  and 
13C  NMR  spectrum  suggesting  the  presence  of  the 
expected compound, the high resolution mass spectrum did not confirm the structure 
and the subsequent reaction was abandoned. 
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2.5 Dehalogenation 
 
Dehalogenation  of  aromatic  halides  is  an  important  chemical  transformation  in 
organic synthesis
32 and a great number of methods have been developed over the 
years
33 but there are only a few efficient methods for the dechlorination of aromatic 
chlorides, as it is well known that they are much less reactive than aromatic bromides 
and iodides. 
Heck et al. reported that aromatic halide groups can be removed at 50-100 
oC by 
palladium-catalysed reduction with triethylammonium formate, Scheme 63.
34  
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Scheme 63.
34 
 
Sajiki and co-workers described a mild and efficient one-pot method for the Pd/C-
catalysed  hydrodechlorination  of  aromatic  chlorides  at  room  temperature  under 
ambient  hydrogen  pressure  and  in  the  presence  of  Et3N,  which  involves  a  single 
electron transfer (SET),
 Scheme 64.
35 A few years later these workers published an 
extensive  study  outlining  the  optimised  reaction  conditions,  in  which  they 
investigated various nitrogen-containing bases, and also optimised the solvent and the 
reaction temperature.
36  
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36 Hydrodechlorination of aromatic chloride 
 
A  possible  mechanism  for  the  dehalogenation  of  aromatic  chlorides  (Pd/C-Et3N) 
involves the SET mechanism – the initial step is the single electron transfer from 
Et3N to the palladium activated benzene ring of A, which results in the anion radical 
B. Elimination of the chloride anion and then hydrogenation of the benzene radical 
will result in the dehalogenated benzene ring C, Scheme 65. 
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Scheme 65. Possible mechanism of the hydrodechlorination 
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The  complete  dechlorination  of  3,5-dichloro-1H-pyrrole-2,4-dicarboxaldehyde  41 
was  carried  out  with  10%  Pd/C  and  Et3N  in  MeOH  and  gave  1H-pyrrole-2,4-
dicarbaldehyde 218 in 4 hours at 65 
oC, in 70% yield, Scheme 66. 
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Scheme 66 
 
Characterisation of the dialdehyde 218 was achieved from the spectroscopic data; the 
1H NMR spectrum of 1H-pyrrole-2,4-dicarboxaldehyde 218 showed the presence of 
two new CH signals, at ʴ7.42 and 7.97, with a coupling constant of J = 2.1 Hz, thus 
indicating  the  disappearance  of  the  chloro  substituents.  The  HH-COSY  spectrum 
(Figure  20)  showed  that  H-3  is  coupled  to  H-5  and,  in  addition,  2  CH  signals 
appeared in the DEPT 135 spectrum. 
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Figure 20. HH-COSY spectrum of 1H-pyrrole-2,4-dicarboxaldehyde 218 (300 MHz, 
DMSO-d6) 
 
The reaction of the methyl substituted pyrrole 42 under the same conditions resulted 
in the selective dehalogenation at C-5 in 6 hours, in high 94% yield, Scheme 67. 
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Scheme 67 
 
 
The structure of the monochloropyrrole 219 was confirmed by elemental analysis and 
spectroscopic data. The 
1H NMR spectrum showed the appearance of H-5 at ʴ7.36  
85 
and the DEPT 135 spectrum showed a new CH signal at ʴ132.7. It is obvious from 
the HMBC spectrum that the dehalogenation has occurred at the C-5 position since 
the H-5 proton shows connectivity to C-4 (at ʴ127.0) and the CH3 (at ʴ38.4), Figure 
21.  
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Figure 21. HMBC spectrum of compound 219 (300 MHz, CDCl3) 
 
 
 
2.6 Synthesis of pyrrole-2,4-dicarboxylate derivatives 
 
 
Matsumoto et al. investigated the reaction of alkyl isocyanoacetate 221 with a variety 
of aliphatic and aromatic aldehydes 220 in THF, using 1,8-diazabicyclo[5.4.0]undec-
7-ene (DBU) as the base, Scheme 68.
37  
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Scheme 68.
37 Synthesis of pyrrole-2,4-dicarboxylate derivatives 222 by reaction of 
aldehydes and isocyanoacetates
 
 
Bhattacharya and his group also described an efficient one-pot synthesis of pyrrole-
2,4-dicarboxylate derivatives 222
38 by treatment of a mixture of acetylenic esters 223 
and ethyl isocyanoacetate 221 with KH in MTBE for 4-20 hours at room temperature. 
The pyrrole derivatives were obtained in good to excellent yields, Scheme 69. 
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Scheme 69.
38 Synthesis of pyrrole-2,4-dicarboxylate derivatives 222 from acetylenic  
esters 
 
Our initial idea was to synthesise diethyl 1H-pyrrole-2,4-dicarboxylate 226, following 
the  method  of  Matsumoto.  The  condensation  of  two  equivalents  of  ethyl 
isocyanoacetate  225  with  formaldehyde  224,  in  the  presence  of  DBU  in  THF, 
afforded  a  known  pyrrolodiester  226,  Scheme  70.  Comparison  of  the  analysis 
obtained with that of the analysis acquired from the original synthesis showed clearly  
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that the product was the desired pyrrolodiester. Next, we decided to investigate the 
selective halogenation of this pyrrole ester, since only a few examples exist in the 
literature.
39 The brominated pyrroles 227 and 228 were prepared from compound 226 
using NBS in THF at -78 
oC. On addition of 1 and 1.5 equivalents of NBS, it became 
evident that no reaction occurred. Using 2 equivalents of NBS we obtained the 5-
bromo-1H-pyrrole-2,4-dicarboxylic  acid  diethyl  ester  227  as  the  major  product, 
together with the dibromo derivative 228. In order to optimise the formation of the 
dibromo compound 228, and especially to obtain only the 3,5-dibromo-1H-pyrrole-
2,4-dicarboxylic  acid  diethyl  ester  228,  the  bromination  was  attempted  with  4 
equivalents of NBS, Scheme 70. Evidence for the formation of the expected product 
228 was given by the 
1H NMR spectrum, with the disappearance of the 2 CH signals 
at ʴ7.23 and ʴ7.47 and also the 
1H NMR spectrum of the monobromo compound 227 
showed a singlet of the H-3 at ʴ7.03.  
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Scheme 70. Selective halogenation of pyrrolodiester 226  
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2.7 Palladium catalysed cross-coupling reactions 
 
Heterocycles have been widely functionalised by using palladium(0)-catalysed cross-
coupling reactions
40 and metal catalysed carbon-carbon bond cross-coupling reactions 
play  an  increasingly  important  role  in  the  preparation  of  polyfunctionalised 
heterocycles, especially the Suzuki, Negishi, Stille and Sonogashira reactions. 
A typical cross-coupling reaction includes four major steps, Figure 22. The first step 
in this cycle is the oxidative addition of the halide component with a palladium(0)  
complex  to  give  a  palladium-(II)  species,  followed  by  metathesis,  and 
transmetallation to form an intermediate which must undergo isomerisation to the cis 
complex  before  reductive  elimination  can  occur.  The  final  step  is  the  reductive 
elimination of the desired products and the regeneration of the Pd(0) complex. 
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Figure 22. The general catalytic cycle of Pd(0)-catalysed cross-coupling reactions 
  
89 
2.7.1 Suzuki reaction 
 
Bach and Schroter investigated the regioselective Suzuki cross-coupling reactions of 
halogenated  nitrogen-,  oxygen-,  and  sulfur-containing  heterocycles,  Scheme  71.
41 
They  focused  on  the  optimization  of  the  reaction  conditions  for  ethyl  2,3,4-
tribromopyrrole-5-carboxylate 229 and found Pd(PPh)3, Pd2(dba)3/P(2-furyl)3 to be 
the best catalysts for the cross-coupling reaction to give phenylpyrrole 230. They also 
established  the  optimum  reaction  temperature  to  be  between  130-150 
oC,  in  the 
presence of Cs2CO3 as base and the best solvent system to consist of an aromatic 
hydrocarbon (xylene or mesitylene), ethanol and water in a ratio of 5:1:1.
42  
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Scheme 71.
42 Suzuki cross coupling reaction of polyhalogenated pyrrole 
 
Langer and his research group were interested in the palladium(0)-catalyzed cross-
coupling reactions of tetrahalopyrroles 231 as this had not previously been reported 
because of the unstable nature of these compounds.
43 These workers demonstrated 
that  the  stoichiometry,  temperature,  solvent  and  the  presence  of  water  play  an 
important role in terms of yield, Scheme 72. They reported the best yields (57-78%) 
were obtained using a solvent mixture (DMF/toluene/EtOH/H2O = 4:1:1:1) and an 
increased amount of catalyst (10-20 mol%).   
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Scheme 72.
43 Synthesis of 2,5-diaryl-3,4-dibromo- and tetraarylpyrroles, Reagent and 
conditions;  a)  Ar
1-B(OH)2,  Pd(PPh3)4  (10  mol%),  K3PO4,  Toluene-
H2O (5:1), 90 
oC; b) Ar
2-B(OH)2, Pd(PPh3)4 (20 mol%), K3PO4, DMF, 
Toluene, EtOH, H2O (4:1:1:1), 90 
oC, 96 h; c) Ar-B(OH)2, Pd(PPh3)4 
(20 mol%), K3PO4, DMF, Toluene, EtOH, H2O, (4:1:1:1), 90 
oC, 96 h; 
 
Handy  and  co-workers  reported  an  unusual  dehalogenation  of  4-bromopyrrole-2-
carboxylate.
44 The coupling reaction with phenylboronic acid resulted in a mixture of 
the desired coupling adduct (55%) and the debrominated compound (28%) but when 
the N-protected pyrrole 232 (BOC, TIPS, alkyl) was reacted as the starting material 
with  2-3  equivalents  of  boronic  acid,  the  expected  compound  233  was  the  main 
product and only a slight amount (<5%) of dehalogenated compound was obtained, 
Scheme 73.  
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Scheme 73.
44 Suzuki coupling reaction of N-protected pyrrole 
 
Handy and Zhang later established a simple guide for predicting regioselectivity in 
the  coupling  of  polyheteroaromatics  using  a 
1H  NMR  method  in  which  they 
investigated a series of dibromo compounds under Suzuki coupling and found that the 
more electron deficient site undergoes coupling first, Scheme 74.
45 
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Scheme 74.
45 
 
2.7.2 Preparation of biaryl compounds 
 
The Suzuki coupling reaction is one of the most extensively studied methods for the 
preparation  of  biaryls  and  several  applications  have  been  described  in  pyrrole 
chemistry.
46 We were also interested in the study of the palladium-catalysed C-C 
bond forming reactions of 3,5-dihalogenated pyrroles. Our initial study involved the  
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coupling of mono-bromosubstituted pyrrole 227 with commercially available boronic 
acids, Scheme 75. Our initial attempt involved the conversion of bromopyrrole 227 to 
the corresponding diethyl-5-phenyl-1H-pyrrole-2,4-dicarboxylate with phenylboronic 
acid in the presence of Pd(OAc)2, PPh3 and K2CO3. Following the reaction by TLC 
did not show any expected product and only starting material was observed. A repeat 
of the reaction was attempted by changing the reaction solvent and base, but again, 
only  starting  material  was  recovered.  We  thus  assumed  that  the  problem  was 
associated with the catalyst, therefore, the experiment was repeated in the presence of 
Pd(PPh3)4 and fortunately, TLC indicated the appearance of new compound. As a 
result of the optimisation of the reaction, we identified Pd(PPh3)4 as a good catalyst 
for  the  cross-coupling  reactions  and  Na2CO3  was  used  as  the  base  since  other 
carbonates,  such  as  K2CO3,  Cs2CO3,  did  not  promote  the  reaction.  The  coupling 
reaction of mono- and dibromopyrroles 227 and 228 was then carried out under the 
optimised Suzuki conditions with various boronic acids, Table 2. We hoped that by 
using carefully controlled conditions and equimolar quantities of phenylboronic acids, 
a regioselective Suzuki-Miyaura cross–coupling reaction with the dibromide might 
occur. Unfortunately, when equimolar quantities of the substrate were heated at 90 
oC 
a complex mixture of mono- and dibromo compounds was produced. 
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Scheme 75. Suzuki reaction of bromo-substituted pyrrole  
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Starting 
Material    R
1  R
2  Boronic acid  Time  Product  Yield (%) 
227  H  Br 
 
 
14h  234a  58%
a 
227  H  Br 
 
 
6h  234b  88%
a 
227  H  Br 
 
 
18h  234c  0%
a 
227  H  Br 
 
 
18h  234d  0%
a 
228  Br  Br 
 
 
9h  235a  68%
b 
228  Br  Br 
 
 
14h  235b  71%
b 
 
 
 
Table 2. Suzuki products 234-235. a) using 1.2 equivalents of boronic acid, b) using 3 
equivalents of boronic acid 
 
 
B(OH)2
B(OH)2
OCH3
OCH3
B(OH)2
NO2
B(OH)2
OH
B(OH)2
B(OH)2 
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All the structures were confirmed by NMR and IR spectroscopy and high resolution 
mass spectrometry or elemental analysis.  
 
The  Suzuki  reaction  was  also  successfully  carried  out  on  the  chloro  substituted 
pyrrole 236, using the same conditions as above, Scheme 76, and the structure of the 
compounds was again confirmed by high resolution mass spectrometry and 
1H and 
13C  NMR  spectroscopy;  new  aromatic  signals  appeared  on  the 
1H  spectra  of 
compound 237a at ʴ7.38 and ʴ7.46 as multiplets 
 
N
OHC
CHO R1
R2
CH3
N
OHC
CHO R3
R4
CH3
ArB(OH)2
PdPPh3, DMF
Na2CO3, H2O

236a R1 = R2 = Cl
236b R1 = H, R2 = Cl
237a R3 = R4 = Ph
237b R3 = H, R4 = Ph 
Scheme 76 
 
2.8 Wittig reaction 
 
Rambaldi et al. investigated the synthesis of indolecarboxylic acids as potential anti-
inflammatory  agents  and  they  reported  a  new  series  of  indoleacrylic  and 
methylacrylic  acids.
47  The  starting  aldehyde  238  was  reacted  with 
(carbethoxyethylidene)-  or  (carbethoxymethylene)triphenylphosphorane  in 
acetonitrile. Hydrolysis of the crude intermediate ester 239 resulted in the expected 
indolecarboxylic acid 240 in 70-80% yield, Scheme 77.   
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Scheme 77.
47 Synthesis of indolecarboxylic acids 
 
In addition to the synthesis of indolecarboxylic acids 240, we decided to attempt to 
prepare some pyrrole analogues. The appropriate aldehydes 41, 42, 43 were reacted 
under Wittig conditions for 9-12 h then, following the standard work up, the pyrrole 
acrylates 241, 242 were obtained in 35-64% yield, Scheme 78. 
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Scheme 78. Preparation of pyrrole acrylates. For definition of R, R
1 see Table 3. 
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Entry  R  R
1  Product
a,b  Yield (%) 
a  Me  H  241a
a  35% 
b  Me  H  242a
b  45% 
c  H  Me  241b
a  35% 
d  H  H  242b
b  39% 
e  Et  H  241c
a  43% 
f  Et  H  242c
b  64% 
 
 
Table 3. a) using 1.05 equivalent of Ph3P=CR
1CO2Et, b) using 1.75 equivalent of 
Ph3P=CR
1CO2Et 
 
Identification of the products was achieved by spectroscopic data and high resolution 
mass spectrometry. In the 
1H NMR spectra, the coupling constant (J = 16 Hz) of the 
olefinic protons indicated the trans configuration. 
 
 
 
 
 
 
2.9 Conclusion 
 
The  aim  of  this  part  of  the  work  was  to  investigate  the  chemoselectivity  of  the 
reactions of polyfunctional pyrroles with a range of reagents in order to examine the 
use of these multi-substituted pyrroles as starting materials for a range of pyrrole 
libraries and in the generation of other heterocyclic libraries.  
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First we studied the synthesis of 3,5-dichloro-1H-pyrrole-2,4-dicarboxaldehyde and 
we successfully improved the yield from 44% to 70% using continuously extraction. 
Next, we turned our attention to investigate the selective oxidation and reduction of 
the aldehyde functions in the parent pyrrole, selective transformation into nitrile and 
amide and also selective dehalogenation. We explored interesting reactions of the two 
electrophilic centres in the parent pyrrole which are close enough to each other to 
allow the reaction of both groups simultaneously.  
During this project we successfully synthesised pyrrole-2,4-dicarboxylate derivatives 
and we investigated the selective bromination of these pyrrole esters. 
The structures of the synthesised novel compounds were fully characterised by 
1H 
NMR, 
13C  NMR  and  IR  spectroscopy  and  high  resolution  mass  spectroscopy  or 
elemental analysis. We  used 2D-NMR  spectra to identify the regioisomers  which 
formed in the oxidation and reduction of these polyfunctionalized pyrroles, as well as 
the  products  of  other  reactions,  including  the  Suzuki,  Wittig,  and  dehalogenation 
reactions. 
 
 
 
 
 
 
 
 
 
  
98 
2.10 References  
 
1.  Balasundaram, B.; Venugopal, M.; Perumal, P. T.; Tetrahedron Lett. 1993, 34, 
4249. 
2.  Zaytsev,  A.  V.;  Anderson,  R.  J.;  Meth-Cohn,  O.;  Groundwater,  P.  W.; 
Tetrahedron, 2005, 61, 5831. 
3.  Smith, R. F.; Albright, J. A.; Waring, A. M.; J. Org. Chem., 1966, 31, 4100. 
4.  Judkins, B. D..; Allen, D. G.; Cook, T. A.; Evans, B.; Shardharwala, T. E.; Synth. 
Commun., 1996, 26, 4351. 
5.  a) Blatter, H. M.; Lukaszewski, H.; Stevens, G.; J. Am. Chem. Soc., 1961, 83, 
2203; b) Fizet, C.; Streith, J.; Tetrahedron Lett., 1974, 3187. 
6.  George, A.; Olah, T. K.; Synthesis, 1979, 112. 
7.  Nohara, A.; Umetani, T.; Sanno, Y.; Tetrahedron Lett., 1973, 22, 1995. 
8.  Reddy, G. J.; Latha, D.; Thirupathaiah, C.; Rao, S. K.; Tetrahedron Lett., 2004, 
45, 847. 
9.  a) Cheung, Y.-F.; Tetrahedron Lett., 1979, 3809; b) Istvan, E. M.; Abdelaziz, 
Mekhalfia; Tetrahedron Lett., 1990, 31, 7237. 
10. Hudlicky, M.; Reduction in Organic Chemistry, 1984. 
11. Borch, R. F.; Bernstein, M. D.; Durst, H. D.; J. Am. Chem. Soc., 1971, 93, 2897. 
12. Andreani, D. B.; Rambaldi, M.; Guarnieri, A.; J. Med. Chem., 1977, 20, 1344. 
13. Beller, M.; Sayyed, I. A.; Alex, K.; Tillack, A.; Schwarz, N.; Maichalik, D.; Eur. 
J. Org. Chem., 2007, 4525. 
14. Sayyed, I. A.; Alex, K.; Tillack, A.; Schwarz, N.; Spannenberg, A.; Maichalik, 
D.; Beller, M.; Tetrahedron, 2008, 64, 4590.  
99 
15. a) Clinton, F. L.; Synthesis, 1975, 135; b) Shinya, S.; Takeshi, S.; Etsuko, M.; 
Yasuo, K.; Tetrahedron, 2004, 60, 7899. 
16. a)  Hollingworth,  G.  J.;  Comprehensive  Organic  Functional  Group 
Transformations; Katritzky, A. R.; Meth-Cohn, O.; Rees, C. W.; Pattenden, G.; 
Eds.; Elsevier Science: Oxford, 1995; 5; b) Hudlicky, M.; Oxidations in Organic 
Chemistry;  ACS  Monograph  Series  186;  American  Chemical  Society: 
Washington, DC, 1990. 
17. Andreani, A.; Massimiliano, G.; Leoni, A.; Locatelli, A.; Morigi, R.; Rambaldi, 
M.; Roda, A.; Assimo, G.; Traniello, S.; Spisani, S.; Eur. J. Med. Chem., 2004, 
39, 785. 
18. a) Radspieler, A.; Liebscher, J.; Synthesis, 2001, 5, 745; b) Showalter, H.; Sercel, 
A. D., Leja, B. M.; Wolfangel, C. D.; Ambroso, L. A.; Elliott, W. L.; Fry, D. W.; 
Kraker, A. J.; Howard, C. T.; Lu, G. H.; Moore, C. W.; Nelson, J. M.; Roberts, B. 
J.; Vincent, P. W.; Denny, W. A.; Thompson, A. M.; J. Med. Chem., 1997, 40, 
413. 
19. Scott, I.; Clotilde, P. S.; Tetrahedron Lett., 2000, 41, 2825. 
20. Minkyung, L.; Yoon, C. M.; Gwangil, A.; Hakjune, R.; Tetrahedron Lett., 2007, 
48, 3835. 
21. Coffin, R. A.; Roussell, A. M.; Tserlin, E.; Pelkey, T. E.; J. Org. Chem., 2006, 71, 
6678. 
22. Micheli, F.; Fabio, R.; Cavanni, P.; Rimland, J. M.; Capelli, A. M.; Chiamulera, 
C.;  Corsi,  M.;  Corti,  C.;  Donati,  D.;  Feriani,  A.;  Ferraguti,  F.;  Maffeis,  M.; 
Missio, A.; Ratti, E.; Paio, A.; Pachera, R.; Quartaroli, M.; Reggiani, A.; Sabatini, 
F. M.; Trist, D. G.; Ugolini, A.; Vitulli, G.; Bioorg. Med. Chem., 2003, 11, 171.  
100 
23. Micheli, F.; Fabio, R.; Cavallini, P.; Cavanni, P.; Donati, D.; Faedo, S.; Maffeis, 
M.; Sabbatini, F. M.; Tarzia, G.; Tranquillini, M. E.; Bioorg. Med. Chem. Lett., 
2003, 13, 2113.  
24. a)  March,  J.;  Advanced  Organic  Chemistry;  John  Wiley  &  Sons:  New  York, 
1992; b) Comprehensive Organic Synthesis; Trost, B. M., Ed.; Pergamon Press: 
Oxford, 1991; Vol. 6. 
25. a) Crawley, M. L.; Goljer, I.; Jenkins, D. J.; Mehlmann, J. F.; Nogle, L.; Dooley, 
R.; Mahaney, P. E.; Org. Lett., 2006, 8, 5837; b) Minetto, G.; Raveglia, L. F., 
Sega, A.; Taddei, M.; Eur. J. Org. Chem, 2005, 5277; c) Huang, X.; Shen, R.; 
Zhang, T.; J. Org. Chem, 2007, 72, 1534. 
26. Yavari, M. A.; Sayahi, M. H.; J. Chem. Soc., Perkin Trans 1, 2002, 1517. 
27. Schulte, K. E.; Reisch, J.; Stoess, U.; Arch. Pharmaz., 1971, 523. 
28. Suchy, M.; Peter, K.; Milan, D.; Vladimir, K.; Aldo, A.; Juraj, A.; Tetrahedron 
Lett., 2001, 42, 6961. 
29. Suchy, M.; Peter, K.; Milan, D.; Vladimir, K.; Aldo, A.; Juraj, A.; Maddalena, R.; 
Maria, G.; Tetrahedron,  2002, 58, 9029. 
30. Ivachtchenko, A. V.; Ilyn, A. P.; Loseva, M. V.; Vvedensky, V. Y.; Putsykina, E., 
B.; Tkachenko, S. E.; Kravchenko, D. V.; Khvat, A. V.; Krasavin, M. Y.; J. Org., 
Chem., 2006, 71, 2811. 
31. Dehaen, W.; Bert, M.; Maarten, K.; Gitte, B.; Mario, S.; Tetrahedron, 2006, 62, 
6018. 
32. Hudlicky, M.; Comprehensive Organic Synthesis; Trost, B. M; Eds.; Pergamon: 
Oxford, 1991; Vol. 8. 
33. Alonso, F.; Beletskaya, I. P.; Yus, M.; Chem. Rev. 2002, 102, 4009. 
34. Heck, F.; Cortese, N. A.; J. Org. Chem., 1977, 42, 3491.  
101 
35. Sajiki, H.; Kume, A.; Hattori, K.; Hirota, K.; Tetrahedron Lett., 2002, 43, 7247. 
36. Sajiki,  H.;  Monguchi,  Y.;  Kume,  A.;  Hattori,  K.;  Maegawa,  T.;  Tetrahedron, 
2006, 62, 7926. 
37. a) Matsumoto, K.; Miyoshi, M.; Suzuki, M.; J. Org. Chem., 1974, 39, 1980; b) 
Fink, B. E.; Vite, G. D.; Mastalerz, H.; Kadow, J. F.; Kim, S-H.; Leavitt, K. J.; 
Du, K.; Crews, D.; Mitt, T.; Wong, T. W.; Hunt, J. T.; Vyas, D. M.; Tokarski, J. 
S.; Bioorg. Med. Chem Lett., 2005, 15, 4774.  
38. Bhattacharya, A.; Cherukuri, S.; Plata, R. E.; Patel, N.; Tamez, V.; Grosso, J. A.; 
Peddicord, M.; Palaniswamy, V. A.; Tetrahedron Lett., 2006, 47, 5481. 
39. a) Belanger, P.; Tetrahedron, Lett., 1979, 27, 2505; b) Balsamini, C.; Bedini, A.; 
Diamantini, G.; Spadoni, G.; Tontini, A.; Tarzia, G.; Di Fabio, R.; Feriani, R.; 
Reggiani, A.; Tedesco, G.; Valigi, R.; J. Med. Chem., 1998, 41, 808. 
40. Li, J. J.; Gribble, G. W.; Palladium in Heterocyclic Chemistry; Pergamon Press: 
Oxford, 2000. 
41. Bach, T.; Schroter, S.; Stock, S.; Tetrahedron, 2005, 61, 2245. 
42. Bach, T.; Schroter, S.; Synlett, 2005, 12, 1957. 
43. Dang, T. T.; Ahmad, R.; Reinke, H.; Langer, P.; Tetrahedron Lett., 2008, 49, 
1698. 
44. Handy, T. S.; Howard, B.; Jennifer, L.; Xiaolei, Z.; Yanan, Z.; Tetrahedron Lett., 
2003, 44, 427. 
45. Handy, T. S.; Yanan, Z.; Chem Commun., 2006, 299. 
46. a) Banwell, M. G.; Goodwin, T. E.; NG, S.; Smith, J. A.; Wong, D. J.; Eur. J. 
Org. Chem., 2006, 3043; b) Stanforth, S. P.; Tetrahedron, 1998, 54, 263. 
47. Rambaldi, M.; Andreani, A.; Locatelli, A.; Pifferi, G.; Eur. J. Med. Chem., 1994, 
29, 903.  
102 
 
 
 
 
Chapter Three 
 
Molecular Modelling 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Molecular Modelling                                                                          Chapter Three 
103 
 
3. Molecular Modelling 
 
3.1 Introduction  
 
During  the  last  decade  molecular  modelling  has  become  an  increasingly  popular 
method in drug discovery, partly due to the increased speed of today’s computers. 
This technique allows the computer aided generation of molecular structures, as well 
as the computation of molecular properties. As stated earlier, molecular modelling 
makes it possible to construct models of already known compounds, but molecules 
which have not yet been synthesised can also be investigated. The prediction of three-
dimensional  structures  and  molecular  surface  properties,  and  the  optimisation  of 
drug-receptor interactions by visual inspection can all be achieved through the use of 
molecular modelling.
1 
A  basic  theory  in  pharmacology  is  that  drugs  should  bind  to  a  specific 
macromolecule, called a receptor (which is present on either on the surface of the cell 
membrane or in the cytoplasm) and thus prevent cellular biochemical processes, for 
example enzymatic activity, DNA transcription or protein phosphorylation.  
Any potential molecules (e.g. drug, hormone, or neurotransmitter) which can bind to 
a receptor are called ligands. Receptors have an active site with a specific shape and 
accept only a specific type of ligand with the correct size, shape and charge into the 
binding  site,  which  contains  chemical  groups  that  direct  by  participating  in  the 
binding of the ligand.
2 The ligand can activate (agonist, e.g. nicotine or morphine) or 
deactivate (antagonist, e.g. naloxone) the receptor, and the activation can therefore 
increase or decrease a particular function of the cell.  Molecular Modelling                                                                          Chapter Three 
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3.1.1 Protein tyrosine kinase (PTK) 
 
In the past two decades a main topic of research in the area of cancer biochemistry 
has been the understanding of the role of PTKs in the uncontrolled proliferation of 
malignant cells and the development of inhibitors which are designed to block the 
activity of tyrosine kinases (unregulated activation of these enzymes can result in a 
number of different forms of cancer). Protein tyrosine kinases (PTK) are enzymes 
which catalyse the process of phosphate group transfer from a donor molecule, such 
as adenosine triphosphate (ATP), to an amino acid (tyrosine) residue of a protein, 
Scheme  79.  The  PTK  family  can  be  divided  into  two  major  groups,  the 
transmembrane receptor PTKs and the non-receptor PTKs.
3  
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Scheme 79. Phosphate group transfer 
 
3.1.2 Receptor tyrosine kinase (RTK) 
 
Receptor  tyrosine  kinases  play  an  important  role  in  different  cellular  functions 
including cell growth, cellular differentiation and angiogenesis.
4a All known RTKs 
contain a glycosylated extracellular ligand binding domain, which is connected to the Molecular Modelling                                                                          Chapter Three 
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cytoplasmic domain by a transmembrane region.
4b The signalling pathway involving 
receptor tyrosine kinases in normal cells starts with the binding of the ligand, e.g. 
hormone or growth factor, to a specific site within the extracellular domain of the 
receptor  and  this  initiates  the  binding  of  two  receptor  molecules  to  one  another 
(dimerisation).  The  nascent  signal  crosses  the  membrane  and  activates  the 
intracellular domain, which catalyses the phosphorylation of the tyrosine residue of a 
protein and modulates various cellular responses, e.g. angiogenesis.
4c Growth factors 
(e.g.  vascular  endothelial  growth  factors  (VEGFs),  platelet-derived  growth  factors 
(PDGFs)  and  fibroblast  growth  factors  (FGFs))  are  the  main  regulators  of 
angiogenesis.
 4d 
 
3.1.3 The Vascular Endothelial Growth Factor (VEGF)  
 
The VEGF is an endothelial, cell-specific, growth stimulator which acts by binding 
the VEGF receptor-1 (VEGFR-1 or Flt-1) and VEGF receptor-2 (VEGFR-2 or Flk-
1)
5 and also binds to the VEGFR receptor-3 (VEGFR-3, Flt-4). These receptors are 
mainly  expressed  on  endothelial  cells  but  have  recently  been  found  to  be  over-
expressed  on  non-endothelial  cells,  such  as  malignant  melanoma  or  ovarian 
carcinoma tumour cells.
6 
Each receptor has an extracellular part, with seven immunoglobulin-like domains, a 
single transmembrane region and an intracellular domain. The ligand binding site of 
these receptors is located in their second and third immunoglobulin-like loops, and 
VEGF  binding  leads  to  the  dimerisation  of  the  receptor  in  which  the 
immunoglobulin-like domains are held close to each other, in order to help stabilise 
the receptor dimers. The receptor–ligand complexes instigate a signal being passed to Molecular Modelling                                                                          Chapter Three 
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the intracellular tyrosine kinase domains and the activated tyrosine kinase initiates 
processes  within  the  endothelial  cells  leading  to  cell  migration,  proliferation  and 
survival, Figure 23.
 7  
 
 
Figure 23. Suggested model for the activation of the RTKs of the VEGF receptor 
family
7 
 
The VEGFR-1 plays an important role in the development of angiogenesis while the 
VEGFR-2  is  the  major  mediator  of  endothelial  cell  proliferation,  microvascular 
permeability, migration and survival.
8 The VEGFR-3 is located mainly on the surface 
of  the  lymphatic  endothelial  cells  and  this  receptor  is  involved  in  tumour 
lymphangiogenesis. The importance of the VEGF in tumour angiogenesis and the 
pathogenesis of human cancers is well-established and so different strategies have 
been developed for the inhibition of VEGF-mediated tumour growth.
8  
Several agents target the VEGF, including soluble VEGFRs or VEGF antibodies. For 
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biological activity of VEGF by preventing it from binding to its normal receptor, 
while Bevacizumab (Avastin) is a monoclonal antibody, which inhibits the interaction 
of the VEGF with the corresponding receptor.
9  
An alternative method of blocking VEGF-mediated processes uses small-molecule 
kinase  inhibitors,  with  several  VEGFR  inhibitors  in  preclinical  and  clinical 
evaluation,  for  example  the  anilinoquinazoline  derivatives  ZD4190,  ZD6474  and 
AZD2171.
9,10  There are, however, only a few examples in the literature of pyrrole-
containing inhibitors, such as Semaxanib (SU5416), SU6668, SU10944
11 (Figure 24) 
and Sunitinib (SU11248),
12 (Figure 25). 
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Figure 24. Examples of VEGFR inhibitors 
 
An attractive starting point for the design of novel inhibitors of the VEGFR-2 kinase 
domain is the Sutent (SU11248) structure, Figure 25.  
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3.1.4 Sutent 
 
Sutent (previously known as SU11248;  chemical name sunitinib malate) 243 is  a 
novel, oral, multi-targeted receptor tyrosine kinase (RTK) inhibitor that exhibits anti-
cancer and anti-angiogenic effects, Figure 25.
12a  
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Figure 25. The 3D
12b - and 2D-chemical structures of Sutent  
 
Sutent was approved by the FDA (Food and Drug Administration) for the treatment 
of renal cell carcinoma (RCC) and gastrointestinal stromal tumor (GIST) in 2006, 
becoming the first cancer drug simultaneously approved for two different indications. 
The  cellular  targets  of  this  drug  are  the  multiple  RTKs,  including  the  vascular 
endothelial growth factor receptor (VEGFR), and the platelet-derived growth factor 
receptor (PDGFR).
13 Sutent exhibits competitive inhibition of VEGFR-2 and PDGF-
dependent PDGFR-β phosphorylation, with an IC50 = 10 nM for both RTKs, and also 
inhibits the VEGF- induced proliferation of the HUVEC cell line, with an IC50 = 40 
nM.
14  The  simultaneous  inhibition  of  these  targets  leads  to  reduced  tumour 
vascularisation, cancer cell death, and also tumour shrinkage. Molecular Modelling                                                                          Chapter Three 
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3.2 Structure Based Drug Design (SBDD) 
 
The process of designing a new drug and then bringing it to the market is very time 
consuming, and it takes around 10-15 years and $1 billion for the average new drug to 
reach the clinic. Structure based drug design has been around since the early to mid – 
1980s and success stories are only just  starting to appear.
2,15 There are numerous 
examples of current pharmaceuticals that were developed by structure based design, 
including  for  example  Zanamivir  (Relenza
16,  a  neuraminidase  inhibitor  for  the 
treatment  of  the  influenza  virus),  Sildenafil  (Viagra
17,  a  phosphodiesterase-5 
inhibitor) and Saquinavir (Fortovase
18, an HIV protease inhibitor), Figure 26. 
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Structure  Based  Drug  Design  is  an  iterative  process,  which  starts  with  the 
identification  of  the  potential  target  (receptor  or  an  enzyme),  followed  by  the 
characterisation of the target (X-ray crystallography, Nuclear Magnetic Resonance) 
and identification of a possible ligand binding site (ideally, the target site is a pocket 
with  a  variety  of  potential  hydrogen  bond  donors  and  acceptors,  hydrophobic 
characteristics, etc.). The next step is to design an inhibitor which will bind to the 
active site of the target and prevent the usual chemical reaction.  
Once  the  inhibitor  hit  compound  is  identified,  it  can  be  synthesised  and  a  small 
library can be prepared (five to ten compounds) around the proposed ligand in order 
to obtain structure-activity relationship (SAR) data. After they have been synthesised, 
the  target  compounds  can  be  tested  in  a  relevant  biological  assay  in  order  to 
determine if the SBDD has been successful. The for possible scenarios for structure 
based drug design are shown in the figure below, Figure 27.
19  
The first approach involves the structure of both the ligand and the protein being 
known. Another method is combinatorial chemistry if the structures of the ligand and 
proteins are not known, while a third scenario is the de novo design technique, which 
is used if the protein structure is known and the ligand structure unknown. Finally, 
QSAR and pharmacophore generation can be used when the ligand structure is known 
and the protein structure is unknown. 
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Figure 27. Scenarios for structure based drug design
19 
 
3.2.1 The process of structure based drug design 
 
The crystal structure of the VEGFR-2 (1ywn)
20 and EGFR kinase domain (2ity)
21  
(Figure  28)  were  downloaded  from  the  RSCB  Protein  Data  Bank  (PDB)  and 
molecular modelling was carried out using InsightII, Cerius
2 and Catalyst (Accelrys, 
San Diego).  InsightII was  used to  minimise the protein and correct  the structure, 
structure based drug design was performed on Cerius
2,
 and Catalyst was used to view 
the pharmachopores. 
      
Figure 28. Crystal structure of VEGFR-2 (1ywn) and EGFR (2ity)
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The process of structure based drug design is shown in the flow diagram in, Figure 
29. 
Import PDB file data into InsightII
Check for any problems in structure and add / delete 
any bonds which are missing / extraneous
Add H atoms
Import into Cerius2
Disconnect covalently bound ligand
Minimise enzyme
Search database
 
 
Figure 29. Structure based drug design 
 
3.2.2 InsightII 
 
The  crystal  structure  of  the  VEGFR-2  (1ywn)  in  complex  with  a  novel  4-
aminofuro[2,3-d]pyrimidine was downloaded into InsightII, Figure 30. Hydrogens are 
not  resolved  in  the  PDB  (Protein  Data  Bank)  files  obtained  from  X-ray  crystal 
structures, as they are difficult to observe by X-ray crystallography, so they were first 
added to the crystal structure using the Builder section, then the pH was set to 7, the 
potentials were fixed (using the CFF91 forcefield) and all atoms and bonds of the Molecular Modelling                                                                          Chapter Three 
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residue were corrected. Next, the crystal structure was transferred to Cerius
2, still in 
complex  with  the  ligand,  and  used  in  the  LigandFit  and  structure-based  focusing 
(SBF) modules.  
 
 
 
Figure 30. The VEGF receptor-2 complexed with the ligand (yellow) and solvent 
(red) 
 
3.2.3 Cerius
2 
3.2.3.1 LigandFit 
 
LigandFit
22 is designed to investigate the docking of a ligand into a protein binding 
site based upon its shape. During this process, the protein is rigid while the ligand 
remains  flexible,  so  allowing  different  ligand  conformations  to  be  searched  and 
docked within the binding site. 
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  the definition of the active site of the protein based upon the protein shape or a 
docked ligand, 
  the  generation  of  possible  ligand  conformations  for  docking,  using  a  Monte 
Carlo algorithm, and  
  the docking of the conformations into the active site and the computation of the 
docking scores. 
 
The protein was imported into Cerius
2 as a PDB file, and the first step involved was 
to remove the solvent, then to separate the ligand atoms from the protein atoms before 
minimising both structures to find the local minimum of the system. Atomic motion 
in the protein was allowed only for the hydrogen atoms in order to maintain the shape 
of the active site. Next, the site model was generated in order to define the active site 
and then modified in order to remove parts of the active site that could not reasonably 
bind a ligand. PDB files containing a ligand docked into the active site allow for a 
more accurate search for a possible binding site than those without a ligand.  
After a flexible docking process, a Monte Carlo algorithm was employed to generate 
ligand conformers. The  shape matching method selected the conformers from  the 
database  (Maybridge  2005)  which  fitted  into  the  binding  site  and,  finally,  their 
energies were optimised. 
Once the docking was complete, from the hits obtained, pyrrole-containing molecules 
(and  other  5-membered  heterocycles)  were  chosen  then  clustered,  and  the  top 
conformers were prioritised using the scoring functions.  
Several scoring functions have been developed to rank hits relative to one another. 
For  the  best  docked  conformers  we  computed  scores  using  the  empirical  based 
LigScore1,  LigScore2,
23  Jain,
24  Dockscore,  and  Ludi1,  Ludi2  scoring  functions.
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Scoring functions are used to describe various types of interactions between the two 
binding  partners  (e.g.  ligand-receptor)  such  as  hydrogen-bond  or  aliphatic-  and 
aromatic-liphophilic  interactions.  The  12  top  scoring  5-membered  heterocycle 
compounds are shown in Figure 31. 
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3.2.3.2 Structure Based Focusing 
 
Structure Based Focusing (SBF) is a method that uses the known active site of a 
protein to select compounds which are likely to bind within the defined active site. 
The first step was to define the active site of the protein. The centre of the bound 
ligand atoms was marked and, starting from this point, the radius (including Asp1044, 
Glu883, Glu915, and Cys917 residues) was defined, within 7.5 Ǻ, to assign the active 
site, Figure 32. 
 
    
a                                                         b 
Figure 32. a) Structure of the ligand complexed with VEGFR-2; b) Five feature query 
in the active site of 1ywn. The green spheres shows the hydrogen bond 
acceptor, and purple hydrogen bond donor interactions 
 
From the defined active site, an interaction map was generated (Figure 33) using the 
Ludi program, which contains a list of features, such as liphophilic regions, hydrogen 
bond donors, and acceptors that a ligand is expected to satisfy in order to have a 
reasonable interaction with the protein.  
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Figure 33. Interaction map of VEGFR complexed with the ligand. Hydrogen bond 
donors are shown in blue / white and hydrogen bond acceptors are shown 
in red / grey  
 
Once the interaction model was complete, the next step was to generate the volume 
exclusion model, which defines regions within the active site that a ligand may not 
overlap.  This  process  makes  the  search  more  specific  and  precludes  ligands  that 
would  clash  with  protein  atoms  in  the  active  site.  The  exclusion  model  does  not 
include hydrogen atoms, which allows for some flexibility in the protein when fitting 
a ligand to the search query, Figure 34. 
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Figure 34. Volume exclusion model 
 
The next step was to generate the 3D queries and then import them into Catalyst to 
check for any overlaying features and that the exclusion model did not interfere with 
any  of  the  features.  Ten  of  the  top  queries  were  then  chosen  to  search  in  the 
previously downloaded Maybridge 2005 database, and the results are summarised in 
Figure 35. 
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In  the  Sunderland  Pharmacy  School,  several  current  projects  are  aimed  at  the 
development  of  novel  anti-cancer  agents  through  the  testing  of  inhibitors  of  the 
dimerisation of the epidermal growth factor receptor (EGFR), so we also chose to 
study this process. 
The  crystal  structure  of  the  EGFR  kinase  domain  (2ity)  was  downloaded  into 
InsightII and LigandFit was performed on the EGFR in the same manner as for the 
VEGFR-2. The difference between these two processes was only in the searching of 
the database – for the VEGFR, the Maybridge 2005 database (which contains around 
60,000 molecules) was used, while in the second part (EGFR) a virtual library was 
created from previously found hit molecules. Once the active site of the protein was 
defined, a Monte Carlo search was used to generate different ligand conformers for 
docking and then shape matching was applied to select conformers which are similar 
to the shape of the active site. After fitting, the docked conformers were clustered 
and, according to the selected method and criteria, the redundant conformers were 
removed. The top conformers of each ligand were saved, then prioritised with Ligand 
Scoring and the results are summarised in Table 4.  
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  Ligscore1  Ligscore2   Jain   Dockscore  Ludi1  Ludi2  Conscore 
3026  2.25  4.6  2.11  50.328  531  445  6 
6074  2  5.48  1.6  53.477  493  399  6 
SEW-04300-01  2.11  4.85  1.57  47.29  510  401  6 
SEW-04300-03  2.02  4.92  1.01  47.241  552  435  6 
SEW-04300-04  1.77  5.16  3.22  57.207  536  423  6 
SEW-04300-02  1.76  5.28  0.89  55.991  546  434  6 
13282  1.75  5.27  2.1  45.194  450  427  5 
14401  1.63  4.63  1.76  43.437  466  422  5 
14402  1.94  4.68  2.6  27.882  555  488  5 
14590  2.19  5.59  1.53  -3.62  494  425  5 
HTS-04255  1.49  4.57  2.31  45.411  500  462  5 
HTS-04258-03  3.32  4.59  3.28  50.418  450  392  5 
SEW-04300-08  2.3  4.46  1.23  42.137  554  455  5 
SEW-04300-05  1.73  4.66  0.97  37.956  543  470  5 
SEW-04300-06  2.31  5.05  0.72  55.574  549  439  5 
SEW-04300-07  1.86  4.68  1.46  52.081  460  358  5 
13282-01  1.67  4.99  0.99  46.182  405  389  4 
14401-01  2.12  5.4  0.58  44.007  468  380  4 
14402-01  2.06  5.49  -0.06  41.971  473  418  4 
14584  3.19  5.03  2.37  45.753  401  356  4 
15145  1.46  4.54  1.42  43.749  437  400  4 
7561  1.47  5.1  0.97  42.124  454  383  4 
9502  1.73  4.75  0.48  44.153  437  392  4 
 
Table 4. Prioritisation of ligand hits for EGFR 
 
Consensus Scoring
25 is a fast means of identifying ligands that score very highly in 
more than one scoring function. For each scoring function the ligands were prioritised 
by the score (in descending order) then a value of 1 was assigned to ligands in the top 
40%. The remaining ligands were given a value of 0 in the ranking list. For each 
ligand, the rank value (either 0 or 1) was added across the different scoring functions Molecular Modelling                                                                          Chapter Three 
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to  obtain  the  consensus  score  for  the  ligand,  with  the  maximum  consensus  score 
being equal to the number of scoring functions used.  
The evaluation of the results of the LigandFit and Structure Based Focusing methods 
suggested the synthesis  of compound  249 (14402)  and its  derivatives  as  they are 
potential inhibitors of both the VEGF and EGF receptors. 
 
3.3 Synthesis of 5-(3´-fluoro-phenyl)-2-methyl-1-phenyl-1H-pyrrole-3-carboxylic 
acid p-tolylamide and its derivatives 
 
The synthetic route to the target compounds is outlined in Schemes 80-82. The first 
step in this synthesis is the preparation of 1,4-diketone 245 from the commercially 
available ketoester 243 and an appropriate halophenacyl bromide 244, Scheme 80.
26 
After stirring for 20 hours at room temperature, the TLC indicated the completion of 
the reaction and chromatographic purification gave the products 245 in low yield (11-
15%). Increasing the temperature and the reaction time did not give a significant 
improvement  in  the  yields.  Characterisation  of  the  compounds  was  achieved  by 
spectroscopic data. In the 
1H NMR spectrum of ethyl 2-[2-(4-fluorophenyl)-2-oxo-
ethyl]-3-oxobutanoate 245a, the singlet of the methylene of the halophenacyl bromide 
had disappeared and the CH2 protons were found to exhibit geminal coupling as part 
of an ABX spin system at ʴ3.39 ppm (J = 18 Hz, CH2-a) and ʴ3.60 ppm (J = 18 Hz, 
CH2-b). In the IR spectrum of this 1,4-dicarbonyl the three C=O peaks were seen at 
1682, 1716, and 1733 cm
-1. 
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Scheme 80. Preparation of 1,4-diketones from ketoester 243 and halophenacyl 
bromide 244 
 
The condensation of the 1,4-diketones 245 with aniline in methanol
27 did not result in 
any  products,  only  starting  materials  were  obtained,  but  changing  the  solvent,  to 
toluene, gave the expected pyrroles 246 in good 75-78% yield. Compounds 246 were 
then hydrolysed in a solution of potassium hydroxide in ethanol / water to afford the 
acids 247 in 77-80% yields, Scheme 81.  
The structure of compound 247a was confirmed by its infra-red spectrum, with a 
broad OH stretch at 2584 and carbonyl stretch at 1686 cm
-1 and its 
1H NMR spectrum 
with the presence of a CH group at ʴ6.71 ppm (singlet) belonging to the pyrrole ring, 
and the disappearance of the ester group.  
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Scheme 81. Preparation of the pyrrole acids  
 
The acid chlorides 248 were then prepared by heating compounds 247, with SOCl2 in 
toluene.  Thus  crude  248  were  stirred  in  the  presence  of  p-toluidine  at  room 
temperature, to obtain the desired pyrrole derivatives 249 in good yield (88-91%). As 
the acid chlorides 248 were unstable, they were used directly in the next step without 
further purification, Scheme 82. 
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Scheme 82. Synthesis of the potential inhibitors 
 
The  identification  of  the  final  compounds  was relatively  straightforward,  and 
involved the comparison of their spectra with those of the previous intermediates in 
the synthetic route. The 
1H NMR spectra of both the Cl and F substituted compounds 
were similar, but the 
13C NMR spectrum was different as the peaks for carbons close 
to the fluoro group are doublets. From the coupling constants for these peaks it was 
easy to define the position in the ring of the carbon atoms, because the carbon atom 
with the larger 
13C-
19F coupling constant is located closer to the fluoro group. For 
example, the coupling constant for C-1´ at ʴ133.3 is J = 3.2 Hz, while that for C-4´ at 
ʴ161.7 is J = 245.5 Hz. A similar approach was used to determine C-2´, C-6´ at 
ʴ129.9 with J = 7.9 Hz and C-3´, C-5´ at ʴ115.2 with J = 22.5 Hz.  Molecular Modelling                                                                          Chapter Three 
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3.4 Biological activity assay 
3.4.1 MTT assay  
 
The  MTT  (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium  bromide)  cell 
proliferation assay is a simple method for the determination of cell number using 
standard microplate absorbance readers.  
The MTT assay was first described by Mosmann in 1983
28 and it is based on the 
cleavage of the yellow tetrazolium salt, MTT, to form dark purple formazan crystals 
by metabolically active cells, Scheme 83. This purple formazan product accumulates 
within the cell since it cannot pass through the cell  membrane. Upon addition of 
DMSO,  or  another  suitable  solvent,  the  cell  is  solubilised  and  the  dark  purple 
formazan crystals are liberated. The resulting coloured solution can be quantified by 
measuring  (usually  between  500  and  600  nm)  the  absorbance  with  a  UV 
spectrophotometer. 
 
N
N
N
N
S N
H3C CH3
N
N
HN
N
S N
H3C CH3
mitochondrial dehydrogenase
             enzymes
MTT -  yellow Formazan -  purple  
 
Scheme 83. Conversion of the tetrazolium salt MTT to an insoluble purple formazan 
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3.4.2 Materials and Methods 
3.4.2.1 Cell cultures 
 
Human colon cancer cell lines, HT29, CaCo-2, and HaCaT (keratinocytes) cell lines 
were obtained from Sunderland University. Fetal Bovine Serum (FBS), McCoy´s 5a 
Medium  Modified  and  RPMI  1640  Medium  were  obtained  from  Sigma-Aldrich 
Chemicals. 
HT29 cells were cultured in McCoy’s 5A medium, supplemented with 10% Fetal 
Bovine Serum (FBS), 100 µg/ml penicillin and 100 µg/ml streptomycin. The CaCo-2 
cell line was maintained in RPMI 1640 medium supplemented with 5% Fetal Bovine 
Serum, 100 µg/ml penicillin and 100 µg/ml streptomycin.   
HaCaT cell lines were cultered in Dulbecco’s MEM medium supplemented with 10% 
Fetal Bovine Serum (FBS), 100 µg/ml penicillin and 100 µg/ml streptomycin.   
 
3.4.2.2 Cell proliferation assay 
 
The MTT proliferation assays were carried out in 96 well plates with 1×10
4 cells/well 
(see Appendix A). Cells were grown to 60-80% confluence in a serum-free medium 
then trypsinized (in which the cells are detached from the flask surface) and counted 
on a haemocytometer under a microscope. Cells were then re-suspended in 10 ml of 
medium, plated and initially incubated for 24 hours at 37 
oC under 5% CO2. The 
media  was  removed  from  each  well  before  the  assay  was  started.  Drug  samples 
(249a, 249b) were dissolved in dimethylsulphoxide (DMSO) to give 10 mg/ml stock 
solution then a required amount of this stock was added to the media for preparation 
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and all samples were tested at concentration of 200, 100, 50, 25, 12.5, 6.25, 3.125, 
1.563 μg/ml. Plates were incubated for 3 days at 37 
oC with 5% CO2 then the culture 
media  was  removed  again  and  the  cells  were  rinsed  twice  with  PBS  (phosphate 
buffered saline) buffer solution. MTT working solution (0.5 mg/ml in PBS buffer) 
was added to each well and the plates were incubated at 37 
oC. After 2 hours, the 
MTT was removed then each well washed carefully with PBS solution. 
Cells were dissolved in DMSO-isopropanol solution to solubilise the purple formazan 
crystals, the plates were incubated for 10 minutes in the dark and the absorption was 
read  at  595  nm  with  a  spectrophotometric  micro-plate  reader.  The  percentage  of 
growth was calculated by the following formula: 
 
100 % 



Blank Control
Blank Compound
Growth  
Where: 
  Compound is the mean absorbance of the cells treated with compounds 
  Blank is the mean absorbance of the wells which contain only media 
  Control  is  the mean absorbance of the wells  which contain only  cells  (no 
compound) 
 
The calculation was carried out with Microsoft Excel then the results were transferred 
to the GraphPad Prism program to analyse graphically the percentage of growth vs 
the log of tested compound concentration. 
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3.5 Results 
   
Two  synthetic  compounds,  N-(4-methylphenyl)-5-(3´-fluorophenyl)-2-methyl-1-
phenyl-1H-pyrrole-3-carboxamide  (249a)  and  N-(4-methylphenyl)-5-(3´-
chlorophenyl)-2-methyl-1-phenyl-1H-pyrrole-3-carboxamide  (249b)  were  tested  in 
vitro  on  HT29  and  CaCo-2  cell  lines  and  the  results  are  summarised  in  Table  5 
(Appendix B). The cells were treated with various concentrations of the compounds 
for  3  days  and  cell  growth  inhibition  was  determined  using  the  3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The GI50 is the 
concentration of the drug that inhibits 50% of cell growth and the GI50 values were 
obtained from curves which were generated by a nonlinear regression curve fitting, 
Figure  35.  The  results  are  expressed  as  the  average  of  two  experiments  for  each 
compound. 
 
Cell line  Tumour 
type 
GI50  (μM) 
Sutent (lit.data)  249a  249b 
HT29  colon  no effect  23  11 
CaCo-2  colon   N/A  102  19 
       
Table 5. GI50 values of the tested compounds tested for antiproliferative activity 
 
In order to establish the quality of the results, we have to draw a comparison with 
data taken from the literature. The initial plan was to test the synthesised compounds 
in the HUVEC cell line under MTT assay conditions, then compare the results with 
Sutent, which has  a GI50  = 40 nM  in  the HUVEC cell line.
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problems with the growing of the HUVEC cells, we were not able to perform the 
planned tests; therefore, we decided to study the activity of 249a and 249b on two 
human colon cancer cell lines (HT29 and CaCo-2), which are also endothelial cells, 
and were readily available from Sunderland University. A literature search showed 
that Sutent did not have any activity in the HT29 cell line.
29 However, compounds 
249a and 249b both showed activity, with GI50 values of 23 μM and 11 μM in the 
HT29 cell line using the MTT assay. Both compounds also showed activity, with GI50 
values  of  102  μM  and  19  μM,  in  the  CaCo-2  cell  line,  respectively,  Figure  36. 
Unfortunately, no literature data is available on the effect of Sutent on the CaCo-2 
cell line. 
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Figure 36. Dose response curves for 249a and 249b 
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We were also interested in the study of the activity of the designed compounds on the 
HaCaT  cell  line,  which  over-expresses  the  EGF  receptor.  The  results  of  the 
cytotoxicity assay on this cell line are summarised in Table 6.  
 
Compound  
GI50 
HaCaT 
μg/ml       μM 
249a  103        41 
249b  63       24.2 
 
Table 6. GI50 values of the tested compounds on HaCaT cell line 
 
Both compounds inhibited the proliferation of HaCaT cells at high concentration and 
both showed activity, with GI50 values of 103 and 63 μM, Figure 37. 
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Figure 37. Dose response curve for 249 inhibition of the HaCaT cell line 
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3.6 Conclusion 
 
In this part of the work we have identified small molecules 249a and 249b as a novel 
class  of  potential  VEGFR-2  inhibitors  using  structure  based  drug  design.  We 
prepared these compounds in a 5 steps synthesis using regioselective reactions of 
functional groups present on the pyrrole ring. The synthesised compounds were fully 
characterized by spectroscopic data. 
 
N
O
N
H
CH3
F
CH3
N
O
N
H
CH3
Cl
CH3
249a 249b  
 
The antiproliferative activities of the synthesized compounds were tested  in three 
different  cell lines, HT29, CaCo-2 and HaCaT, using the MTT assay.  The tested 
compounds showed antiproliferative activity, with GI50 values of 102 μM and 19 μM, 
in the CaCo-2 cell line and 23 μM and 11 μM in the HT29 cell line, Table 5. The 
lower growth rate indicated that compound 249b has stronger activity in the colon 
cancer cell lines compare to compound 249a. 
We also investigated the activity of the designed compounds in the HaCaT cell line, 
and found that both inhibited proliferation, with GI50 values of 41 μM and 24.2 μM, 
Table 6. These studies could be used as an initial screen for identifying new VEGFR-
2 antagonist molecules. 
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4. Experimental Part 
 
Chemicals were purchased from Aldrich, Fluka, Lancaster and Johnson Matthey, and 
used without further purification. The structures of the synthesised compounds were 
characterised by 
1H NMR, 
13C NMR and IR spectroscopy, and melting point, mass 
spectrometry, high resolution mass spectrometry and elemental analysis. 
 
4.1 Instruments and Techniques   
4.1.1 Nuclear Magnetic Resonance Spectroscopy 
NMR spectra were obtained using a Bruker 300 NMR spectrometer operating at 300 
MHz for proton and 75 MHz for carbon, or using a Bruker 500 NMR spectrometer at 
500 MHz for proton and 125 MHz for carbon.  
Spectra were referenced to residual protonated solvent (ʴH CDCl3 7.25, ʴC CDCl3 
77.16; ʴH DMSO 2.50, ʴC DMSO 39.52) and all chemical shifts are relative to an 
internal standard (tetramethylsilane, TMS). Coupling constants are reported in Hz.  
 
4.1.2 Infra-red Spectroscopy 
Infra-red spectra of liquid or solid samples were obtained on a SpectrumBX fitted 
with Pike Miracle. 
 
4.1.3 Mass Spectrometry 
Low-resolution electrospray mass spectra were obtained on an Esquire 3000+ ion trap 
mass  spectrometer  (ChemiSPEC,  University  of  Sunderland)  and  high-resolution 
spectra  were  obtained  by  means  of  ESI-MS  on  a  Synapt  HDMS  instrument Experimental Part                                                                                Chapter Four 
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(University of Warwick). An internal standard of sodiated maltose in methanol was 
added at an appropriate level for mass correction using the ion at m/z 365.1060. 
 
4.1.4 Elemental Analysis 
Elemental  Analysis  (C,  H,  N)  for  new  compounds  was  performed  on  an  Exeter 
Analytical CE 440 Elemental Analyzer instrument, and all elements for all analyses 
were within ± 0.4 % of the theoretical values.  
 
4.1.5 Melting Points 
Melting points were determined on an Electrothermal 9100, a Gallenkamp melting 
point apparatus, or a Reichert hot stage microscope. 
 
4.1.6 Thin Layer and Flash Column Chromatography 
Thin layer chromatography (TLC) was performed on Merck silica gel 60F254 plates 
and the components were detected under UV light (254 nm). Kieselgel 60 (Merck) 
was used for flash column chromatography 
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4.2 3,5-Dichloro-1H-pyrrole-2,4-dicarboxaldehyde 41 
 
N
H
Cl
Cl OHC
CHO
 
 
Dry DMF (100 ml) was cooled to 0 
oC in an ice bath then POCl3 (29.2 ml) was added 
dropwise over 1 h. N-Acetylglycine (10 g, 85.4 mmol) was added to the solution and 
the resulting mixture stirred for 1 h at room temperature then 6 h at 90 
oC. After 
completion  of  the  reaction,  as  indicated  by  TLC,  the  mixture  was  poured  onto  a 
mixture of crushed ice (1000 ml), sodium acetate (29 g) and water (100 ml). The 
product was continuously extracted overnight with diethyl ether (1000 ml), and dried 
over anhydrous MgSO4. After filtration, the solvent was evaporated under reduced 
pressure and the crude product was purified by column chromatography on silica, 
eluting with ethyl acetate: petroleum ether (60-80 
oC) (50:50) to give pyrrole 41 as a 
yellow solid (11.5 g, 70 %); mp 166-168- 
oC (lit.
1 mp 170 
oC); υmax(KBr)/cm
-1 1671 
(C=O), 1635 (C=O), 1539 (C=C); 
1H NMR (300 MHz, CDCl3) ʴH 9.63 (1H, s, CHO), 
9.92 (1H, s,  CHO), 11.12 (1H, br s,  NH); 
13C NMR  (75 MHz, CDCl3) ʴC 118.3 
(quat.), 125.5 (quat.), 127.6 (quat.), 130.6 (quat.), 177.4 (CHO), 182.7 (CHO); m/z 
Found: [M-H
+]
–, 190. Calc. for C6H3
35Cl2NO2: (M-H
+)
–, 190. 
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4.3 3,5-Dichloro-1-methyl-1H-pyrrole-2,4-dicarboxaldehyde 42 
 
N
CH3
Cl
Cl OHC
CHO
 
 
 A solution of pyrrole 41 (5 g, 26 mmol) in dry DMF (55 ml) was added dropwise to 
a stirred solution of NaH (60 % in oil, 1.35 g, 56 mmol) in dry DMF (55 ml) and the 
mixture stirred for 30 min at room temperature. Methyl iodide (6.55 ml, 105 mmol) 
was then added to the resulting solution and stirring was continued for an additional 3 
h at  room temperature.  The reaction mixture was  quenched  with  water (100 ml), 
extracted with diethyl ether (3 × 100 ml) and dried over anhydrous MgSO4. After 
filtration, the solvent was evaporated under reduced pressure and the crude product 
purified by column chromatography on silica, eluting with ethyl acetate: petroleum 
ether (60-80 
oC) (5:5) to give pyrrole 42 as a yellow solid (4.98 g, 92 %); mp 109-111 
oC (lit.
2 mp 108.5-109.5 
oC); υmax(KBr)/cm
-1 1664 (C=O), 1510 (C=C); 
1H NMR (300 
MHz, CDCl3) ʴH 3.91 (3H, s, CH3), 9.75 (1H, s, 2-CHO), 9.89 (1H, s, 4-CHO); 
13C 
NMR (75MHz, CDCl3) ʴC 33.2 (CH3), 117.0 (quat., C-4), 126.7 (quat., C-3), 127.0 
(quat., C-5), 132.0 (quat., C-2), 177.7 (2-CHO), 182.2 (4-CHO); m/z Found: MNa
+, 
229. Calc. for C7H5
35Cl2NO2Na : MNa
+, 229. 
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4.4 3,5-Dichloro-1-ethyl-1H-pyrrole-2,4-dicarboxaldehyde 43 
 
N Cl
Cl OHC
CHO
CH3  
 
This pyrrole 43 was prepared as described above, and the crude product was purified 
by column chromatography on silica, eluting with ethyl acetate: petroleum ether (60-
80 
oC) (50:50) to give pyrrole 43 as a yellow solid (4.90 g, 86 %); mp 69-71 
oC (lit.
2 
mp 68-69 
oC); υmax(KBr)/cm
-1 1657 (C=O), 1508 (C=C); 
1H NMR (300 MHz, CDCl3) 
ʴH 1.28 (3H, t, J = 7.2 Hz, CH3), 4.45 (2H, q, J = 7.2 Hz, CH2), 9.74 (1H, s, 2-CHO), 
9.89 (1H, s, 4-CHO); 
13C NMR (75 MHz, CDCl3) ʴC 15.1 (CH3), 41.7 (CH2), 117.0 
(quat., C-4), 125.9 (quat., C-3), 127.4 (quat., C-5), 131.1 (quat., C-2), 177.3 (2-CHO), 
182.2 (4-CHO). 
 
4.5 3,5-Dichloro-2-[(dibenzylamino)methylene]-1H-pyrrole-4-carboxaldehyde 
151a  
N Cl
Cl OHC
H
N
1
2
3 4
5
6
7 8
1`
2`
3`
4`
5`
6`
1``
2``
3``
4``
5``
6``
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Pyrrole 41 (0.60 g, 3.13 mmol) was dissolved in ethanol (12 ml) and dibenzylamine 
(2.9 ml, 15.46 mmol) was added slowly to the solution. The reaction mixture was 
stirred at room temperature for 4 h then quenched with brine (30 ml), extracted with 
DCM (3 × 30 ml) and the combined organics dried over MgSO4. After filtration, the 
solvent was evaporated under reduced pressure and the crude product purified by 
column  chromatography  on  silica,  eluting  with  CH2Cl2  /  EtOAc  (95:5)  to  give  a 
yellow solid 151a (0.84 g, 72 %); mp 149-150 
oC; [Found: C, 64.6; H, 4.4; N 7.5. 
C20H16Cl2N2O requires C, 64.7; H, 4.3; N, 7.6 %]; υmax(KBr)/cm
-1 1671 (C=O), 1606 
(enamine C=C); 
1H NMR (300 MHz, CDCl3) ʴH 4.51 (2H, s, CH2), 5.54 (2H, s, CH2), 
7.13 (2H, m, ArH), 7.23 (2H, m, ArH), 7.29 (3H, m, ArH), 7.35 (3H, m, ArH), 7.67 
(1H, s, CH), 9.85 (1H, s, CHO); 
13C NMR (75 MHz, CDCl3) ʴC 53.4 (CH2), 60.7 
(CH2), 121.2 (quat., C-4), 126.9 (quat., C-2), 128.3 (CH), 128.8 (CH), 129.2 (CH), 
129.5 (CH), 130.3 (CH), 132.7 (quat., C-1´ or C-1´´), 134.0 (quat., C-1´ or C-1´´), 
137.1 (quat., C-3), 144.6 (quat., C-5), 147.6 (CH), 183.5 (CHO); m/z Found: MNa
+, 
393. Calc. for C20H16
35Cl2N2O: MNa
+, 393.  
 
4.6 3,5-Dichloro-1H-pyrrole-2,4-dicarboxaldehyde bisoxime 156 
 
N
H
Cl
Cl
H
N
OH
N
HO
H
 
 
A solution of pyrrole 41 (1.00 g, 5.2 mmol) and hydroxylamine hydrochloride (1.10 g 
15.86 mmol) in 95-98 % formic acid (10.2 ml) was refluxed for 40 min and then Experimental Part                                                                                Chapter Four 
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allowed to cool. The mixture was diluted with ice-water (50 ml) then neutralised with 
5% sodium hydroxide solution, and extracted with ethyl acetate (3 × 40 ml). The 
combined organic layer was dried over MgSO4 and evaporated. After filtration, the 
residue was purified by column chromatography on silica, eluting with ethyl acetate: 
petroleum ether (60-80 
oC) (4:6) to give pyrrole 156 as a pale yellow solid (0.91 g, 76 
%); mp 147-148 
oC; υmax(KBr)/cm
-1 3277 (broad NH and OH); 
1H NMR (300 MHz, 
DMSO-d6) ʴH 7.21 (1H, s, CH), 7.83 (1H, s, CH), 11.19 (1H, s, OH), 11.75 (1H, s, 
OH), 12.22 (1H, s, NH); 
13C NMR (75 MHz, DMSO-d6) ʴC 111.1 (quat., C-4), 112.6 
(quat., C-3), 117.8 (quat., C-5), 120.5 (quat., C-2), 133.0 (CH, 2-CH=N), 140.0 (CH, 
4-CH=N); HRMS Found: MH
+, 221.9836. Calc. for C6H6Cl2N3O2: MH
+, 221.9832. 
 
4.7 3,5-Dichloro-4-cyano-1H-pyrrole-2-carboxaldehyde oxime 157 
 
N
H
Cl NC
Cl
N
H
OH
 
 
Method A 
POCl3 (2.92 ml) was added dropwise to dry DMF (10 ml) at 0 
oC. To this solution, N-
acetylglycine (1.00 g, 8.54 mmol) was added and the mixture stirred for 1 h at room 
temperature then 4 h at 90 
oC. After completion of the reaction, as indicated by TLC, 
the  reaction  mixture  was  diluted  with  DCM  (12  ml),  cooled  to  0 
oC  and 
hydroxylamine hydrochloride (1.77 g, 25.5 mmol) in DMF (5 ml) was added. The 
mixture was stirred for 4 h at room temperature. After the reaction was complete, it 
was diluted with water (8 ml) and extracted with DCM (2 × 15 ml). The combined Experimental Part                                                                                Chapter Four 
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organic phases were washed with water (2 × 10 ml), saturated NaHCO3 solution (8 
ml),  and  water  (15  ml)  and  dried  over  MgSO4.  After  filtration,  the  solvent  was 
evaporated under reduced pressure and the crude product was purified by column 
chromatography on silica, eluting with ethyl acetate: petroleum ether (60-80 
oC) (3:7) 
to give a yellow solid 157 (0.72 g, 45 %), spectral data given below. 
 
Method B 
3,5-Dichloro-1H-pyrrole-2,4-dicarboxaldehyde  41  (1.00  g,  5.21  mmol), 
hydroxylamine hydrochloride (0.38 g, 5.47 mmol) and pyridine (0.43 g, 5.43 mmol) 
were refluxed in EtOH for 2 h, to give the crude oxime. To this solution was added 
Ac2O (15 ml), then the mixture was heated under reflux for 1.5 h, cooled, stirred with 
water  (100  ml),  extracted  with  DCM  (3  ×  30  ml)  and  dried  over  MgSO4.  After 
filtration, the solvent was evaporated under reduced pressure and the crude product 
was  purified  by  column  chromatography  on  silica,  eluting  with  ethyl  acetate: 
petroleum ether (60-80 
oC) (3:7) to give a yellow solid 157 (0.78 g, 72 %); mp 158-
159 
oC; υmax(KBr)/cm
-1 3170 (broad NH and OH), 2234 (C≡N); 
1H NMR (300 MHz, 
DMSO-d6) ʴH 4.98 (1H, s, NH), 7.89 (1H, s, CH), 11.53 (1H, s, OH);
 13C NMR (75 
MHz, DMSO-d6) ʴC 100.3 (quat., C-4 or C-5), 111.7 (quat., C-4 or C-5), 112.6 (quat., 
C-2 or C-3), 120.2 (quat., C-2 or C-3), 139.2 (CH); HRMS Found: MH
+, 203.9732. 
Calc. for C6H4Cl2N3O: MH
+, 203.9727. 
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4.8 3,5-Dichloro-1-ethyl-2,4-bis(hydroxymethyl)-1H-pyrrole 174 
 
N
HO
OH Cl
Cl
CH3  
 
Methanol (15 ml) was added dropwise to sodium borohydride (37 mg, 0.97 mmol) 
then the reaction mixture was stirred for 5 min at room temperature. 3,5 -Dichloro-1-
ethyl-1H-pyrrole-2,4-dicarboxaldehyde  43  (0.40  g,  1.82  mmol)  was  added  to  the 
solution  which  was  then  refluxed  for  4  h.  After  completion  of  the  reaction,  as 
indicated by TLC, the solvent was evaporated under reduced pressure, and the residue 
quenched with water (20 ml), extracted with ether (3 × 30 ml) and the combined 
organics dried over MgSO4. After filtration, the solvent was evaporated under reduced 
pressure and the crude product was purified by column chromatography on silica, 
eluting with ethyl acetate: petroleum ether (60-80 
oC) (5:5) to give pyrrole 174 as a 
white solid (0.23 g, 75 %); mp 139-140 
oC; υmax(KBr)/cm
-1 3338 (broad OH); 
1H 
NMR (300 MHz, DMSO-d6) ʴH 1.25  (3H, t, J = 7.2 Hz, CH3), 4.01 (2H, q, J = 7.2 
Hz, CH2), 4.24 (2H, s, CH2-C4), 4.42 (2H, s, CH2-C2), 4.71 (1H, br s, OH), 5.13 (1H, 
br s, OH); 
13C NMR (75 MHz, DMSO-d6) ʴC 16.3 (CH3), 39.9 (CH2), 52.3 (CH2-C4), 
53.1 (CH2-C2),109.8 (quat., C-3), 114.2 (quat., C-5), 116.8 (quat., C-4), 128.1 (quat., 
C-2); HRMS Found: MH
+, 224.0244. Calc. for C8H12Cl2NO2: MH
+, 224.0240. 
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4.9 3,5-Dichloro-1-methyl-2-hydroxymethyl-1H-pyrrole-4-carboxaldehyde 176 
 
N
OHC
OH Cl
Cl
CH3  
 
3,5-Dichloro-1-methyl-1H-pyrrole-2,4-dicarboxaldehyde 42 (0.50 g, 2.43 mmol) and 
sodium cyanoborohydride (0.15 g, 2.3 mmol) were dissolved in methanol (10 ml) and 
2M  HCl-methanol  (3  ml,  20:80)  added  dropwise,  with  stirring,  to  the  solution. 
Stirring was continued for an additional 1 h then the methanol was evaporated under 
reduced pressure, the residue was taken up in water (7 ml), saturated with sodium 
chloride,  extracted with ether (3  × 20 ml)  and  the  combined organics  dried over 
MgSO4.  After filtration, the solvent was evaporated under reduced pressure and the 
crude product was purified by column chromatography on silica, eluting with ethyl 
acetate: petroleum ether (60-80 
oC) (3:7)  to give pyrrole 176 as a yellow solid (0.21 
g,  42  %);  mp  129-130 
oC;  υmax(KBr)/cm
-1  3353  (broad  OH),  1710  (C=O),  1511 
(C=C); 
1H NMR (300 MHz, DMSO-d6) ʴH 3.72  (3H, s, CH3), 4.54 (2H, s, CH2), 5.38 
(1H, br s, OH), 9.84 (1H, s, CHO); 
13C NMR (75 MHz, DMSO-d6) ʴC 31.9 (CH3), 
51.8 (CH2), 109.8 (quat., C-3), 115.3 (quat., C-4), 124.7 (quat., C-5), 131.8 (quat., C-
2),  182.7  (CHO);  HRMS  Found:  MH
+,  207.9937.  Calc.  for  C7H8Cl2NO2:  MH
+, 
207.9927. 
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4.10 3,5-Dichloro-1-ethyl-2-hydroxymethyl-1H-pyrrole-4-carboxaldehyde 177 
 
N
OHC
OH Cl
Cl
CH3  
 
3,5-Dichloro-1-ethyl-1H-pyrrole-2,4-dicarboxaldehyde  43  (0.40  g, 1.82 mmol) and 
sodium cyanoborohydride (0.08 g, 1.84 mmol) were dissolved in methanol (15 ml) 
and 2M HCl-methanol (3 ml, 2:8) was added dropwise, with stirring, to the solution. 
Stirring was continued for an additional 1 h then the methanol was evaporated under 
reduced pressure, the residue was taken up in water (10 ml), saturated with sodium 
chloride,  extracted with ether (3 × 20 ml)  and  the  combined organics  dried over 
MgSO4.  After filtration, the solvent was evaporated under reduced pressure and the 
crude product was purified by column chromatography on silica, eluting with ethyl 
acetate: petroleum ether (60-80 
oC) (3:7)  to give pyrrole 177 as a yellow solid (0.21 
g, 53 %); mp 122-123 
oC; υmax(KBr)/cm
-1 3350 (broad OH), 1662 (C=O); 
1H NMR 
(300 MHz, CDCl3) ʴH 1.24 (3H, t, J = 7.2 Hz, CH3), 4.38 (2H, q, J = 7.2 Hz, CH2), 
4.50 (2H, s, CH2), 9.60 (1H, s, CHO); 
13C NMR (75 MHz, CDCl3) ʴC 15.8 (CH3), 
41.3 (CH2CH3), 52.5 (CH2), 119.1 (C-4 or C-5), 120.3 (C-3), 124.7 (C-4 or C-5), 
126.3 (C-2), 176.9 (CHO); HRMS Found: MH
+, 222.0099. Calc. for C8H10Cl2NO2: 
MH
+, 222.0084. 
 
 
 Experimental Part                                                                                Chapter Four 
147 
4.11 3,5-Dichloro-4-formyl-1-methyl-1H-pyrrole-2-carboxylic acid 183 
 
N
OHC
COOH Cl
Cl
CH3  
 
3,5-Dichloro-1-methyl-1H-pyrrole-2,4-dicarboxaldehyde 42 (0.50 g, 2.43 mmol) was 
dissolved in acetone (40 ml) and treated with a solution of KMnO4 (0.78 g, 4.9 mmol) 
in H2O (13 ml). The reaction mixture was refluxed for 12 h then decolourised with 
charcoal.  After  filtration,  the  solvent  was  evaporated  under  reduced  pressure, 
acidified with 2M HCl and the crude product was recrystallised from methanol to 
give pyrrole 183 as a white solid (0.30 g, 55 %); mp 173-175 
oC; υmax(KBr)/cm
-1 2588 
(broad OH), 1662 (C=O); 
1H NMR (300 MHz, DMSO-d6) ʴH 3.87 (3H, s, CH3), 9.72 
(1H, s, CHO), 13.15 (1H, br s, OH); 
13C NMR (75 MHz, DMSO-d6) ʴC 33.6 (CH3), 
111.4  (C-4),  125.1  (C-3),  126.5  (C-5),  130.7  (C-2),  162.1  (C=O),  178.4  (CHO); 
HRMS Found: MH
+, 259.9261. Calc. for C7H6NO3Cl: MH
+, 259.9278. 
 
4.12  3,5-Dichloro-1-methyl-1H-pyrrole-2,4-dicarboxylic acid 185 
 
N
HOOC
COOH Cl
Cl
CH3  
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This pyrrole was prepared, as described above, to give a white solid 185 (0.23 g, 39 
%); mp 179-180 
oC; [Found: C, 35.9; H, 2.3; N, 5.5. C7H5Cl2NO4 requires C, 35.5; H, 
2.1; N, 5.8 %]; υmax(KBr)/cm
-1 2591 (broad OH), 1661 (C=O); 
1H NMR (300 MHz, 
DMSO-d6) ʴH 3.84 (3H, s, CH3); 
13C NMR (75 MHz, DMSO-d6) ʴC 34.6 (CH3), 
111.3 (C-4), 118.9 (C-3), 121.5 (C-5), 126.7 (C-2), 160.8 (COOH), 162.6 (COOH); 
m/z Found: MNa
+ 260. Calc. for C7H5
35Cl2NO4Na : MNa
+, 260. 
 
4.13 General procedure for preparation of compounds 187a-e and 191   
 
A solution of 3,5-dichloro-4-formyl-1-methyl-1H-pyrrole-2-carboxylic acid 183 (1.35 
mmol) and SOCl2 (0.49 ml) in toluene (5 ml) was refluxed for 4 h. After evaporation 
of the solvent, the crude mixture was dissolved in DCM (5 ml) and a solution of 
amine or benzyl alcohol (2.01 mmol) and TEA (0.19 ml) in DCM (1.6 ml) was added 
dropwise at 0 
oC. The mixture was stirred for 2 h at room temperature then washed 
sequentially with 5 % aq. HCl (10 ml) and 5 % aq. NaOH (10 ml). The organic layer 
was dried over MgSO4 and, after filtration, the solvent was evaporated under reduced 
pressure and purified by column chromatography or recrystallised. 
 
4.13.1  N-Phenyl-3,5-dichloro-4-formyl-1-methyl-1H-pyrrole-2-carboxamide 
187a 
N
OHC
CH3
Cl
Cl
O
H
N
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The crude product was recrystallised from methanol to give colourless needles 187a 
(0.32 g, 80 %); mp 165-167 
oC; [Found: C, 52.9; H, 3.8; N, 9.0.  C13H10Cl2N2O2 
requires C, 52.6; H, 3.4; N, 9.4 %]; υmax(KBr)/cm
-1 3276 (NH), 1713 (C=O), 1660 
(C=O); 
1H NMR (300 MHz, CDCl3) ʴH 3.91 (3H, s, CH3), 7.11 (1H, m, Ar-H), 7.31 
(2H, m, Ar-H), 7.53 (2H, m, Ar-H), 7.91 (1H, br s, NH), 9.70 (1H, s, CHO); 
13C 
NMR (75 MHz, CDCl3) ʴC 33.3 (CH3), 114.5 (quat.), 120.2 (CH, Ar), 120.4 (quat.), 
120.5 (CH, Ar), 122.8 (quat.), 124.9 (CH, Ar), 125.2 (quat.), 125.9 (quat.), 129.1 
(CH, Ar), 129.2 (CH, Ar), 137.4 (C=O), 177.6 (CHO). 
 
4.13.2  N,N-Diisopropyl-3,5-dichloro-4-formyl-1-methyl-1H-pyrrole-2-carbox-
amide 187b 
N
OHC
CH3
Cl
Cl
O
N
 
 
The crude product was recrystallised from methanol give white crystals 187b (0.28 g, 
68 %); mp 141-142 
oC; [Found: C, 51.1; H, 5.9; N, 8.9. C13H18Cl2N2O2 requires C, 
51.1; H, 5.9; N, 9.1 %]; υmax(KBr)/cm
-1 1675 (C=O), 1635 (C=O), 1536 (C=C); 
1H 
NMR (300 MHz, CDCl3) ʴH 1.13 (6H, m, Hz, 2 × CH3), 1.47 (6H, m, 2 × CH3), 3.45 
(1H, m, CH), 3.76 (1H, m, CH), 3.85 (3H, s, CH3), 9.62 (1H, s, CHO); 
13C NMR (75 
MHz, CDCl3) ʴC 20.4 (CH3), 20.5 (CH3), 21.2 (CH3), 21.3 (CH3), 33.2 (NCH3), 46.3 
(CH), 51.7 (CH), 119.5 (quat., C-3 or C-4), 122.4 (quat., C-3 or C-4), 124.5 (quat., C-
5), 125.4 (quat., C-2), 160.9 (C=O), 177.3 (CHO); m/z Found: MNa
+, 327. Calc. for 
C13H18
35Cl2N2O2Na: MNa
+, 327. 
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4.13.3  N-Allyl-3,5-dichloro-4-formyl-1-methyl-1H-pyrrole-2-carboxamide 187c 
 
N
OHC
CH3
Cl
Cl
O
H
N
 
 
This pyrrole was prepared, as described above and the crude product was purified by 
column chromatography on silica, ethyl acetate: petroleum ether (60-80 
oC) (4:6) to 
give an orange solid 187c (0.19 g, 54 %); mp 125-126 
oC; υmax(KBr)/cm
-1 3262 (NH), 
1668 (C=O), 1635 (C=O), 1535 (C=C); 
1H NMR (300 MHz, DMSO-d6) ʴH  3.88 (3H, 
s, CH3), 4.01 (2H, m, CH2), 5.13 (1H, t, J = 1.8 Hz, =CH2-a), 5.19 (1H, t, J = 1.8 Hz, 
=CH2-b), 5.86 (1H, m, CH), 6.27 (1H, br s, NH), 9.69 (1H, s, CHO); 
13C NMR (75 
MHz,  DMSO-d6)  ʴC  33.2  (CH3),  41.9  (CH2),  114.3  (quat.),  116.7  (=CH2),  123.0 
(quat.), 125.7 (quat.), 129.4 (quat.), 133.8 (CH), 160.1 (C=O), 177.6 (CHO); m/z 
Found:  MH
+,  261.  Calc.  for  C10H10
35Cl2N2O2:  MH
+,  261.  HRMS  Found:  MH
+, 
260.0203. Calc. for C10H11Cl2N2O2: MH
+, 261.0193. 
 
4.13.4  N-Butyl-3,5-dichloro-4-formyl-1-methyl-1H-pyrrole-2-carboxamide 187d 
 
N
OHC
CH3
Cl
Cl
O
H
N
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Method A 
3,5-Dichloro-1-methyl-1H-pyrrole-2,4-dicarboxaldehyde 42 (0.40 g, 1.96 mmol) was 
dissolved in dry CCl4 (10 ml). To this solution was added AIBN (0.005 g, 0.033 
mmol) and NBS (0.45 g, 2.52 mmol). The reaction mixture was refluxed for 15 min 
then cooled to 0 
oC (ice-water bath) and n-butylamine (0.33 g, 4.5 mmol) was added 
dropwise.  The  ice-bath  was  removed  and  the  suspension  was  stirred  at  room 
temperature for 10 min. The solid material was removed by filtration and washed 
with CCl4 (10 ml). The filtrate was extracted with water (2 × 10 ml) and the combined 
organics  dried  over  MgSO4.  After  filtration,  the  solvent  was  evaporated  under 
reduced pressure and the crude product was purified by column chromatography on 
silica, eluting with ethyl acetate: petroleum ether (60-80 
oC) (2:8) to give a yellow 
solid 187d (0.24 g, 45 %). 
 
Method B 
A solution of 3,5-dichloro-4-formyl-1-methyl-1H-pyrrole-2-carboxylic acid 183 (0.30 
g, 1.35 mmol) and SOCl2 (0.49 ml) in toluene (5 ml) was refluxed for 4 h. After 
evaporation of the solvent, the crude mixture was dissolved in DCM (5 ml) and a 
solution of n-butylamine (0.31 ml, 3.1 mmol) and TEA (0.19 ml) in DCM (2 ml) was 
added dropwise at 0 
oC. The mixture was stirred for 2 h at room temperature then 
washed sequentially with 5 % aq. HCl (10 ml) and 5 % aq. NaOH (10 ml).  The 
organic layer was dried over MgSO4 and, after filtration, the solvent was evaporated 
under reduced pressure and the residue purified by column chromatography on silica, 
eluting with ethyl acetate: petroleum ether (60-80 
oC) (3:7) and give a yellow solid 
187d (0.28 g, 68 %);  mp 134-135 
oC; υmax(KBr)/cm
-1 3273 (NH), 1671 (C=O), 1637 
(C=O), 1554 (C=C); 
1H NMR (300 MHz, DMSO-d6) ʴH 0.89 (3H, t, J = 7.2 Hz, Experimental Part                                                                                Chapter Four 
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CH3), 1.34 (2H, q, J = 7.2 Hz,  CH2), 1.47 (2H, q, J = 6.9 Hz, CH2), 3.20 (2H, q, J = 
6.9 Hz, CH2), 3.86 (3H, s, CH3), 8.21 (1H, br s, NH), 9.66 (1H, s, CHO); 
13C NMR 
(75  MHz,  DMSO-d6)  ʴC  14.1  (CH3),  19.9  (CH2),  31.5  (CH2),  33.4  (NCH3),  39.0 
(CH2), 118.1 (quat.), 122.1 (quat.), 125.5 (quat.), 126.2 (quat.), 160.0 (C=O), 177.9 
(CHO); HRMS Found: MH
+ 277.0515. Calc. for C11H15Cl2N2O2: MH
+, 277.0506. 
 
4.13.5  Benzyl 3,5-dichloro-4-formyl-1-methyl-1H-pyrrole-2-carboxylate 191 
 
N
OHC
CH3
Cl
Cl
O
O
1`
2` 3`
4`
5`
6`
 
 
This pyrrole was prepared, as described above, and the crude product was purified by 
column chromatography on silica, eluting with ethyl acetate: petroleum ether (60-80 
oC) (5:5) to give pyrrole 191 as a white solid (0.15 g, 38 %); mp 124-125 
oC; [Found: 
C,  53.5;  H,  3.8;  N,  4.2.  C14H11NO3Cl2  requires  C,  53.8;  H,  3.6;  N,  4.5  %]; 
υmax(KBr)/cm
-1 1707 (C=O), 1664 (C=O); 
1H NMR (300 MHz, DMSO-d6) ʴH  3.89 
(3H, s, CH3), 5.34 (2H, s, CH2), 7.39-7.45 (5H, m, Ar-H), 9.73 (1H, s, CHO);
 13C 
NMR (75 MHz, DMSO-d6) ʴC 33.7 (CH3), 66.4 (CH2), 110.2 (quat.), 124.9 (quat.), 
126.7 (quat.), 128.3 (2 × CH), 128.5 (CH), 128.9 (2 × CH), 130.9 (quat.), 136.3 
(quat., C-1´), 160.5 (C=O), 178.5 (CHO). 
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4.14 Methyl 3,5-dichloro-4-formyl-1-methyl-1H-pyrrole-2-carboxylate 188   
 
N
OHC
CH3
Cl
Cl
O
O
CH3
 
 
This pyrrole was prepared, as described above, and recrystallised from methanol to 
give a white solid 188 (0.22 g, 80 %); mp 108-110 
oC; [Found: C, 40.5; H, 2.9; N, 
5.7. C8H7Cl2NO3 requires C, 40.7 ; H, 2.9; N, 5.9 %]; υmax(KBr)/cm
-1 1711 (C=O), 
1654 (C=O), 1511 (C=C); 
1H NMR (300 MHz, DMSO-d6) ʴH  
 3.87 (3H, s, NCH3), 
3.94 (3H, s, OCH3), 9.79 (1H, s, CHO); 
13C NMR (75 MHz, DMSO-d6) ʴC 33.7 
(NCH3), 52.2 (OCH3), 110.4 (quat.), 124.8 (quat.), 126.7 (quat.), 130.7 (quat.), 161.1 
(C=O), 178.5 (CHO). 
 
4.15 Ethyl 3,5-dichloro-4-formyl-1-methyl-1H-pyrrole-2-carboxylate 189    
 
N
OHC
CH3
Cl
Cl
O
O CH3
 
 
A  solution  of  3,5-dichloro-4-formyl-1-methyl-1H-pyrrole-2-carboxylic  acid  183 
(0.30 g, 1.35 mmol) and SOCl2 (0.49 ml) in toluene (5 ml) was refluxed for 4 h. After 
evaporation of the solvent, the crude mixture was cooled to 0 
oC and treated with dry 
ethanol (10 ml) at 40 
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and the crude mixture was diluted with water (10 ml), extracted with EtOAc (3 × 20 
ml)  and  the  combined  organics  dried  over  MgSO4.  The  product  was  purified  by 
column chromatography on silica, eluting with petroleum ether (60-80 
oC): diethyl 
ether (60:40) to give ester 189 (0.25 g, 86 %) as white solid; mp 78-80 
oC; [Found: C, 
43.3; H, 3.8; N, 5.4. C9H9Cl2NO3 requires C, 43.2; H, 3.6; N, 5.6 %]; υmax(KBr)/cm
-1 
1706 (C=O), 1662 (C=O), 1512 (C=C); 
1H NMR (300 MHz, DMSO-d6) ʴH 1.35 (3H, 
t,  J = 7.2 Hz, CH2CH3), 3.93 (3H, s, NCH3), 4.35 (2H, q, J = 7.2 Hz, CH2), 9.76 (1H, 
s,  CHO); 
13C  NMR  (75  MHz,  DMSO-d6)  ʴC  14.5  (CH2CH3),  33.6  (NCH3),  60.9 
(CH2), 110.5 (quat., C-3 or C-4), 124.8 (quat., C-3 or C-4), 126.6 (quat., C-5), 130.6 
(quat.,  C-2),  160.6  (C=O),  178.4  (CHO);  m/z  Found:  MNa
+,  272.  Calc.  for 
C9H9
35Cl2NO3Na : MNa
+, 272. 
 
4.16 General procedure for the preparation of compounds 195a-b   
 
Triphenylphosphine (0.41 g, 1.56 mmol) and pyrrole 41 (0.30 g, 1.56 mmol) were 
dissolved  in  DCM  (16  ml).  To  this  solution  was  added  dropwise  a  mixture  of 
dimethyl acetylenedicarboxylate (0.22 g, 1.56 mmol) in DCM (5.45 ml), at 0 
oC over 
10 min. The reaction mixture was then allowed to warm to room temperature and 
stirred for a further 20 min. The solvent was removed under reduced pressure and the 
residue was extracted with ether (4 × 30 ml). The combined ether layers were dried 
over  anhydrous  MgSO4.  After  filtration,  the  solvent  was  removed  under  reduced 
pressure  and  the  crude  product  was  purified  by  column  chromatography  or  by 
recrystallisation. 
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4.16.1  Dimethyl 5,7-dichloro-6-formyl-3H-pyrrolizine-2,3-dicarboxylate 195a 
 
 
 
 
The crude product was purified by column chromatography on silica, eluting with 
ethyl acetate: petroleum ether (60-80 
oC) (3:7), to give a yellow solid 195a (0.29 g, 58 
%); mp 121-122 
oC; υmax(KBr)/cm
-1 1741 (C=O), 1714 (C=O), 1677 (C=O); 
1H NMR 
(300 MHz, CDCl3) ʴH 3.78 (6H, s, 2 × CH3), 6.05 (1H, d, J = 1.8 Hz, CH-3), 7.85 
(1H, d, J = 1.8 Hz, CH-1), 9.79 (1H, s, CHO); 
13C NMR (75 MHz, CDCl3) ʴC 52.8 
(OCH3), 54.1 (OCH3), 65.1 (CH, C-3), 106.8 (C-3), 120.2 (C-4), 123.7 (C-5), 130.3 
(CH,  C-1),  133.2  (C-2),  135.7  (C-7),  161.9  (C=O),  165.9  (C=O),  183.2  (CHO); 
HRMS Found: MH
+, 339.9770. Calc. for C12H10Cl2NO5: MH
+, 339.9749. 
 
4.16.2  Diethyl 5,7-dichloro-6-formyl-3H-pyrrolizine-2,3-dicarboxylate 195b 
 
N
OHC Cl
Cl
EtO2C CO2Et
H
H
1
2 3
4
5
6 7
8
 
 
 
N
OHC Cl
Cl
MeO2C CO2Me
H
H
1
2 3
4
5
6 7
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Purified by column chromatography on silica, eluting with ethyl acetate: petroleum 
ether (60-80 
oC) (3:7) to give a yellow solid 195b (1.17 g, 65 %); mp 129-131 
oC; 
υmax(KBr)/cm
-1 1725 (C=O), 1703 (C=O), 1663 (C=O); 
1H NMR (300 MHz, CDCl3) 
ʴH 1.29 (3H, t, J = 6.9 Hz, OCH2CH3), 1.36 (3H, t, J = 7.2 Hz, OCH2CH3), 4.27 (2H, 
q,  J = 6.9 Hz, OCH2CH3), 4.38 (2H, q, J = 7.2 Hz, OCH2CH3), 6.79 (1H, s, H-3), 
6.87 (1H, s, H-1), 9.84 (1H, s, CHO); 
13C NMR (75 MHz, CDCl3) ʴC 13.9 (CH3), 
14.2 (CH3), 61.3 (CH2), 62.2 (CH2), 67.8 (CH, C-3), 109.9 (CH, C-1), 125.6 (quat.), 
126.6 (quat.), 136.1 (quat.), 136.8 (quat.), 139.5 (quat.), 158.3 (C=O), 162.4 (C=O), 
181.4  (CHO);  HRMS  Found:  MH
+,  368.0073.  Calc.  for  C14H14Cl2NO5:  MH
+, 
368.0062. 
 
4.17  N-Ethoxythiocarbonyl 3,5-dichloro-4-formyl-1-methyl-1H-pyrrole-2-
carboxamide 208a 
 
N
OHC
CH3
Cl
Cl
O
H
N O
S
CH3
 
 
A solution of 3,5-dichloro-4-formyl-1-methyl-1H-pyrrole-2-carboxylic acid 183 (0.57 
g, 2.57 mmol) and SOCl2 (0.92 ml) in toluene (10 ml) was refluxed for 4 h. After 
evaporation of the solvent, the crude mixture was cooled to 0 
oC and treated with a 
solution of KSCN (0.27 g, 2.70 mmol) in dry acetone (15 ml). After stirring for 2 h at 
room temperature, the mixture was filtered, then the solvent was evaporated under 
reduced pressure and the crude product was used in the next reaction without any Experimental Part                                                                                Chapter Four 
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further purification 207 (0.21 g, 31 %). The isothiocyanate (0.21 g, 0.79 mmol) in dry 
ethanol (15 ml) was refluxed for 2 h at 60 
oC. After completion of the reaction, as 
indicated  by  TLC,  the  solvent  was  evaporated  under  reduced  pressure,  the  crude 
mixture was diluted with water (8 ml) and extracted with EtOAc (2 × 15 ml). The 
combined organic phases were washed with 4 % aqueous NaHCO3 solution (8 ml), 
then  with  water  (15  ml)  and  dried  over  MgSO4.  After  filtration,  the  solvent  was 
evaporated under reduced pressure and the crude product was purified by column 
chromatography on silica, eluting with ethyl acetate: petroleum ether (60-80 
oC) (3:7) 
to give the thiocarbamic acid ester 208a (0.065 g, 26 %) as a white solid, mp 115-116 
oC; υmax(KBr)/cm
-1 3377 (NH), 1703 (C=O), 1670 (C=O), 1170 (C=S); 
1H NMR (300 
MHz, CDCl3) ʴH 1.38 (3H, t, J = 7.2 Hz, OCH2CH3), 3.91 (3H, s, CH3), 4.59 (2H, q, J 
= 7.2 Hz, OCH2CH3), 9.22 (1H, s, NH), 9.73 (1H, s, CHO); 
13C NMR (75 MHz, 
CDCl3) ʴC 13.7 (CH3), 33.4 (NCH3), 69.5 (OCH2), 112.8 (quat.), 123.3 (quat.), 126.2 
(quat.), 130.9 (quat., C-4), 155.3 (C=S), 177.6 (C=O), 188.6 (CHO); HRMS Found: 
MH
+, 308.9866. Calc. for C10H11Cl2N2O3S: MH
+, 308.9862. 
 
4.18  N-Methoxythiocarbonyl 3,5-dichloro-4-formyl-1-methyl-1H-pyrrole-2-
carboxamide 208b 
 
N
OHC
CH3
Cl
Cl
O
H
N O
S
CH3
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This pyrrole was prepared in a similar way as described above, to give a yellow solid 
208b (0.89 g, 45 %); mp 120-121 
oC; υmax(KBr)/cm
-1 1719 (C=O), 1649 (C=O), 1163 
(C=S); 
1H NMR (300 MHz, CDCl3) ʴH 3.92 (3H, s, NCH3), 4.12 (3H, s, OCH3), 9.30 
(1H, s, NH), 9.73 (1H, s, CHO); 
13C NMR (75 MHz, CDCl3) ʴC 33.5 (NCH3), 59.4 
(OCH3), 112.6 (quat.), 123.2 (quat.), 126.2 (quat.), 131.1 (quat., C-4), 155.3 (C=S), 
177.6 (C=O), 189.4 (CHO); HRMS Found: MH
+, 294.9716. Calc. for C9H9Cl2N2O3S: 
MH
+, 294.9706. 
 
4.19  1H-Pyrrole-2,4-dicarboxaldehyde 218 
 
N
OHC
CHO
H
H
H
 
 
3,5-Dichloro-1H-pyrrole-2,4-dicarboxaldehyde  41  (0.80  g,  4.16  mmol),  10  % 
palladium  on  carbon  (24  mg)  and  Et3N  (0.71  ml,  5.1  mmol)  were  dissolved  in 
methanol (80 ml) then stirred under hydrogen (1 atmosphere) at ambient temperature 
(ca.  23 
oC).  After  4  h  the  reaction  mixture  was  filtered  through  celite,  and  the 
methanol was concentrated in vacuo. The residue was extracted with ethyl acetate (3 
× 40 ml), and the combined organic layer was washed with brine (70 ml) and dried 
over MgSO4. After filtration, the solvent was evaporated under reduced pressure and 
the crude product was  purified by column chromatography on silica, eluting with 
ethyl acetate: petroleum ether (60-80 
oC) (3:7) to give a white solid 218 (0.36 g, 70 
%);  mp  103-104 
oC;  υmax(KBr)/cm
-1  3117  (NH),  1666  (C=O),  1637  (C=O),  1540 
(C=C); 
1H NMR (300 MHz, DMSO-d6) ʴH 7.42 (1H, s, H-3), 7.97 (1H, s,  H-5), 9.62 Experimental Part                                                                                Chapter Four 
159 
(1H, s, CHO), 9.81 (1H, s, CHO), 12.85 (1H, br s, NH); 
13C NMR (75 MHz, DMSO-
d6) ʴC 118.9 (CH, C-3), 127.6 (quat., C-2), 133.5 (CH, C-5), 134.6 (quat., C-4), 181.5 
(CHO),  186.4  (CHO);  HRMS  Found:  MH
+,  124.0395.  Calc.  for  C6H6NO2:  MH
+, 
124.0394. 
 
4.20  3-Chloro-1-methyl-1H-pyrrole-2,4-dicarboxaldehyde 219 
 
N
OHC
CHO
CH3
Cl
H
 
 
3,5-Dichloro-1-methyl-1H-pyrrole-2,4-dicarboxaldehyde 42 (0.8 g, 4.16 mmol), 5% 
Pd on charcoal (24 mg) and Et3N (0.71 ml, 5.1 mmol) were dissolved in methanol (80 
ml) then stirred under hydrogen (4 bar) at 60 
oC. After 4 h the reaction mixture was 
filtered through celite, and the methanol was concentrated in vacuo. The residue was 
extracted with ethyl acetate (3 × 40 ml) and the combined organic layer was washed 
with brine (70 ml) and dried over MgSO4. After filtration, the solvent was evaporated 
under reduced pressure and recrystallised from petroleum ether (60-80 
oC) to give a 
white powder 219 (0.79 g, 94 %); mp 100-101 
oC; [Found: C, 48.8; H, 3.5; N, 8.0. 
C7H6NO2Cl requires C, 49.0; H, 3.5; N, 8.2 %]; υmax(KBr)/cm
-1 1715 (C=O), 1653 
(C=O), 1508 (C=C); 
1H NMR (300 MHz, CDCl3) ʴH 3.91 (1H, s, CH3), 7.36 (1H, s, 
H-5), 9.80 (1H, s, CHO), 9.83 (1H, s, CHO); 
13C NMR (75 MHz, CDCl3) ʴC 38.4 
(CH3), 121.6 (quat., C-3), 127.0 (quat., C-4), 127.6 (quat., C-2), 132.7 (CH, C-5), 
178.6 (4-CHO), 183.4 (2-CHO). 
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4.21 Diethyl 1H-pyrrole-2,4-dicarboxylate 226 
 
N H
H EtO2C
CO2Et
H  
 
Diethyl 1H-pyrrole-2,4-dicarboxylate was prepared by the method of Kazuo.
3 To a 
mixture of ethyl isocyanoacetate (2.19 ml, 0.02 mol) and DBU (2.99 ml, 0.02 mol) in 
THF (30 ml), formaldehyde (0.27 ml, 0.01 mol) was added dropwise at 45-50 
oC. 
After stirring for an additional 4 h at the same temperature, the reaction mixture was 
neutralised with acetic acid then the solvent was removed under reduced pressure. 
The residue was diluted with water (8 ml) and extracted with ethyl acetate (2 × 15 
ml). The combined organic phases were washed with 5 % aq. HCl (2 × 15 ml) and 
dried  over  MgSO4.  After  filtration,  the  solvent  was  evaporated  under  reduced 
pressure and the crude product was purified by column chromatography on silica, 
eluting with ethyl acetate: petroleum ether (60-80 
oC) (50:50) to give diester 226 
(0.39 g, 19 %) as a white solid; mp 186-188 
oC (lit.
5 mp 183-185 
oC); υmax(KBr)/cm
-1 
3277 (NH), 1707 (C=O), 1673 (C=O), 1566 (C=C); 
1H NMR (300 MHz, CDCl3) ʴH  
6.14 (6H, t, J = 7.2 Hz, 2 × CH3), 4.25 (4H, q, J = 7.2 Hz, 2 × CH2), 7.23 (1H, dd, J = 
3.9 and 1.5 Hz, CH), 7.47 (1H, dd, J = 3.9 and 1.5 Hz, CH), 9.81 (1H, br s, NH); 
13C 
NMR (75 MHz, CDCl3) ʴC 14.3 (CH3), 14.4 (CH3), 60.2 (CH2), 60.9 (CH2), 115.9 
(CH, C-3), 118.4 (quat., C-4), 123.8 (quat., C-2), 127.0 (CH, C-5), 161.1 (C=O), 
164.1 (C=O); m/z Found: MH
+, 212. Calc. for C10H14NO4: MH
+, 212. 
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4.22  Diethyl 5-bromo-1H-pyrrole-2,4-dicarboxylate 227a 
 
N Br
H EtO2C
CO2Et
H  
 
Method A 
A solution of N-bromosuccinimide (0.60 g, 3.39 mmol) in THF (6 ml) was added 
dropwise  to  the  1H-pyrrole-2,4-dicarboxylic  acid  diethyl  ester  226  (0.34  g,  1.61 
mmol) in THF (5 ml) at -78 
oC, under argon. The mixture was warmed to room 
temperature and stirred for a further 4 h. The solvent was evaporated under reduced 
pressure, the crude product diluted with CCl4 (5 ml) and the precipitate formed was 
filtered off. The filtrate was evaporated under reduced pressure and the crude product 
was  purified  by  column  chromatography  on  silica,  eluting  with  ethyl  acetate: 
petroleum ether (60-80 
oC) (4:6) to give diester 227 as a white solid (0.15 g, 32 %); 
spectral data given below. 
 
Method B 
Bromine  (0.72  ml,  14.05  mmol)  in  chloroform  (5  ml)  was  added  dropwise  to  a 
solution of pyrrole 226 (1.5 g, 7.11 mmol) in chloroform (40 ml) at room temperature 
and stirred for 4 h at the same temperature. The reaction mixture was then poured into 
0.1 % w/v aqueous sodium metabisulphite, extracted with DCM (3 × 30 ml) and the 
combined organics dried over MgSO4. After filtration, the solvent was evaporated 
under reduced pressure and the residue recrystallised from hexane to give the diester Experimental Part                                                                                Chapter Four 
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227 as white solid (1.89 g, 91 %); mp 133-134 
oC; υmax(KBr)/cm
-1 3213 (NH),
 1709 
(C=O), 1665 (C=O); 
1H NMR (300 MHz, DMSO-d6) ʴH 1.22 (6H, t, J = 7.2 Hz, 2 × 
CH3), 4.17 (4H, q, J = 7.2 Hz, 2 × CH2), 7.03 (1H, s, CH), 13.27 (NH);
 13C NMR (75 
MHz, DMSO-d6) ʴC 14.7 (2 × CH3), 60.2 (CH2), 60.8 (CH2), 111.0 (quat.), 115.4 
(quat.), 117.4 (CH, C-3), 124.5 (quat.), 159.6 (C=O), 162.4 (C=O); HRMS Found: 
MH
+, 290.0033. Calc. for C10H13BrNO4: MH
+, 290.0023. 
 
4.23  Diethyl 5-bromo-1-methyl-1H-pyrrole-2,4-dicarboxylate 227b 
 
N Br
H EtO2C
CO2Et
CH3  
 
This pyrrole was prepared in a similar way  as described above, and recrystallised 
from hexane to give diester  227b as a white solid (1.47 g, 93 %); mp 92-93 
oC; 
υmax(KBr)/cm
-1 1697 (C=O), 1540 (C=C); 
1H NMR (300 MHz, DMSO-d6) ʴH 1.35 
(6H, m, 2 × CH3), 3.97 (3H, s, NCH3), 4.29 (4H, m, 2 × CH2), 7.31 (1H, s, CH);
 13C 
NMR (75 MHz, DMSO-d6) ʴC 14.6 (CH3), 14.7 (CH3), 33.3 (NCH3), 60.3 (CH2), 60.9 
(CH2), 114.4 (quat., C-4), 116.9 (quat., C-5), 118.9 (CH, C-3), 124.4 (quat., C-2), 
159.8 (C=O), 162.1 (C=O); HRMS Found: MH
+, 304.0199. Calc. for C11H15BrNO4: 
MH
+, 304.0179. 
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4.24  Diethyl 3,5-dibromo-1H-pyrrole-2,4-dicarboxylate 228 
 
N Br
Br EtO2C
CO2Et
H  
 
This pyrrole was prepared in a similar way as described above, and recrystallised 
from methanol to give the diester 228 as white crystals (1.49 g, 85 %); mp 159-160 
oC; [Found: C, 32.4; H, 2.9 ; N, 3.6. C10H11Br2NO4 requires C, 32.5; H, 3.0; N, 3.8 
%]; υmax(KBr)/cm
-1 3210 (NH), 1698 (C=O), 1661 (C=O), 1530 (C=C); 
1H NMR 
(300 MHz, DMSO-d6) ʴH 1.31 (6H, t, J = 7.2 Hz, 2 × CH3), 4.28 (4H, q, J = 7.2 Hz, 2 
× CH2), 13.61 (1H, br s, NH); 
13C NMR (75 MHz, DMSO-d6) ʴC 15.0 (CH3), 15.1 
(CH3),  61.2  (CH2),  61.5  (CH2),  104.2  (quat.),  111.6  (quat.),  116.3  (quat.),  123.5 
(quat.),  159.2  (C=O),  162.1  (C=O);  m/z  Found:  (M-H)
-,  368.  Calc.  for  C10H10 
Br2NO4: (M-H)
-, 368. 
 
4.25 General procedure for the Suzuki reaction of bromo derivatives   
 
Pyrrole (1.04 mmol) was dissolved in DMF (10 ml) and the mixture was stirred under 
argon. Palladium tetrakistriphenylphosphine (0.053 mmol) and a boronic acid (1.25 
mmol) were added to this solution, sequentially, at room temperature. The reaction 
mixture  was  heated  to  70  °C  and  sodium  carbonate  (9.3  mmol)  dissolved  in  the 
minimum of water was added to the solution. The mixture was refluxed at 110 °C 
then the reaction mixture was allowed to cool to room temperature, diluted with water Experimental Part                                                                                Chapter Four 
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(48 ml), extracted with  Et2O (3 × 50 ml), and the combined organics  dried over 
MgSO4. After filtration, the solvent was evaporated under reduced pressure and the 
crude product was purified by column chromatography or recrystallised. 
 
4.25.1  Diethyl 5-phenyl-1H-pyrrole-2,4-dicarboxylate 234a 
 
N
H
EtO2C
CO2Et
H
1`
2`
3`
4`
5`
6`
1
2
3 4
5
 
 
The crude product was purified by column chromatography on silica, eluting with 
ethyl acetate: petroleum ether (60-80 
oC) (2:8) to give diester 234a as a white solid 
(0.29  g,  58  %);  mp  117-118 
oC;  υmax(KBr)/cm
-1  3275  (NH),  1714  (C=O),  1668 
(C=O); 
1H NMR (300 MHz, DMSO-d6) ʴH 1.22 (3H, t, J = 6.9 Hz, CH3), 1.35 (3H, t, 
J = 7.2 Hz, CH3), 4.16 (2H, q, J = 6.9 Hz, CH2), 4.32 (2H, q, J = 7.2 Hz, CH2), 7.25 
(1H, s, CH), 7-35-7.47 (3H, m, ArH), 7.62 (2H, m, ArH), 12.60 (1H, br s, NH); 
13C 
NMR (75 MHz, DMSO-d6) ʴC 14.5 (CH3), 14.6 (CH3), 59.8 (CH2), 60.5 (CH2), 113.5 
(quat.), 118.2 (CH, C-3), 122.9 (quat.), 127.9 (2 × CH), 129.5 (CH), 130.4 (2 × CH), 
160.4 (C=O), 163.7 (C=O); HRMS Found: MH
+, 288.1235, Calc. for C16H18NO4: 
MH
+, 288.1231. 
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4.25.2  Diethyl 5-(3,4-dimethoxyphenyl)-1H-pyrrole-2,4-dicarboxylate 234b 
 
N
H
EtO2C
CO2Et
H
1`
2`
3`
4`
5`
6`
H3CO
H3CO
1
5 2
3 4
 
 
The crude product was recrystallised from petroleum ether (60-80 
oC) to give diester 
234b as white crystals (0.42 g, 88 %); mp 157-158 
oC; [Found: C, 62.2; H, 6.1; N, 
4.0. C18H21NO6 requires C, 62.2; H, 6.1; N, 4.0 %]; υmax(KBr)/cm
-1 3275 (NH), 1715 
(C=O), 1679 (C=O); 
 1H NMR (300 MHz, CDCl3) ʴH 1.22 (3H, t, J = 7.2 Hz, CH3), 
1.28 (3H, t, J = 6.9 Hz, CH3), 3.85 (6H, s, 2 × OCH3), 4.17 (2H, q, J = 7.2 Hz, CH2), 
4.23 (2H, q, J = 6.9 Hz, CH2), 6.85 (1H, d, J = 8.4 Hz, H-5´), 7.12 (1H, dd, J = 8.4 
and 1.8 Hz, H-6´), 7.17 (1H, d, J = 1.8 Hz, H-2´), 7.31 (1H, s, H-3), 9.32 (1H, s, NH); 
13C NMR (75 MHz, CDCl3) ʴC 14.3 (CH3), 14.4 (CH3), 56.0 (OCH3), 56.1 (OCH3), 
60.0 (CH2), 60.9 (CH2), 110.9 (CH), 112.8 (CH), 113.8 (quat.), 118.4 (CH, C-3), 
121.8 (CH), 121.9 (quat.), 123.5 (quat.), 140.6 (quat.), 148.6 (quat., C-3´ or C-4´), 
149.9 (quat., C-3´ or C-4´), 161.0 (C=O), 164.1 (C=O) ; m/z Found: MNa
+, 370. Calc. 
for C18H21NO6Na: MNa
+, 370. 
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4.25.3  Diethyl 3,5-bis(biphenyl-3-yl)-1H-pyrrole-2,4-dicarboxylate 235a 
 
N
H
EtO2C
CO2Et
1
2
3
4
5
6
1`
2`
3`
4`
5`
6`
1``
2``
3`` 4``
5``
6`` 1```
2```
3```
4```
5```
6```
 
 
The crude product was recrystallised from methanol to give diester 235a as white 
crystals (0.47 g, 68 %); mp 154-155 
oC; [Found: C, 78.8; H, 5.7; N, 2.6. C34H29NO4 
requires C, 79.2; H, 5.7; N, 2.7 %]; υmax(KBr)/cm
-1 3258 (NH), 1708 (C=O), 1664 
(C=O); 
1H NMR (300 MHz, CDCl3) ʴH 0.73 (3H, t, J = 7.2 Hz, CH3), 0.90 (3H, t, J = 
6.9 Hz, CH3), 3.89 (2H, q, J = 6.9 Hz, CH2), 3.96 (2H, q, J = 7.2 Hz, CH2), 7.25 (1H, 
m, ArH), 7.28 (1H, m, ArH), 7.33 (5H, m, ArH), 7.40 (1H, m, ArH),  7.41-7.45 (1H, 
m, ArH),  7.46-7.48 (1H, m, ArH),  7.49-7.51 (1H, m, ArH),  7.52-7.55 (6H, m, ArH), 
7.78 (1H, s, ArH), 9.50 (1H, s, NH); 
13C NMR (75 MHz, CDCl3) ʴC 13.5 (CH3), 13.9 
(CH3), 60.0 (CH2), 60.6 (CH2), 115.1 (quat.), 119.9 (quat.), 125.8 (CH), 127.11 (CH), 
127.15 (2 × CH), 127.2 (2 × CH), 127.5 (CH), 127.6 (CH), 127.7 (CH), 127.8 (2 × 
CH), 127.9 (CH), 128.7 (2 × CH), 128.8 (CH), 128.9 (2 × CH), 128.9 (CH), 129.0 
(CH), 131.7 (quat.), 133.3 (quat.), 135.1 (quat.), 138.9 (quat.), 139.9 (quat.), 140.5 
(quat.), 141.4 (quat.), 161.1 (C=O), 164.5 (C=O); m/z Found: MNa
+, 538. Calc. for 
C34H29NO4Na: MNa
+, 538. 
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4.25.4  Diethyl 3,5-diphenyl-1H-pyrrole-2,4-dicarboxylate 235b 
 
N
H
EtO2C
CO2Et
1`
2`
3`
4`
5`
6`
1``
2``
3``
4``
5``
6``
1
2
3 4
5
 
 
The crude product was recrystallised from petroleum ether (60-80 
oC) – ethyl acetate 
to give diester 235b as white crystals (0.21 g, 71 %); mp 110-112 
oC; υmax(KBr)/cm
-1 
3288 (NH), 1712 (C=O), 1661 (C=O);
 1H NMR (300 MHz, DMSO-d6) ʴH  0.83 (3H, 
t, J  = 7.2 Hz, CH3), 1.09 (3H, t, J = 6.9 Hz, CH3), 3.90 (2H, q, J = 7.2 Hz, CH2), 4.11 
(2H, q, J = 6.9 Hz, CH2), 7.29-7.34 (5H, m, ArH), 7.43-7.49 (3H, m, ArH), 7.59-7.61 
(2H, m, ArH), 12.49 (1H, s, NH); 
13C NMR (75 MHz, DMSO-d6) ʴC 13.8 (CH3), 14.3 
(CH3), 59.8 (CH2), 60.1 (CH2), 114.8 (quat.), 119.9 (quat.), 127.0 (CH), 127.4 (CH), 
128.0 (CH), 128.3 (CH), 128.9 (CH), 129.8 (CH), 130.5 (CH), 131.3 (quat.), 132.6 
(quat.), 135.1 (quat.), 138.9 (quat.), 160.5 (C=O), 164.7 (C=O);  HRMS Found: MH
+, 
364.1547. Calc. for C22H21NO4: MH
+, 364.1544. 
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4.25.5  1-Methyl-3,5-diphenyl-1H-pyrrole-2,4-dicarboxaldehyde 237a 
 
N
OHC
CHO
CH3  
 
The crude product was recrystallised from petroleum ether (60-80 
oC) – ethyl acetate 
to give pyrrole 237a as a yellow solid (0.31 g, 74 %); mp 117-119 
oC; [Found: C, 
78.8; H, 5.3; N, 4.8. C19H15NO2 requires C, 78.9; H, 5.2; N, 4.8 %]; υmax(KBr)/cm
-1 
1657 (C=O);
 1H NMR (300 MHz, CDCl3) ʴH 3.78 (3H, s, CH3), 7.29-7.38 (7H, m, 
ArH), 7.41-7.46 (3H, m, ArH), 9.46 (1H, s, 4-CHO), 9.56 (1H, s, 2-CHO); 
13C NMR 
(75 MHz, CDCl3) ʴC 34.5 (CH3), 120.8 (C-3 or C-4), 128.1 (CH), 128.6 (CH), 128.8 
(CH), 129.1 (C-3 or C-4), 130.1 (CH), 130.6 (CH), 131.1 (CH), 140.2 (C-5), 147.2 
(C-2), 181.7 (CHO), 185.9 (CHO); m/z Found: MNa
+, 312. Calc. for C19H15NO2Na: 
MNa
+, 312. 
 
4.25.6  1-Methyl-3-phenyl-1H-pyrrole-2,4-dicarboxaldehyde 237b 
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N
OHC
CHO H
CH3
1
2
3 4
5
1`
2`
3`
4`
5`
6`
 
The crude product was purified by column chromatography on silica, eluting with 
ethyl acetate: petroleum ether (60-80 
oC)  (3:7)  to  give  the  dialdehyde  237b  as  a 
yellow solid (0.082 g, 66 %); mp 120-122 
oC; υmax(KBr)/cm
-11654 (C=O);
 1H NMR 
(300 MHz, DMSO-d6) ʴH 3.99 (3H, s, CH3), 7.42-7.49 (5H, m, ArH), 8.03 (1H, s, 
CH), 9.44 (1H, s, CHO), 9.64 (1H, s, CHO); 
13C NMR (75 MHz, DMSO-d6) ʴC  37.9 
(CH3), 122.6 (C-4), 128.7 (2 × CH), 128.8 (CH), 129.1 (quat., C-2), 130.6 (quat., C-
3), 131.4 (2 × CH), 135.9 (CH, C-5), 139.1 (quat., C-1´), 180.9 (CHO), 185.6 (CHO). 
HRMS Found: MH
+ 214.0876, Calc. for C13H12NO2: MH
+, 214.0869. 
 
4.26 General procedure for the Wittig reaction   
 
The appropriate aldehyde (2.91 mmol) was dissolved in CH3CN (30 ml) and treated 
with  (carbethoxymethylene)triphenylphosphorane  (3.06  mmol)  or 
(carbethoxyethylidene)triphenylphosphorane (3.06 mmol). The reaction mixture was 
refluxed for 9-12 h then the solvent was removed under reduced pressure and the 
residue was treated with water (20 ml), extracted with EtOAc (3 × 30 ml) and the 
combined organics dried over MgSO4. After filtration, the solvent was evaporated 
under  reduced  pressure  and  the  crude  product  was  purified  by  column 
chromatography or recrystallised. 
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4.26.1  Ethyl 3´-(3,5-dichloro-4-formyl-1-methyl-1H-pyrrole-2-yl)acrylate 241a 
 
N
Cl
OHC Cl
H
1
2
3 4
5 1`
2`
3`
CO2Et
H
CH3  
The crude product was purified by column chromatography on silica, eluting with 
ethyl acetate: petroleum ether (60-80 
oC) (2:8), to give the acrylate 241a as a pink 
solid (0.24 g, 35 %); mp 114-116 
oC; υmax(KBr)/cm
-1 1701 (C=O), 1660 (C=O), 1634 
(C=O), 1511 (C=C); 
1H NMR (300 MHz, CDCl3) ʴH 1.27 (3H, t, J = 7.2 Hz, CH3), 
3.89 (3H, s, NCH3), 4.19 (2H, q, J = 7.2 Hz, CH2), 6.61 (1H, d, J = 16 Hz, =CH-3´), 
7.48 (1H, d, J = 16 Hz, =CH-2´), 9.69 (1H, s, CHO); 
13C NMR (75 MHz, CDCl3) ʴC 
14.4 (CH3), 33.5 (CH3), 60.6 (CH2), 114.6 (quat., C-3), 119.1 (CH-3´), 125.3 (quat., 
C-5),  126.5  (quat.,  C-2),  128.8  (quat.,  C-4),  131.8  (CH-2´),  167.1  (C=O),  177.5 
(CHO); HRMS Found: MH
+, 276.0196. Calc. for C11H12Cl2NO3: MH
+, 276.0190. 
 
4.26.2  Ethyl-3´-(3,5-dichloro-4-formyl-1H-pyrrole-2-yl)-2´-methylacrylate 241b 
 
N
H
Cl
OHC Cl
H
1
2
3 4
5 1`
2`
3`
CO2Et
CH3
 
 
The crude product was purified by column chromatography on silica, eluting with 
ethyl acetate: petroleum ether (60-80 
oC) (2:8), to give ester 241b a yellow solid (0.2 
g, 35 %); mp 149-150 
oC; [Found: C, 47.8; H, 4.0; N, 5.0. C11H11Cl2NO3 requires C, Experimental Part                                                                                Chapter Four 
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47.9; H, 4.0; N, 5.1 %]; υmax(KBr)/cm
-1 3180 (NH), 1717 (C=O), 1666 (C=O); 
1H 
NMR (300 MHz, DMSO-d6) ʴH  1.35 (3H, t, J = 7.2 Hz, CH3), 2.13 (3H, d, J = 1.5 
Hz, CH3), 4.28 (2H, q, J = 7.2 Hz, CH2), 7.37 (1H, q, J = 1.5 Hz, =CH), 9.88 (1H, s, 
CHO), 12.96 (1H, br s, NH); 
13C NMR (75 MHz, DMSO-d6) ʴC  14.6 (CH3), 15.2 
(CH3), 61.3 (CH2), 114.3 (quat., C-4), 116.7 (quat., C-3), 123.8 (CH), 125.5 (quat., C-
5), 126.1 (quat., C-2), 128.5 (quat., =C), 167.5 (C=O), 182.9 (CHO); m/z Found: 
MH
+, 276. Calc. for C11H11
35Cl2NO3: MH
+, 276. 
 
4.26.3 Ethyl 3-(3,5-dichloro-1-ethyl-4-formyl-1H-pyrrole-2-yl)acrylate 241c 
 
N
Cl
OHC Cl
H
1
2
3 4
5 1`
2`
3`
CO2Et
H
CH3  
 
The crude product was purified by column chromatography on silica, eluting with 
ethyl acetate: petroleum ether (60-80 
oC) (2:8), to give ester 241c as a pale yellow 
solid (0.2 g, 43 %); mp 108-109 
oC; υmax(KBr)/cm
-1 1706 (C=O), 1665 (C=O), 1634 
(C=O),  1525  (C=C); 
1H  NMR  (300  MHz,  CDCl3)  ʴH  1.25  (3H,  t,  J  =  7.2  Hz, 
OCH2CH3), 1.28 (3H, t, J = 6.9 Hz, NCH2CH3), 4.19 (2H, q,   J = 7.2 Hz, OCH2CH3), 
4.41 (2H, q, J = 6.9 Hz, NCH2CH3), 6.66 (1H, d, J = 16.2 Hz, H-2´), 7.49 (1H, d, J = 
16.2 Hz, H-3´), 9.68 (1H, s, CHO); 
13C NMR (75 MHz, CDCl3) ʴC 14.4 (CH3), 15.3 
(CH3), 41.8 (CH2), 60.6 (CH2), 114.6 (quat., C-2), 119.1 (CH, C-2´), 125.6 (quat., C-
3 or C-5), 125.8 (quat., C-3 or C-5), 127.9 (quat., C-4), 131.8 (CH, C-3´), 167.1 Experimental Part                                                                                Chapter Four 
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(C=O), 177.2 (CHO); HRMS Found: MH
+, 290.0359. Calc. for C12H13Cl2NO3: MH
+, 
290.0346. 
 
 
 
 
4.26.4  3,5-Dichloro-2,4-bis(2-ethoxycarbonylethenyl)-1-methyl-1H-pyrrole 242a 
 
N
Cl
Cl
H
1
2
3 4
5 1`
2`
3`
CO2Et
H
CH3
H
EtO2C
H
1``
2`` 3``
 
 
The crude product was purified by column chromatography on silica, eluting with 
ethyl acetate: petroleum ether (60-80 
oC) (2:8), to give the diester 242a as a yellow 
solid (0.38 g, 45 %); mp 113-114 
oC; υmax(KBr)/cm
-1 1698 (C=O), 1624 (C=O); 
1H 
NMR (300 MHz, DMSO-d6) ʴH 1.30-1.36 (6H, m, 2 × CH3), 3.79 (3H, s, NCH3), 
4.24-4.28 (4H, m, 2 × CH2), 6.64 (1H, d, J = 16.2 Hz, =CH), 6.67 (1H, d, J = 16.2 
Hz, =CH), 7.49 (1H, d, J = 16.2 Hz, =CH), 7.57 (1H, d, J = 16.2 Hz, =CH); 
13C NMR 
(75 MHz, DMSO-d6) ʴC 14.7 (2 × CH3), 33.1 (NCH3), 60.6 (CH2), 60.7 (CH2), 113.6 
(quat.), 114.6 (quat.), 116.9 (CH), 117.4 (CH), 123.8 (quat.), 125.8 (quat.), 129.4 
(CH),  132.6  (CH),  166.7  (2  ×  C=O);  HRMS  Found:  MH
+,  346.0618.  Calc.  for 
C15H18Cl2NO4: MH
+, 346.0608. 
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4.26.5  3,5-Dichloro-2,4-bis(2-ethoxycarbonylethenyl)1H-pyrrole 242b 
 
N
Cl
Cl
H
1
2
3 4
5 1`
2`
3`
CO2Et
H
H
H
EtO2C
H
1``
2`` 3``
 
The crude product was purified by column chromatography on silica, eluting with 
ethyl acetate: petroleum ether (60-80 
oC) (2:8), to give diester 242b as a pink solid 
(0.42 g, 39 %); mp 168-169 
oC; υmax(KBr)/cm
-1 3208 (NH),
 1704 (C=O), 1667 (C=O), 
1624 (C=O), 1542 (C=C); 
1H NMR (300 MHz, DMSO-d6) ʴH  1.29 (6H, t, J = 6.9 Hz, 
2 × CH3), 4.22 (4H, q, J = 6.9 Hz, 2 × CH2), 6.46 (1H, d, J = 16.0 Hz, =CH), 6.59 
(1H, d, J = 16.0 Hz, =CH), 7.39 (2H, m, =CH), 13.18 (1H, s, NH); 
13C NMR (75 
MHz, DMSO-d6) ʴC 14.6 (2 × CH3), 60.5 (2 × CH2), 113.7 (quat.), 115.5 (CH), 115.6 
(quat.),  116.7  (CH),  122.3  (quat.),  125.5  (quat.),  128.7  (CH),  132.6  (CH),  166.5 
(C=O), 166.7 (C=O); HRMS Found: MH
+, 332.0438. Calc. for C14H15Cl2NO4: MH
+, 
332.0452. 
 
4.26.6  3,5-Dichloro-2,4-bis(2´-ethoxycarbonylethenyl)-1-ethyl-1H-pyrrole 242c 
 
N
Cl
Cl
H
1
2
3 4
5 1`
2`
3`
CO2Et
H
H
EtO2C
H
1``
2`` 3``
CH3  
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The crude product was purified by column chromatography on silica, eluting with 
ethyl acetate: petroleum ether (60-80 
oC) (2:8), to give diester 242c as an orange solid 
(0.42 g, 64 %); mp 84-86 
oC; [Found: C, 53.5; H, 5.4; N, 3.8. C16H19Cl2NO4 requires 
C, 53.4; H, 5.3; N, 3.9 %]; υmax(KBr)/cm
-1 1704 (C=O), 1624 (C=O); 
1H NMR (300 
MHz, DMSO-d6) ʴH 1.30-1.36 (9H, m, 3 × CH3), 4.24-4.28 (6H, m, 3 × CH2), 6.65 
(1H, d, J = 16.0 Hz, =CH), 6.68 (1H, d, J = 16.4 Hz, =CH), 7.49 (1H, d, J = 16.0 Hz, 
=CH), 7.57 (1H, d, J = 16.4 Hz, =CH); 
13C NMR (75 MHz, DMSO-d6) ʴC 14.6 (2 × 
CH3), 15.6 (CH3), 40.8 (CH2), 60.6 (CH2), 60.8 (CH2), 113.8 (quat.), 114.8 (quat.), 
117.2 (CH), 117.6 (CH), 122.8 (quat.), 124.6 (quat.), 129.1 (CH), 132.5 (CH), 166.7 
(2 × C=O). 
 
4.27  Ethyl 2-[2´-(4´´-fluorophenyl)-2´-oxoethyl]-3-oxobutanoate 245a
4 
 
O COOEt
O
CH3
F
1
2 3
4
1`
2` 1``
2``
3``
4``
5``
6``
 
 
To a refluxing solution of sodium ethoxide (1.72 g, 25.72 mmol) in EtOH (24 ml) 
was added, dropwise, ethyl acetoacetate  243 (3.26 ml, 25.72 mmol). Stirring was 
continued  for  an  additional  1  h  then  the  reaction  was  allowed  to  cool  to  room 
temperature. 4-Fluorophenacyl bromide 244a (6 g, 25.72 mmol) was added to the 
solution in small portions and stirring was continued overnight at room temperature. 
After the reaction was complete, the solvent was removed under reduced pressure, the 
residue was diluted with water (16 ml), extracted with diethyl ether (2 × 18 ml) and 
the combined organics dried over MgSO4. After filtration, the solvent was evaporated Experimental Part                                                                                Chapter Four 
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under  reduced  pressure  and  the  crude  product  was  purified  by  column 
chromatography  on  silica,  eluting  with  petroleum  ether  (60-80 
oC):  diethyl  ether 
(80:20) to give ester 245a (1.2 g, 11 %) as a white solid; mp 55-56 
oC (lit.
4 mp 52-53 
oC);
 υmax(KBr)/cm
-1 1733 (C=O), 1715 (C=O), 1680 (C=O), 1592 (C=C); 
1H NMR 
(300 MHz, CDCl3) ʴH 1.22 (3H, t, J = 6.9 Hz, OCH2CH3), 2.36 (3H, s, CH3), 3.39 
(1H, dd, J = 18 and 5.7 Hz, CH2-a),  3.60 (1H, dd,  J = 18 and 8.1 Hz, CH2-b), 4.12-
4.19 (3H, m, OCH2CH3, H-2), 7.06 (2H, t, J = 8.7 Hz, CH-3´´,5´´), 7.93 (2H, dd, J = 
8.7 and 5.4 Hz, CH-2´´,6´´); 
13C NMR (75 MHz, CDCl3) ʴC 14.1 (CH3), 30.2 (CH3), 
37.3 (CH2), 53.9 (CH), 61.9 (OCH2), 115.8 (2 × CH, C-3´´,5´´, d, J = 21.9 Hz), 130.8 
(2 × CH, C-2´´,6´´, d, J = 9.4 Hz), 132.6 (quat., C-1´´, d, J = 2.9 Hz), 165.9 (quat., C-
4´´, d, J = 253.8 Hz), 168.8 (C=O, C-2´), 195.6 (C=O, COOEt), 202.2 (C=O, C-3). 
 
4.28  Ethyl 2-[2´-(4´´-chlorophenyl)-2´-oxoethyl]-3-oxobutanoate 245b
4 
 
O COOEt
O
CH3
Cl
1
2 3
4
1`
2` 1``
2``
3``
4``
5``
6``
 
 
The  diketone  was  prepared,  as  described  above,  from  4-chlorophenacyl  bromide 
244b, to give a white solid 245b (1.05 g, 15 %); mp 59-60 
oC (lit.
4 mp 58-59 
oC); 
υmax(KBr)/cm
-1 1737 (C=O), 1714 (C=O), 1685 (C=O), 1589 (C=C); 
1H NMR (300 
MHz, CDCl3) ʴH 1.22 (3H, t, J = 7.2 Hz, OCH2CH3), 2.36 (3H, s, CH3), 3.39 (1H, dd, 
J = 18.3 and 5.7 Hz, CH2-a),  3.59 (1H, dd, J = 18.3 and 8.1 Hz, CH2-b), 4.12-4.19 
(3H, m, OCH2CH3, H-2), 7.37 (2H, d, J = 8.7 Hz), 7.85 (2H, d, J = 8.7 Hz); 
13C NMR 
(75 MHz, CDCl3) ʴC 14.1 (CH3), 30.2 (CH3), 37.3 (CH2), 53.9 (CH), 61.9 (OCH2), Experimental Part                                                                                Chapter Four 
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129.0 (2 ×CH, C-3´´,5´´), 129.6 (2 ×CH, C-2´´,6´´), 134.5 (quat., C-4´´), 140.0 (quat., 
C-1´´), 168.7 (C=O, C-2´´), 195.9 (C=O, COOEt), 202.1 (C=O, C-3). 
 
4.29  Ethyl 5-(4´-fluorophenyl)-2-methyl-1-phenyl-1H-pyrrole-3-carboxylate 
246a
5 
1
2
3 4
5 1`
2`
3`
4`
5`
6` 1``
2``
3``
4``
5``
6``
N CH3
O
O
F
CH3
 
 
A solution of ethyl 2-[2´-(4´´-fluorophenyl)-2´-oxoethyl]-3-oxobutanoate 245a (1 g, 
3.76 mmol), aniline (0.42 ml) and p-TsOH (0.1 g, 0.53 mmol) in toluene (53 ml) was 
refluxed for 20 h. After the reaction was complete, the solvent was evaporated under 
reduced pressure and the crude residue was diluted with water (20 ml) then extracted 
with diethyl ether (2 × 20 ml) and the combined organics dried over MgSO4. After 
filtration, the solvent was evaporated under reduced pressure and the crude product 
was purified by column chromatography on silica, eluting with petroleum ether (60-
80 
oC): ethyl acetate (70:30) to give ester 246a (0.95 g, 78 %) as a white solid; mp 
95-96 
oC (lit.
5 mp 99-100 
oC); υmax(KBr)/cm
-1 1686 (C=O); 
1H NMR  (300 MHz, 
CDCl3) ʴH 1.29 (3H, t, J = 7.2 Hz, OCH2CH3), 2.32 (3H, s, CH3), 4.25 (2H, q, J = 7.2 
Hz, OCH2CH3), 6.68 (1H, s, H-4), 6.75 (2H, t, J = 8.7 Hz, ArH), 6.93 (2H, m, ArH), 
7.04 (2H, m, ArH), 7.30 (3H, m, ArH); 
13C NMR (75 MHz, CDCl3) ʴC 12.5 (CH3), 
14.6 (OCH2CH3), 59.6 (CH2), 109.9 (CH, C-4), 112.9 (quat., C-3), 115.0 (2 × CH, C-
3´,5´, d, J = 21.4 Hz), 128.4 (CH), 128.5 (CH), 128.6 (quat., C-1´´), 129.2 (CH), Experimental Part                                                                                Chapter Four 
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129.9 (2 × CH, C-2´´,6´´, d, J = 7.95 Hz), 132.9 (quat., C-5), 137.9 (quat., C-1´), 
161.6 (quat., C-4´, d, J = 245.0 Hz), 165.5 (C=O); m/z Found: MH
+, 324. Calc. for 
C20H19FNO2: MH
+, 324. 
 
4.30  Ethyl 5-(4´-chlorophenyl)-2-methyl-1-phenyl-1H-pyrrole-3-carboxylate 
246b
5  
1
2
3 4
5 1`
2`
3`
4`
5`
6` 1``
2``
3``
4``
5``
6``
N CH3
O
O
Cl
CH3
 
 
This pyrrole was prepared, as described above, from 1,4-diketone 245b and aniline, to 
give a white solid 246b (0.89 g, 75 %); mp 98-99 
oC (lit.
5 103-105 
oC); υmax(KBr)/cm
-
1 1705 (C=O); 
1H NMR (300 MHz, CDCl3) ʴH 1.30 (3H, t, J = 7.2 Hz, OCH2CH3), 
2.32 (3H, s, CH3), 4.26 (2H, q, J = 7.2 Hz, OCH2CH3), 6.72 (1H, s, H-4), 6.89 (2H, d, 
J = 8.4 Hz, ArH), 7.04 (4H, m, ArH), 7.32 (3H, m, ArH); 
13C NMR (75 MHz, CDCl3) 
ʴC 12.5 (CH3), 14.6 (CH3), 59.6 (CH2), 110.4 (CH, C-4), 113.1 (quat.), 128.2 (CH), 
128.5 (CH), 129.2 (CH), 129.3 (CH), 130.9 (quat.), 132.5 (quat.), 132.7 (quat.), 137.9 
(quat.), 138.4 (quat.), 165.4 (C=O); m/z Found: MH
+, 340. Calc. for C20H20
35ClNO2: 
MH
+, 340. 
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4.31  5-(4´-Fluorophenyl)-2-methyl-1-phenyl-1H-pyrrole-3-carboxylic acid 247a
5 
 
1
2
3 4
5 1`
2`
3`
4`
5`
6` 1``
2``
3``
4``
5``
6``
N CH3
O
OH
F
 
 
To  a  solution  of  ethyl  5-(4´-fluorophenyl)-2-methyl-1-phenyl-1H-pyrrole-3-
carboxylate 246a (0.8 g, 2.48 mmol) in EtOH (19 ml) was added KOH (0.7 g) in 
water (4 ml) and the solution was refluxed for 2 h. After the reaction was complete, 
the solvent was evaporated under reduced pressure then the crude residue was diluted 
with  1M  aq.  HCl  (15  ml),  extracted  with  DCM  (2  ×  20  ml)  and  the  combined 
organics  dried  over  MgSO4.  After  filtration,  the  solvent  was  evaporated  under 
reduced pressure and the crude product was purified by column chromatography on 
silica, eluting with petroleum ether (60-80 
oC): ethyl acetate (70:30) to give acid 247a 
(0.56 g, 77 %) as a white solid; mp 53-54 
oC (lit.
5 57-59 
oC); υmax(KBr)/cm
-1 1654 
(C=O); 
1H NMR (300 MHz, DMSO-d6) ʴH 2.34 (3H, s, CH3), 6.70 (1H, s, H-4), 7.08 
(4H, m, ArH), 7.29 (2H, d, J = 7.5 Hz, ArH), 7.51 (3H, m, ArH),  11.96 (1H, s, OH); 
13C NMR (75 MHz, DMSO-d6) ʴC 12.6 (CH3), 110.4 (CH, C-4), 113.3 (quat., C-3), 
115.6 (CH, C-3´,5´, d, J = 21.3 Hz), 128.9 (CH), 129.0 (CH), 129.1 (quat., C-1´´), 
129.9 (CH), 130.3 (CH, C-2´,6´, d, J = 8.1 Hz), 132.6 (quat., C-5), 137.8  (quat., C-1´, 
d, J = 1.4 Hz), 161.3 (quat., C-4´, d, J = 243 Hz), 166.5 (C=O); m/z Found: MH
+, 
296. Calc. for C18H15FNO2: MH
+, 296. 
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4.32  5-(4´-Chlorophenyl)-2-methyl-1-phenyl-1H-pyrrole-3-carboxylic acid 247b
5 
 
1
2
3 4
5 1`
2`
3`
4`
5`
6` 1``
2``
3``
4``
5``
6``
N CH3
O
OH
Cl
 
 
This pyrrole was prepared, as described above, to give a white solid 247b (0.22 g, 80 
%); mp 249-250 
oC (lit.
5 mp 249-250 
oC); υmax(KBr)/cm
-1 1657 (C=O); 
1H NMR (300 
MHz, DMSO-d6) ʴH 2.34 (3H, s, CH3), 6.76 (1H, s, H-4), 7.08 (2H, d, J = 8.4 Hz, 
ArH), 7.28 (4H, m, ArH), 7.51 (3H, m, ArH), 11.99 (1H, s, OH); 
13C NMR (75 MHz, 
DMSO-d6) ʴC 12.6 (CH3), 110.9 (CH), 113.5 (quat.), 128.6 (CH), 128.9 (CH), 129.1 
(CH),  129.8  (CH),  129.9  (CH),  131.4  (quat.),  131.7  (quat.),  132.7  (quat.),  137.8 
(quat.),  138.2  (quat.),  166.4  (C=O);  m/z  Found:  [M-H
+]
-,  310.  Calc.  for 
C18H13
35ClNO2: [M-H
+]
-, 310. 
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4.33  N-(4´´´-Methylphenyl)-5-(4´-fluorophenyl)-2-methyl-1-phenyl-1H-pyrrole-
3-carboxamide 249a 
N
O
N
H
CH3
F
CH3
1
2
3 4
5 1`
2`
3`
4`
5`
6` 1``
2``
3``
4``
5``
6``
1```
2```
3```
4```
5``` 6```
 
 
A  solution  of  5-(4´-fluorophenyl)-2-methyl-1-phenyl-1H-pyrrole-3-carboxylic  acid 
247a (0.4 g, 1.36 mmol) and SOCl2 (0.47 ml) in toluene (7.5 ml) was refluxed for 4 h 
and, after evaporation of the solvent, the crude mixture was dissolved in DCM (8 ml) 
and a solution of p-toluidine (0.26 g, 2.43 mmol) and TEA (0.2 ml) in DCM (1.5 ml) 
was added dropwise at 0 
oC. The mixture was stirred for 2 h at room temperature then 
washed with 5 % aq. HCl (12 ml) and 5 % aq. NaOH (12 ml). The organic layer was 
dried over MgSO4 and, after filtration,  the solvent  was  evaporated under reduced 
pressure.  The  crude  product  was  purified  by  column  chromatography  on  silica, 
eluting with petroleum ether (60-80
oC): ethyl acetate (70:30) to give a yellow solid 
249a (0.46 g, 88 %); mp 205-206 
oC; [Found: C, 76.8; H, 5.4; N, 7.0. C25H21ON2F 
requires C, 76.5; H, 5.7; N, 7.0 %]; υmax(KBr)/cm
-1  3281 (NH), 1633 (C=O); 
1H 
NMR (300 MHz, CDCl3) ʴH 2.26 (3H, s, C-2-CH3), 2.37 (3H, s, CH3), 6.45 (1H, s, H-
4), 6.78 (2H, t, J = 8.7 Hz ArH), 6.94 (2H, m, ArH), 7.06 (4H, m, ArH), 7.32 (3H, m, 
ArH), 7.45 (2H, d,  J = 8.4 Hz, ArH), 7.49 (1H, br s, NH); 
13C NMR (75 MHz, 
CDCl3) ʴC 12.5 (CH3), 20.9 (C-2-CH3), 106.7 (CH, C-4), 115.2 (CH, C-3´,5´, d, J = 
22.5 Hz), 115.8 (quat., C-3), 120.1 (CH), 128.4 (CH), 128.5 (CH), 129.3 (CH), 129.5 Experimental Part                                                                                Chapter Four 
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(CH), 129.9 (CH, C-2´,6´, d,  J = 7.9 Hz), 133.3 (quat., C-1´, d, J = 3.1 Hz), 135.9 
(quat.),  136.7  (quat.),  137.8  (quat.),  161.7  (quat.,  C-4´,  d,    J  =  245.5  Hz),  163.9 
(C=O). 
 
4.34  N-(4´´´-Methylphenyl)-5-(4´-chlorophenyl)-2-methyl-1-phenyl-1H-pyrrole-
3-carboxamide 249b 
N
O
N
H
CH3
Cl
CH3
1
2
3 4
5 1`
2`
3`
4`
5`
6` 1``
2``
3``
4``
5``
6``
1```
2```
3```
4```
5``` 6```
 
 
This pyrrole was prepared, as described above, from 5-(4´-chlorophenyl)-2-methyl-1-
phenyl-1H-pyrrole-3-carboxylic acid, to give a white solid 249b (0.35 g, 91 %); mp 
214-215 
oC; [Found: C, 74.4; H, 5.3; N, 6.9. C25H21ON2Cl requires C, 74.9; H, 5.3; 
N, 6.9 %]; υmax(KBr)/cm
-1 3352 (NH), 1704 (C=O);  
1H NMR (300 MHz, CDCl3) ʴH 
2.25 (3H, s, C-2-CH3), 2.37 (3H, s, CH3), 6.49 (1H, s, H-4), 6.89 (2H, d, J = 8.7 Hz, 
ArH), 7.06 (6H, m, ArH), 7.34 (3H, m, ArH), 7.43 (2H, d, J = 8.4 Hz, ArH), 7.52 
(1H, br s, NH); 
13C NMR (75 MHz, CDCl3) ʴC 12.5 (CH3), 20.9 (C-2-CH3), 107.1 
(CH, C-4), 116.1 (quat.), 120.2 (CH), 128.4 (CH), 128.5 (CH), 129.3 (CH), 129.4 
(CH), 129.5 (CH), 130.8 (quat.), 132.6 (quat.), 132.8 (quat.), 133.5 (quat.), 135.9 
(quat.), 137.2 (quat.), 137.8 (quat.), 163.8 (C=O). 
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APPENDIX A 
 
The layout of a 96-well plate, used for the antiproliferative assay. 
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APPENDIX B 
 
MTT 96-well Assay Calculation Forms 
 
 
MTT 96-well Assay Calculation Form 
Compound 249a / CaCo-2 
                           
  Conc  Conc  Absorbances (at 595nm), n=6  Mean  SD  % SD  Corrected Ab  %Growth 
Blank  μg/mL  μM  0,105  0,099  0,123  0,121  0,123  0,146  0,120  0,016  13,80  N/A  N/A 
Control      0,237  0,204  0,158  0,170  0,145  0,209  0,187  0,035  18,76  0,068  100 
1  200  521,00  0,136  0,128  0,156  0,160  0,102  0,120  0,134  0,022  16,46  0,014  20,94 
2  100  260,50  0,200  0,151  0,133  0,141  0,122  0,143  0,148  0,027  18,31  0,029  42,61 
3  50  130,25  0,195  0,161  0,146  0,210  0,155  0,189  0,176  0,012  6,88  0,057  83,50 
4  25  65,13  0,169  0,189  0,172  0,198  0,183  0,196  0,185  0,012  6,56  0,065  96,06 
5  12,5  32,56  0,226  0,254  0,183  0,226  0,192  0,243  0,221  0,028  12,67  0,101  149,51 
6  6,25  16,28  0,222  0,187  0,208  0,193  0,187  0,235  0,205  0,020  9,71  0,086  126,85 
7  3,125  8,14  0,227  0,200  0,213  0,213  0,245  0,243  0,224  0,018  8,07  0,104  153,69 
8  1,5625  4,07  0,244  0,240  0,210  0,229  0,202  0,359  0,247  0,057  23,10  0,128  188,92 
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MTT 96-well Assay Calculation Form 
Compound 249b / CaCo-2 
                           
  Conc  Conc  Absorbances (at 595nm), n=6  Mean  SD  % SD  Corrected Ab  %Growth 
Blank  μg/mL  μM  0,109  0,114  0,135  0,126  0,127  0,145  0,126  0,013  10,51  N/A  N/A 
Control      0,543  0,355  0,259  0,426  0,58  0,636  0,467  0,145  31,00  0,341  100 
1  200  499,00  0,217  0,147  0,186  0,195  0,161  0,144  0,175  0,029  16,61  0,049  14,39 
2  100  249,50  0,155  0,189  0,164  0,191  0,162  0,176  0,173  0,015  8,64  0,047  13,75 
3  50  124,75  0,180  0,194  0,190  0,213  0,278  0,256  0,219  0,036  16,68  0,093  27,17 
4  25  62,38  0,216  0,209  0,201  0,246  0,178  0,281  0,222  0,036  16,43  0,096  28,14 
5  12,5  31,19  0,263  0,253  0,364  0,377  0,267  0,408  0,322  0,068  21,27  0,196  57,56 
6  6,25  15,59  0,262  0,365  0,422  0,502  0,433  0,325  0,385  0,085  22,20  0,259  76,02 
7  3,125  7,80  0,306  0,600  0,416  0,708  0,430  0,587  0,508  0,148  29,21  0,382  112,14 
8  1,5625  3,90  0,664  0,397  0,279  0,667  0,466  0,462  0,489  0,152  31,16  0,363  106,66 
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MTT 96-well Assay Calculation Form 
Compound 249a / HaCaT 
                           
  Conc  Conc  Absorbances (at 595nm), n=6  Mean  SD  % SD  Corrected Ab  %Growth 
Blank  μg/mL  μM  0,072  0,076  0,097  0,089  0,094  0,116  0,091  0,016  17,50  N/A  N/A 
Control      0,655  0,5  0,579  0,533  0,561  0,539  0,561  0,053  9,48  0,471  100 
1  200  499,00  0,263  0,229  0,209  0,237  0,249  0,237  0,237  0,018  7,69  0,147  31,17 
2  100  249,50  0,237  0,309  0,315  0,311  0,325  0,301  0,300  0,032  10,58  0,209  44,42 
3  50  124,75  0,286  0,346  0,376  0,378  0,363  0,355  0,351  0,040  11,27  0,260  55,26 
4  25  62,38  0,356  0,366  0,416  0,395  0,418  0,316  0,378  0,040  10,46  0,287  61,03 
5  12,5  31,19  0,349  0,393  0,400  0,466  0,412  0,342  0,394  0,045  11,51  0,303  64,40 
6  6,25  15,59  0,341  0,426  0,444  0,383  0,470  0,355  0,403  0,051  12,77  0,313  66,42 
7  3,125  7,80  0,314  0,382  0,425  0,398  0,372  0,329  0,370  0,042  11,32  0,279  59,37 
8  1,5625  3,90  0,408  0,411  0,418  0,45  0,434  0,399  0,420  0,019  4,47  0,329  70,00 
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MTT 96-well Assay Calculation Form 
Compound 249b / HaCaT 
                           
  Conc  Conc  Absorbances (at 595nm), n=6  Mean  SD  % SD  Corrected Ab  %Growth 
Blank  μg/mL  μM  0,072  0,086  0,097  0,094  0,113  0,135  0,100  0,022  22,10  N/A  N/A 
Control      0,461  0,507  0,532  0,515  0,665  0,508  0,531  0,070  13,10  0,432  100 
1  200  521,00  0,104  0,125  0,135  0,150  0,133  0,189  0,139  0,029  20,54  0,040  9,22 
2  100  260,50  0,294  0,320  0,275  0,263  0,278  0,266  0,283  0,021  7,53  0,183  42,42 
3  50  130,25  0,272  0,359  0,330  0,349  0,415  0,337  0,344  0,068  19,79  0,244  56,54 
4  25  65,13  0,376  0,399  0,409  0,511  0,495  0,338  0,421  0,068  16,14  0,322  74,53 
5  12,5  32,56  0,576  0,417  0,475  0,532  0,496  0,422  0,486  0,062  12,77  0,387  89,58 
6  6,25  16,28  0,409  0,453  0,482  0,471  0,504  0,421  0,457  0,036  7,98  0,357  82,71 
7  3,125  8,14  0,397  0,584  0,488  0,502  0,457  0,449  0,480  0,063  13,10  0,380  88,00 
8  1,5625  4,07  0,562  0,467  0,439  0,488  0,644  0,408  0,501  0,087  17,39  0,402  93,05 
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MTT 96-well Assay Calculation Form 
Compound 249a / HT29 
                           
  Conc  Conc  Absorbances (at 595nm), n=6  Mean  SD  % SD  Corrected Ab  %Growth 
Blank  μg/mL  μM  0,099  0,109  0,109  0,129  0,116  0,145  0,118  0,017  14,08  N/A  N/A 
Control      0,357  0,374  0,416  0,559  0,595  0,58  0,480  0,109  22,80  0,362  100 
1  200  521,00  0,172  0,202  0,183  0,181  0,215  0,214  0,195  0,018  9,42  0,077  21,16 
2  100  260,50  0,189  0,170  0,203  0,218  0,281  0,285  0,224  0,048  21,46  0,107  29,39 
3  50  130,25  0,203  0,185  0,204  0,264  0,260  0,322  0,240  0,022  9,38  0,122  33,62 
4  25  65,13  0,210  0,212  0,237  0,183  0,247  0,218  0,218  0,022  10,32  0,100  27,60 
5  12,5  32,56  0,271  0,214  0,301  0,305  0,340  0,286  0,286  0,042  14,75  0,168  46,46 
6  6,25  16,28  0,329  0,342  0,574  0,448  0,425  0,43  0,425  0,088  20,76  0,307  84,68 
7  3,125  8,14  0,372  0,447  0,379  0,357  0,481  0,407  0,407  0,048  11,82  0,289  79,85 
8  1,5625  4,07  0,315  0,493  0,549  0,424  0,399  0,374  0,426  0,084  19,76  0,308  84,96 
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MTT 96-well Assay Calculation Form 
Compound 249b / HT29 
                           
  Conc  Conc  Absorbances (at 595nm), n=6  Mean  SD  % SD  Corrected Ab  %Growth 
Blank  μg/mL  μM  0,111  0,111  0,138  0,118  0,168  0,217  0,144  0,042  29,16  N/A  N/A 
Control      0,222  0,209  0,271  0,246  0,327  0,305  0,263  0,046  17,66  0,120  100 
1  200  499,00  0,178  0,246  0,221  0,183  0,249  0,207  0,214  0,030  14,18  0,070  58,72 
2  100  249,50  0,224  0,219  0,213  0,250  0,293  0,259  0,243  0,030  12,54  0,099  82,98 
3  50  124,75  0,225  0,214  0,241  0,271  0,293  0,287  0,255  0,016  6,18  0,111  93,17 
4  25  62,38  0,201  0,209  0,224  0,232  0,245  0,221  0,222  0,016  7,11  0,078  65,41 
5  12,5  31,19  0,230  0,187  0,211  0,403  0,253  0,297  0,264  0,078  29,60  0,120  100,14 
6  6,25  15,59  0,200  0,235  0,288  0,357  0,281  0,308  0,278  0,055  19,81  0,134  112,41 
7  3,125  7,80  0,233  0,285  0,252  0,392  0,322  0,319  0,301  0,057  19,02  0,157  131,10 
8  1,5625  3,90  0,228  0,266  0,352  0,354  0,351  0,345  0,316  0,055  17,36  0,172  144,07 
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